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1. COMPUTATIONAL DRUG DISCOVERY 
Computational methods have become standard in today‘s 
medicinal chemistry toolkit. Judging from the table of contents of 
medicinal chemistry journals or conference programs, there is a 
seamless integration of these disciplines into the early drug 
discovery process. While being confined at their beginning to the 
visualization of potential drug interactions in the targeted enzyme 
binding, today these techniques permeate all aspects of drug 
discovery and are indispensable prerequisites to support medicinal 
chemistry programs.
1 
Computational tools can offer significant advantages over the 
conventional ones, being orders of magnitude cheaper and faster or 
offering the possibility to predict molecular behaviours that cannot 
be elucidated in any other way. Moreover, recent developments in 
software and hardware make it possible to simulate more and more 
complex molecular environments, widening the applicability of in 
silico studies from the interactions of small molecules with key 
protein residues, to the simulation of the dynamic evolution of 
complex biological systems with atomic resolution.
2
 
Nowadays, various computational disciplines are available and 
they can be broadly classified as structure-based or ligand-based 
approaches. The former is used in the presence of three-
dimensional information of the target (generally derived from 
crystallographic or NMR studies). The latter methodologies are 
applied when the 3D structure of the target is not known, and 
information about the binding mode is derived from a series of 
related active compounds. 
It is important to keep in mind that working with these techniques 
there is no single generic workflow, but is the combination of several 
methods that provide the best results. All methods should be seen 
as one multifaceted discipline contributing to the early drug 
                                                        
1 
Jorgensen, W. L. The many roles of computation in drug discovery. Science 2004, 303, 1813-
1818.  
2 
Zonta, N.; Coluccia, A.; Brancale, A. Advanced in silico approaches in antiviral research. Antivir. 
Chem. Chemother. 2010, 20, 147-151. 
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discovery process. However, the computer can just help in preparing 
the data, and at the end it is up to the project team to make use of 
all available information to ensure that the right choices are made 
and the most promising candidates are progressed. 
1.1. Structure – Based Approaches 
Structure-Based Drug Design (SBDD), is a well – established, 
successful and highly attractive strategy that uses three-dimensional 
protein structure information in the development of new biologically 
active molecules. As a creative and knowledge – driven approach, 
an essential requirement for structure-based studies is a substantial 
understanding of the spatial and energetic aspects that affect the 
binding affinities of protein – ligand complexes. Considering that the 
shape and the chemical nature of the binding site of a specific target 
protein are known, and the possible intermolecular interactions 
between ligands and the protein within its active site have been 
identified, this qualified information can be directly employed for the 
identification of new ligands and the optimization of lead 
compounds. This opens new possibilities to boost the search up for 
new lead molecules and to limit the number of compounds that need 
to be evaluated experimentally.
3,4 
Molecular docking and scoring technology is one of the most 
used computational technique when the three-dimensional structure 
of the desired target is available. In particular, docking can be 
defined as the positioning of a ligand in a protein binding site, and 
scoring, the quality assessment of docked ligands. This technology 
is applied at different stages of the drug discovery process for three 
main purposes: (1) predicting the binding mode of a known ligand; 
(2) identifying new ligands using virtual screening (VS); (3) 
predicting the binding affinities of related compounds from a known 
active site series. Of these three challenges, successful prediction of 
                                                        
3 
Andricopulo, A. D.; Salum, L. B.; Abraham, D. J. Structure-based drug design in medicinal 
chemistry. Curr. Top. Med. Chem. 2009, 9, 771-790. 
4 
Cavasotto, C. N.; Orry, A. J. Ligand docking and structure-based virtual screening in drug 
discovery. Curr. Top. Med. Chem. 2007, 7, 1006-1014. 
CHAPTER 1  COMPUTATIONAL APPROACHES 
  
11 
 
a ligand binding mode in a protein active site is perhaps the most 
straightforward and is the area where most success has been 
achieved.
5
 Docking a ligand into a binding site models several 
degrees of freedom. These are the six degrees of translational and 
rotational freedom of one body relative to another and then the 
conformational degrees of freedom of the ligand and of the protein. 
The first docking algorithms only considered translational and 
orientation, with both ligand and protein treated as rigid bodies. 
Increases in computer performance and new algorithms enabled the 
ligand conformation degrees of freedom (ligand flexibility) to be 
explored.
5
 Most docking programs today treat the ligand as flexible 
with a rigid (or nearly rigid) receptor structure. Receptor flexibility still 
remains one of the major challenges for the field. 
Ligand Flexibility Algorithms – Usually, it is not known which 
conformation of a ligand interacts most favourably with a receptor 
and, therefore, a conformational searching during docking is 
necessary. Ligand flexibility algorithms can be divided in three types 
of searches, namely systematic, stochastic, and deterministic 
searches. Some algorithms use more than one of these approaches. 
Systematic search algorithms are based on a grid of values for each 
formal degree of freedom, and each of these grid values is explored 
in a combinatorial fashion during the search. An example of a 
systematic search is the anchor-and-grow or incremental 
construction algorithm.
6
 Stochastic search algorithms make random 
changes usually changing one degree of freedom of the system at a 
time. One of the major concerns with stochastic searches is the 
uncertainty of convergence. In order to improve convergence, 
multiple, independent runs can be performed. Examples of 
stochastic searches are Monte Carlo (MC) methods and 
evolutionary algorithms. In deterministic searches the initial state 
determines the move that can be made to generate the next state, 
which generally has to be equal to or lower in energy than the initial 
                                                        
5
 Leach, A. R.; Shoichet, B. K.; Peishoff, C. E. Prediction of protein-ligand interactions. Docking 
and scoring: Successes and gaps. J. Med. Chem. 2006, 49, 5851-5855. 
6
 Broojimans, N.; Kuntz, I. D. Molecular recognitions and docking algorithms. Annu. Rev. Biophys. 
Biomol. Struct. 2003, 32, 335-373. 
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state. Deterministic searches performed on exactly the same 
starting system (including each degree of freedom) with the same 
parameters will generate exactly the same final state. A problem 
with deterministic algorithms is that they often get trapped in local 
minima because they cannot traverse barriers. Example of 
deterministic methods are energy minimization methods and 
molecular dynamics (MD) simulations.
6
 
Receptor Flexibility Methods – Allowing ligand flexibility was a 
huge step forward, but changes in receptor structure upon ligand 
binding are observed frequently as well.
7
 Actually, many molecular 
systems undergo rearrangements upon ligand binding, which range 
from local motions of side-chains to large domain movements. In 
any case, receptor flexibility might have a dramatic impact in the 
ligand docking problem as well as in virtual screening. Therefore, 
the inclusion of some structural variability in a docking study 
becomes of fundamental importance. However, the representation 
of protein flexibility is still a challenge for the state-of-the-art flexible 
ligand docking protocols. 
Cross-docking is a feasible technique that accounts for protein 
flexibility and how it affects docking experiments per se.
8,9
 
Compared to self-docking studies, cross-docking analysis better 
verifies how efficiently docking studies can support lead 
identification and structure-activity relationship studies where no 
structural information are experimentally available for the ligands of 
interest. In this case, the ligand of interest is docked into an 
available protein structure that is usually complexed with a different 
ligand (e.g., a ligand A from a receptor-ligand A complex is docked 
into a receptor B from receptor-ligand B complex, where the 
receptor is the same biological target). Cross-docking analysis 
essentially simulates this situation because it evaluates how 
                                                        
7 
Cavasotto, C. N.; Abagyan, R. A. Protein flexibility in ligand docking and virtual screening to 
protein kinases. J. Mol. Biol. 2004, 337, 209-225. 
8 
Birch, L.; Murray, C. W.; Hartshorn, M. J.; Tickle, I. J.; Verdonk, M. L. Sensitivity of molecular 
docking to induced fit effects in influenza virus neuraminidase. J. Comput. Aided Mol. Des. 2003, 
16, 855-869. 
9
 Kramer, B.; Rarey, M.; Lengauer, T. Evaluation of the FlexX incremental construction algorithm 
for protein-ligand docking. Proteins 1999, 37, 228-241. 
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efficiently a docking software package is able to reproduce the 
experimentally determined binding pose of a ligand by docking it into 
a protein whose 3D structure was determined in complex with a 
different ligand.
10
 
Methods that specifically deal with receptor flexibility also exist. 
Some of them use conformational libraries to sample receptor 
flexibility.
11,12
 Other methods use to pre-calculate receptor 
contributions to the binding free energy on a grid, a procedure that 
significantly increases the speed of docking algorithms. However, 
the grid also constricts docking to a rigid receptor because the grid 
is only calculated once. Different approaches try to overcome this 
problem by incorporating multiple receptor structures into the 
grid.
13,14,15
 Some methods that sample ligand flexibility are also 
suited to sample receptor flexibility, namely Genetic Algorithms 
(GAs), MD methods, and MC methods.
6
 
Scoring Functions – Once the configurations of a system are 
sampled, docking programs must evaluate and correctly rank the 
predicted ligand conformations. Even when binding conformations 
are correctly predicted, the calculations ultimately do not succeed if 
they do not differentiate correct poses from incorrect ones, and if 
‗true‘ ligands cannot be identified. So, the design of reliable scoring 
functions and schemes is of fundamental importance.  
There are three important applications of scoring functions in 
molecular docking. The first of these is the determination of the 
binding mode and site of a ligand on a protein. Given a protein 
target, molecular docking generates hundreds of thousands of 
                                                        
10
 Tuccinardi, T.; Botta, M.; Giordano, M.; Martinelli, M. Protein Kinases: Docking and Homology 
Modeling Reliability J. Chem. Inf. Model. 2010, 50, 1432-1441. 
11
 Leach, A. R. Ligand docking to proteins with discrete side-chain flexibility. J. Mol. Biol. 1994, 
235, 345-356. 
12
 Jackson, R. M.; Gabb, H. A.; Sternberg, M. J. E. Rapid refinement of protein interfaces 
solvation: application to the docking problem. J. Mol. Biol. 1998, 276, 265-285. 
13
 Knegtel, R. M. A.; Kuntz, I. D.; Oshiro, C. M. Molecular docking to ensembles of protein 
structures. J. Mol. Biol. 1997, 76, 269-281. 
14
 Osterberg, F.; Morris, G. M.; Sanner, M. F.; Olson, A. J.; Goodsell, D. S. Automated docking to 
multiple target structures: incorporation of protein mobility and structural water heterogeneity in 
AutoDock. Proteins 2002, 46, 34-40. 
15
 Rarey, M.; Kramer, B.; Lengauer, T. Fast flexible docking method using an incremental 
construction algorithm. J. Mol. Biol. 1996, 261, 470-489. 
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putative ligand binding orientations/conformations at the active site 
around the protein. A scoring function is used to rank these ligand 
orientations/conformations by evaluating the binding tightness of 
each of the putative complexes. An ideal scoring function would rank 
the experimentally determined binding mode most highly. Given the 
determined binding mode of a ligand, scientists would be able to 
gain a deep understanding of the molecular mechanism of ligand 
binding and to further design an efficient drug by modifying the 
protein or ligand.
16
 
The second application of a scoring function, which is related to 
the first application, is to predict the absolute binding affinity 
between protein and ligand. This is particularly important in lead 
optimization.
17
 Lead optimization refers to the process to improve 
the tightness of binding for low-affinity hits or lead compounds that 
have been identified. During this process, an accurate scoring 
function can greatly increase the optimization efficiency and save 
costs by computationally predicting the binding affinities between the 
protein and modified ligands before the much more expensive step 
of ligand synthesis and experimental testing. 
The third application, perhaps the most important one in 
structure-based drug design, is to identify the potential drug 
hits/leads for a given protein target by searching a large ligand 
database, i.e., virtual database screening.
18
 A reliable scoring 
function should be able to rank known binders most highly according 
to their binding scores during database screening. Given the 
expensive cost of experimental screening and sometimes 
unavailability of high-throughput assays, virtual database screening 
has played an increasingly important role in drug discovery. 
All of these three applications, ligand binding mode identification, 
binding affinity prediction, and virtual database screening, are 
                                                        
16
 Rajamani, R.; Good, A. C. Ranking poses in structure-based lead discovery and optimization: 
Current trends in scoring function development. Curr. Opin. Drug Discov. Dev. 2007, 10, 308-315. 
17
 Shoichet, B.K.; McGovern, S. L.; Wei, B.; Irwin, J. J. Lead discovery using molecular docking 
Curr. Opin. Chem. Biol. 2002, 6, 439-446. 
18
 Seifert, M. H.J.; Kraus, J.; Kramer, B. Virtual high-throughput screening of molecular databases. 
Curr. Opin. Drug Discov. Dev. 2007, 10, 298-307. 
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related to each other. Presumably, an accurate scoring function 
would perform equally well on each of them. Despite over a decade 
of development, scoring is still an open question. Many existing 
scoring functions perform well only on one or two of the three 
applications. Roughly, the scoring functions can be grouped into 
three basic types according to how they are derived: force field-
based (i.e., a function expressing the energy of a system as a sum 
of diverse molecular mechanics or other terms), empirical, and 
knowledge-based. 
Force field (FF) scoring functions are developed based on 
physical atomic interactions, including van der Waals interactions, 
electrostatic interactions, and bond stretching/bending/torsional 
forces. Force field functions and parameters are usually derived 
from both experimental data and ab initio quantum mechanical 
calculations according to the principles of physics. Despite its lucid 
physical meaning, a major challenge in the force field scoring 
functions is how to treat the solvent in ligand binding.
19
 
Empirical scoring functions are fit to reproduce experimental 
data, such as binding energies and/or conformations, as a sum of 
several parameterized functions. The design of empirical scoring 
functions is based on the idea that binding energies can be 
approximated by a sum of individual uncorrelated terms. The 
coefficients of the various terms are obtained from regression 
analysis using experimentally determined binding energies and, 
potentially, X-ray structural information.19 
A third kind of scoring functions are knowledge-based scoring 
functions (also referred to as statistical-potential based scoring 
functions), which employ energy potentials that are derived from the 
structural information embedded in experimentally determined 
atomic structures essentially designed to reproduce experimental 
                                                        
19
 Huang, Sh. Y.; Grinter, S. Z.; Zou, X. Scoring functions and their evaluation methods for 
protein–ligand docking: recent advances and future directions. Phys. Chem. Chem. Phys. 2010, 
12, 12899-12908. 
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structures rather than binding energies.
20
 So, in common with 
empirical methods, knowledge-based scoring functions attempt to 
implicitly capture binding effects that are difficult to model explicitly.
21
 
In Chart 1.1 a number of currently used scoring functions are 
summarized. 
Force-field based Empirical Knowledge-based 
D-score
9
 
G-score
9
 
Gold
22
 
AutoDock
23
 
DOCK
24
 
LUDI
25
 
F-score
15
 
ChemScore
26
 
SCORE
27
 
Fresno
28
 
X-SCORE
29
 
PMF
30
 
DrugScore
31
 
SMoG
32
 
Chart 1.1 Types of scoring functions used in various docking software. 
 
                                                        
20
 Sippl, M. J. Calculation of conformational ensembles from potentials of mean force. An 
approach to the knowledge-based prediction of local structures in globular proteins. J. Mol. Biol. 
1990, 213, 859-883. 
21
 Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. Docking and scoring in virtual screening 
for drug discovery: methods and applications. Nat. Rev. Drug Discov. 2004, 3, 935-949. 
22
 Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J. Murray, C. W.; Taylor, R. D. Improved protein-
ligand using GOLD. Proteins 2003, 52, 609-623. 
23
 Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. 
Automated docking using a Lamarckian genetic algorithm and an empirical free energy scoring 
function. J. Comput. Chem. 1998, 19, 327-346. 
24
 Ewing, T. J. A.; Makino, S.; Skillman, A. G.; Kuntz, I. D. DOCK 4.0: search strategies for 
automated docking of flexible molecule databases. J. Comput. Aided Mol. Des. 2001, 15, 411-
428. 
25
 Böhm, H. J. The development of a simple empirical scoring function to estimate the binding 
constant for a protein-ligand complex of known three-dimensional structure. J. Comput. Aided 
Mol. Des. 1994, 8, 243-256. 
26
 Eldrige, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V. Mee, R. P. Empirical scoring 
functions: I. The development of a fast empirical scoring function to estimate the binding affinity of 
ligands in receptor complexes. J. Comput. Aided Mol. Des. 1997, 11, 425-445. 
27
 Wang, R.; Liu, L.; Lai, L.; Tang, Y. SCORE: a new empirical method for estimating the binding 
affinity of a protein-ligand complex. J. Mol. Model. 1998, 4, 379-394. 
28
 Rognan, D.; Lauemoller, S. L.; Holm, A.; Buus, S.; Tschinke, V. Predicting binding affinities of 
protein ligands from three-dimensional models: application to peptide binding to class I major 
histocompatibility proteins. J. Med. Chem. 1999, 42, 4650-4658. 
29
 Wang, R.; Lai, L.; Wang, S. Further development and validation of empirical scoring functions 
for structure-based binding affinity prediction. J. Comput. Aided Mol. Des. 2002, 16, 11-26. 
30
 Muegge, I. A knowledge-based scoring function for protein-ligand interactions: probing the 
reference state. Perspect. Drug Discov. Des. 2000, 20, 99-114. 
31
 Gohlke, H.; Hendlich, M.; Klebe, G. Knowledge-based scoring function to predict protein ligand 
interactions. J. Mol. Biol. 2000, 295, 337-356. 
32
 DeWitte, R. S; Shakhnovic, E. I. SMoG: de novo design method based on simple, fast, and 
accurate free energy estimates. 1. Methodology and supporting evidence. J. Am. Chem. Soc. 
1996, 118, 11733-11744. 
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Structure-based virtual screening – Docking and scoring is a 
technology that is also used for identifying new ligands using virtual 
screening (VS). This term, which was coined in the late 1990s, 
describes the use of computational algorithms and models for the 
identification of novel bioactive molecules.
33
 VS methodology may 
involve searching databases containing hundreds-of-thousands, if 
not millions, of molecules and has rapidly become an essential 
component of the modern drug discovery process.
11,34,35,36,37,38
 
Structure-based virtual screening (SBVS) approaches explore 
information about the target protein structure in order to select 
molecules that are likely to favourably interact and that can be 
further selected for in vitro biological tests. High-performance 
hardware and specialized software, combined with advanced 
knowledge of three-dimensional protein structure and small-
molecule binding modes, have made this technology a useful 
complement, and in some cases a reasonable alternative to HTS.
4,34
 
SBVS typically encompasses a sequence of crucial 
computational steps, including target preparation, chemical 
database selection, docking, scoring, post-docking analysis, ranking, 
visual inspection and priorization of compounds for testing as 
schematically shown in Figure 1.1. The knowledge-based SBVS 
approach is strongly affected by the quantity and quality of the 
information about the systems under investigation. The process of 
selection and preparation of the macromolecular target involves 
essential issues, such as druggability of the target receptor, 
selection of the most relevant geometry, flexibility, assignment of 
                                                        
33
 Schneider, G. Virtual screening: an endless staircase? Nat. Rev. Drug Discov. 2010, 9, 273-
276. 
34
 Guido, R. V. C.; Oliva, G.; Andricopulo, A. D. Virtual screening and its integration with modern 
drug design technologies. Curr. Med. Chem. 2008, 15, 37-46. 
35
 Joseph-McCarthy, D.; Baber, J. C.; Feyfant, E.; Thompson, D. C.; Humblet, C. Lead 
optimization via high-throughput molecular docking. Curr. Opin. Drug Discov. Dev. 2007, 10, 264-
274. 
36
 Lyne, P. D. Structure-based virtual screening: An overview. Drug Discov. Today 2002, 7, 1047-
1055. 
37
 Klebe, G. Virtual Ligand Screening: Strategies, perspectives and limitations. Drug Discov. 
Today 2006, 11, 580-594. 
38
 Ghosh, S.; Nie, A.; An, J.; Huang, Z. Structure-based virtual screening of chemical libraries for 
drug discovery. Curr. Opin. Chem. Biol. 2006, 10, 194-202. 
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charges, protonation and tautomeric states, ionization, and the 
inclusion of conserved water molecules in the binding cavity. Some 
relevant molecular characteristics such as partial charges, 
stereochemistry, ionization and tautomeric states must also be 
correctly assigned to the small molecule compounds.
21,34,36,39 
 
 
 
 
Figure 1.1. Flowchart of the computational steps in Structure-Based VS strategy. 
 
Regardless the source of the small-molecule database, 
screening libraries generally contain a large number of molecules 
                                                        
39
 Klebe, G. Recent developments in Structure-Based Drug design. J. Mol. Mod. 2000, 78, 269-
281. 
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Binding modes, affinity prediction 
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with broad chemical diversity. In the important process of library 
design, several molecular filters can be used to reduce the number 
of compounds to be screened. Common filtering methods are 
variations of Lipinski‘s rule of five that include physicochemical and 
pharmacokinetic parameters in order to guide the selection of 
compounds with lead-like, fragment-like, and drug like properties. 
The chemical space can also be reduced by taking into account 
molecular properties presented by series of modulators with known 
biological activity, or through the identification of specific features 
required for ligand binding. Additional filters are often applied to 
remove specific chemical structures associated with chemical 
instability and toxicity.
36,40,41
 All of these computational (virtual) 
screening filters are useful to improve the quality of small-molecule 
libraries and are crucial to the application of SBVS methods. 
Receptor-based pharmacophore modelling – The term 
pharmacophore has been used in medicinal chemistry for many 
years. The official 1998 IUPAC definition of a pharmacophore is as 
follows: ‗A pharmacophore is the ensemble of steric and electronic 
features that is necessary to ensure the optimal supramolecular 
interactions with a specific biological target structure and to trigger 
(or to block) its biological response‘.
42
  
The most straightforward way to derive a 3D pharmacophore 
from a protein structure is through the direct observation of specific 
interactions between protein and ligand(s). Such a pharmacophore 
can then be used in the usual way, for example, to search a 3D 
database in order to identify compounds for focused screening. 
Database searching methods based on 3D pharmacophores are in 
general much faster than structure-based methods such as docking, 
and so this can be a more effective way to screen very large 
databases. Alternatively, the 3D pharmacophore search can act as 
                                                        
40
 Walters, W. P.; Stahl, M. T.; Murcko, M. A. Virtual screening – An overview. Drug Discov. 
Today 1998, 3, 160-178. 
41
 Walters, W. P.; Namchuk, M. Designing screens: How to make your hits a hit. Nat. Rev. Drug 
Discov. 2003, 2, 259-266. 
42
 Wermuth, C. G.; Ganellin, C. R.; Lindberg, P.; Mitscher, L. A. Glossary of terms used in 
medicinal chemistry (IUPAC recommendations). Pure Appl. Chem. 1998, 70, 1129-1143. 
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the first stage in a docking workflow. A large database can be pre-
screened, using a pharmacophore query, to create a much smaller 
subset for docking. A pharmacophore, if properly constructed, will 
give very few false negatives (false negatives might arise from 
different binding modes or poor feature definition). The scores of 
docked hits may then become more useful.  
Knowledge of the protein structure enables the pharmacophore 
to incorporate more detailed information about regions that are not 
accessible to the ligand. This is most commonly achieved through 
the use of exclusion volumes and/or inclusion regions
.43,44
 When 
used for database searching, such pharmacophore queries have the 
distinct advantage of finding hits that not only contain the key 
binding elements but are also able to fit in to the active site, thereby 
reducing the false positive rate.  
Structure-based 3D pharmacophores derived solely on the 
interactions observed in known protein-ligand complexes may be 
unnecessarily restrictive. An alternative is to define pharmacophores 
based on an analysis of the ‗hot spots‘ in the active site. A number 
of methods can in principle be used to identify such hot spots (or site 
points). These include programs such as GRID
45
 that probe the site 
with small molecules or functional groups and calculate the enthalpy 
of the interaction between the probe and the protein atoms at points 
on a grid lattice to generate a molecular interaction field (MIF). 
These fields can then be contoured by energy to find the most 
favourable regions for an acceptor or a donor (or any other type of 
feature) to interact with the protein. Programs such as LUDI
46
 and 
                                                        
43
 Greenidge, P. A.; Carlsson, B.; Bladh, L.-G.; Gillner, M. Pharmacophores incorporating 
numerous excluded volumes defined by X-ray crystallographic structure in three-dimensional 
database searching: application to the thyroid hormone receptor. J. Med. Chem. 1998, 41, 2503-
2512. 
44
 Tintori, C.; Corradi, V.; Magnani, M.; Manetti, F.; Botta, M. Targets looking for drugs: a multistep 
computational protocol for the development of structure-based pharmacophores and their 
applications for hit discovery. J. Chem. Inf. Model. 2008, 48, 2166-2179. 
45
 Goodford, P. J. A computational-procedure for determining energetically favourable binding-
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SUPERSTAR
47
 use a knowledge-based approach in which rules are 
used to generate a set of interaction sites for each atom or 
functional group of the protein that is capable of participating in a 
non bonded contact. The rules are largely based on statistical 
analysis of experimental structures from the Protein Data Bank or 
small molecule crystal structures and take into account the chemical 
nature of the atoms as well as the orientational preferences of 
features such as hydrogen bond donors/acceptors. From the 
locations of the site points it is then necessary to construct one or 
more 3D pharmacophores. The simplistic approach would be to 
combine all such points into a single pharmacophore, but the 
resulting query would typically be matched (if at all) only by a 
molecule filling the entire active site. Rather, all possible 3D 
pharmacophores (containing three, four, or more features) are 
enumerated from the set of site points. The most important step in 
such a procedure is to triage the set of pharmacophore queries. 
Commercially available programs that can perform the entire 
process from site to pharmacophores include Structure-Based 
Focusing
48
 and LigandScout.
49
 
De novo drug design (DNDD) – DNDD is another interesting 
structure-based methodology. This approach can be described as 
the process of producing novel molecular structures with desired 
pharmacological properties, using the structural information of the 
biological target.
50
 It is a fascinating field, but its use has been 
somehow restricted by some inherent limitations of the technique, in 
particular the inability of computers of assessing accurately the 
chemical feasibility of the proposed structures. For this reason, often 
an extensive user intervention in the design process is required. 
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1.2. Ligand – Based Approaches 
Quantitative Structure – Activity Relationship (QSAR) predictions 
are possibly the most significant example of ligand-based drug 
design. These methods have been applied for decades in the 
development of relationships between physicochemical properties of 
chemical substances and their biological activities to obtain a 
reliable statistical model for prediction of the activities of new 
chemical entities. QSAR, in simple terms, is a method for building 
computational or mathematical models which attempts to find a 
statistically significant correlation between structure and function 
using a chemometric technique. In terms of drug design, structure 
here refers to the properties or descriptors of the molecules, their 
substituents or interaction energy fields, function corresponds to an 
experimental biological/biochemical endpoint like binding affinity, 
activity, toxicity or rate constants, while chemometric method include 
multiple linear regression (MLR),51 partial least squares analysis 
(PLS),52 principal component analysis (PCA),53 principal component 
regression (PCR),54 artificial neural networks (ANN),55 genetic 
analysis (GA),
56
 etc. Various QSAR approaches have been 
developed gradually over a time span of more than a hundred years 
and have served as a valuable predictive tool, particularly in the 
design of pharmaceuticals and agrochemicals. The methods have 
evolved from Hansch (1962) and Free-Wilson‘s one or two-
dimensional linear free-energy relationships (1964), via Cramer‘s 
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three-dimensional QSAR (1988) to Hopfinger‘s fourth
57
 and Vedani‘s 
fifth and sixth-dimensions.
58,59
 Irrespective of the type, all QSAR 
formalisms presume that every molecule included in the study binds 
to the same site of the same target receptor.
60
 
Objectives of QSAR – Mostly all QSAR methods focus on the 
following goals: 
 To quantitatively correlate and recapitulate the relationships 
between trends in chemical structure alterations and 
respective changes in biological endpoint for comprehending 
which chemical properties are most likely determinates for 
their biological activities. 
 To optimize the existing leads so to improve their biological 
activities. 
 To predict the biological activities of untested and sometimes 
yet unavailable compounds.
60
 
Rationale behind QSAR Modelling – The extent of reliability in 
opting for QSAR modelling depends on the nature of property being 
predicted, the stage of the project and the relative ease and cost of 
compound synthesis and subsequent testing. Often QSAR models 
provide useful information but many times they fail, despite of good 
statistics generated from internal data used in training. Regardless 
of all such problems, QSAR becomes a useful alternative because 
of the following reasons: 
 Conventional synthesis methods are expensive and time-
consuming. 
                                                        
57
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Am. Chem. Soc. 1997, 119, 10509-10524. 
58
 Vedani, A.; Dobler, M. 5D-QSAR: The key for simulating induced fit? J. Med. Chem. 2002, 45, 
2139-2149. 
59
 Vedani, A.; Dobler, M.; Lill, M. A. Combining protein modeling and 6D-QSAR — Simulating the 
binding of structurally diverse ligands to the estrogen receptor. J. Med. Chem. 2005, 48, 3700-
3703. 
60
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 Biological assays are often too costly, time and/or sacrifice of 
animals requiring, or compounds in their pure forms. 
 Drug failures due to poor ADMET profiles at later stages of 
development (or even after commercialization) are 
exceedingly expensive and painful. 
 Large number of compounds are available due to 
combinatorial chemistry and HTS approaches, but estimations 
for prioritization of synthesis and screening.
60
 
Classification of QSAR methodologies. Based on 
dimensionality – Frequently, QSAR methods are categorized into 
the following classes, based on the structural representation or by 
the way of derivation of the descriptor values:
60
 
 1D-QSAR, correlating biological activity with global molecular 
properties like pKa, logP etc. 
 2D–QSAR, correlating biological activity with structural 
patterns like connectivity indices, 2D-pharmacophores etc., 
without taking into account the three dimensional 
representations of these properties. 
 3D-QSAR, correlating biological activity with non-covalent 
interaction fields surrounding the molecules. 
 4D-QSAR, additionally including ensemble of ligand 
configurations in 3D-QSAR. 
 5D-QSAR, that explicitly represent different induced-fit models 
in 4D-QSAR. 
 6D-QSAR, further incorporating different solvation models in 
5D-QSAR. 
Based on the type of chemometric method used – Sometimes 
QSAR methods are also classified into following two categories, 
depending upon the type of correlation technique employed to 
establish a relationship between structural properties and biological 
activity: 
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 Linear methods including linear regression (LR),
61
 multiple 
linear regression (MLR),
51
 partial least-squares (PLS),
52
 and 
principal component analysis/regression (PCA/PCR).
53,54
 
 Non-linear methods of artificial neural networks (ANN),
55
 k-
nearest neighbours (kNN),
62
 and Bayesian neural nets.
63
 
Limitations of classical QSAR methodologies – Classical 
QSAR methods are much simpler, faster and more amenable 
automation than 3D-QSAR approaches. They include clearly-
defined physiochemical descriptors and are best suited for the 
analysis of large number of compounds and computational 
screening of molecular databases. Though they have been used for 
decades to correlate and predict the activity of molecules, they 
suffer from serious limitations in certain situations some of which are 
as follows:
64
 
 Only 2D – structures are considered. 
 Unavailability of appropriate physiochemical parameters (e.g., 
numerical descriptors for new or unusual substituents), 
rendering the compound unfit for inclusion in QSAR analysis. 
 Insufficient parameters for describing drug-receptor 
interactions (e.g., steric parameter Es, Hammett constant σ, 
etc.). 
 Confined to only few substitutions in a common reference 
structure (simple variation of aromatic substituents) and works 
best with a congeneric series. 
 No representations of stereochemistry or 3D-structure of 
molecules, regardless of their availability. 
 Provide no unique solutions. 
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 Higher risk of chance correlations. 
 High risk of failure due to ‗too far outside‘ predictions. 
 No graphical output thereby making the interpretation of 
results in familiar chemical terms, frequently difficult if not 
impossible. 
 Requires considerable knowledge of substituent constants in 
physical organic chemistry to design a molecule, since 
classical QSAR equation do not directly suggest new 
compounds to synthesize. 
Progress in 3D-QSAR approaches 3D-QSAR is a broad term 
encompassing all those methods which correlate macroscopic target 
properties with computed atom-based descriptors derived from the 
spatial (three-dimensional) representation of the molecular 
structures.
65,66,67
 The methodology has emerged as a natural 
extension to the classical QSAR approaches pioneered by Hansch 
and Free-Wilson. The most frequently applied methods include 
comparative molecular field analysis (CoMFA),
68
 comparative 
molecular similarity indices analysis (CoMSIA)
69
 and the 
GRID/GOLPE program (generating optimal linear PLS 
estimations).
70,71 
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The primary aim of 3D-QSAR methods is to understand 
structure–activity relationships and to employ this knowledge in 
order to propose novel compounds with enhanced activity and 
selectivity profile for a specific therapeutic target. 3D-QSAR 
methods, are nowadays used widely in drug design, since they are 
computationally not demanding and afford fast generation of QSARs 
from which the biological activity of newly synthesized molecules 
can be predicted. The basic assumption in 3D-QSAR is that a 
suitable sampling of the molecular interaction fields around a set of 
aligned molecules might provide all the information necessary for 
understanding their biological activities.
72
 The suitable sampling is 
achieved by calculating interaction energies between each molecule 
and an appropriate probe at regularly spaced grid points 
surrounding the molecules. The resulting energies derived from 
simple potential functions can then be contoured to give a 
quantitative spatial description of molecular properties. If correlated 
with biological activity, 3D-fields can be generated, which describe 
the contribution of a region of interest surrounding the ligands to the 
target properties. However there is one main difficulty in the 
application of 3D-QSAR methods: for a correct model, a spatial 
orientation of the ligands towards one another has to be found, 
which is representative for the relative differences in the binding 
geometry at the protein binding site. The success of a molecular 
field analysis is therefore determined by the quality of the choice of 
the ligand superimposition.
73,74,75,76 
In most cases, the first step in a 
3D-QSAR study is the generation of a reliable pharmacophore 
model. Many alignment strategies have been reported and 
compared for this purpose (a detailed comparison of different 
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methods can be found in Holtje et al. work).
77
 Depending on the 
molecular flexibility and the structural diversity of the investigated 
compounds this task of unique pharmacophore generation becomes 
less feasible. Despite the difficulties concerning the molecular 
alignment many successful 3D-QSAR studies applying the 3D-
QSAR approaches have been reported in the last few years.
78,79,80,81 
A major factor for the ongoing enthusiasm for CoMFA-related 
approaches comes from the proven ability of several of these 
methods to correctly estimate the biological activity of novel 
compounds. However, very often the predictive ability of QSAR 
models is only tested in retrospective studies rather than taking the 
ability to design and develop novel bioactive molecules. Despite the 
known limitations of 3D-QSAR, the possibility to predict biological 
data is gaining respect as scientists realize that we are far away 
from the hoped-for fast and accurate forecast of affinity from (the 
structure of a) protein–ligand complexes by free-energy perturbation 
or empirical scoring methods.
21,82,83 
Assumptions in 3D-QSAR methods 
 There is an underlying relationship between molecular 
structure and biological activity. 
 Receptor binding is directly proportional to the biological 
activity. Differential effects on second messengers or other 
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signalling steps which transpire between receptor binding 
and experimentally observed response, are not taken into 
consideration. 
 Molecular structure can be measured and represented with a 
set of numbers usually called descriptors, which encode all 
physical, chemical and biological properties of the molecule. 
 Molecules with common or related structures generally have 
similar physicochemical properties (the similarity principle), 
and thus have similar binding modes and consequently 
comparable biological activities. The reverse also holds true. 
Similiarly, molecules located in the same region of the 
descriptor space present similar activity (the neighbourhood 
principle). 
 Structural properties which lead to an observed biological 
response are most commonly determined by the non-
bonding forces, mainly steric and electrostatic. 
 The observed biological effect is produced by the modelled 
ligand itself, and not by its metabolite or degradation 
product. 
 The lowest energy conformation of the ligand is its bioactive 
conformation, and it is this single conformation of the ligand 
which exerts the binding effects. 
 With few exceptions, the geometry of the receptor binding 
site is considered rigid. 
 The loss of translational and rotational degrees of freedom 
(entropy) upon binding is believed to follow a similar pattern 
for all the molecules. 
 Total number of rotatable bonds is the only method most 
frequently used to estimate the entropic cost for freezing 
non-terminal single-bond rotors. 
 For all modelled ligands, the protein binding site is assumed 
to be same. 
 For all the modelled compounds, the on-off rate is supposed 
to be similar i.e., the system is considered to be in 
equilibrium, and kinetic aspects are usually ignored. 
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 Some of the major factors like desolvation energetic, 
temperature, diffusion, transport, pH, salt concentration etc. 
Which contribute to the overall free energy of binding are 
difficult to handle, and thus usually ignored. 
 In molecular mechanics based 3D-QSAR methods, free 
energy of binding is largely explained by the enthalpic 
component (i.e., the internal energy), which is prone to the 
inherent force field errors. 
 Resulting QSAR model may represent one of potentially 
several solutions to the property-activity correlation problem. 
Several parameters which significantly control the overall 
performance of a developed 3D-QSAR model are: 
1. Biological data – The popular ‗GIGO‘ (garbage in 
garbage out) principle applies in every computational 
technique. In 3D-QSAR also, one should utilize accurate 
activity data in order to develop a good model. Though 3D-
QSAR methods can be applied to heterogeneous data sets, 
some considerations for maintaining the accuracy of biological 
data are necessary.
67,84
 
1a. Compounds should belong to a congeneric series. 
1b. Compounds should have the same mechanism of 
action and same/comparable binding mode. 
1c.  The biological activities of compounds should 
correlate to their binding affinity and their 
enumerated biological responses should be 
measurable. 
1d. Biological data for molecules should be obtained 
using uniform protocols (radioligand, activator, 
cofactor, pH, buffer etc.) and preferably from a 
single source (organism/tissue/cell/protein) and 
single lab. 
1e.  Activity data for all the compounds should be in 
same units of measurement (binding/functional/ 
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IC50/Ki). Ki value is preferred instead of the IC50 data, 
since it is independent of the substrate 
concentration. 
1f. The ranges of bioactivity covered should be as large 
as possible, keeping the mode of action identical. 
Preferably, activity range should be much larger 
than the standard deviations of the data; more than 
3 log units with an even spread of data is preferred. 
1g. If possible, biological data should be symmetrically 
distributed around their mean, and their precision 
should be evenly distributed over its range of 
variation. If not, such skewness can be removed by 
log transforming the data and expressing it as log 
(1/C), where C refers to the molar concentration of 
drug producing a standard response. It is 
noteworthy that free energy change is proportional 
to the inverse log of concentration of the compound. 
2. Compounds selection and series optimization – One of 
the major applications of QSAR is to optimize the existing 
leads by structural modifications so as to improve their activity 
and reduce/eliminate side effects. However, there are many 
issues to be taken care of while selecting substituents for the 
modification of compounds; some of the most important ones 
are given below:66
,
84 
2a. The compounds/substituents selected should be 
convincingly different from the existing ones, so as to 
minimize collinearity among the variables. 
2b.  The chosen compounds/substituents should have the 
properties which behave independent of each other, 
thereby maximizing dissimilarity and orthogonality. 
2c.  The selection should be done in such a manner so as 
to map the substituent (descriptor) space with 
minimum number of compounds. 
2d.  Synthetic accessibility/feasibility of the selected 
compounds should also be taken into consideration. 
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3. Optimization of the 3D-structure of the molecules – An 
important issue in 3D-QSAR is how to generate and represent 
molecular structure for analysis. The problem can be resolved 
both by experimental as well as computational techniques.84 
A large number of well-resolved experimentally crystal 
structures are available in databases like Cambridge 
Structural Database
85
 and Protein Data Bank.
86
 The crystal 
structures offer the advantage that some conformational 
information about the flexible molecule is included. However, 
molecular modelling methods are particularly useful for 
compounds that have not been made or cannot even exists 
under normal conditions. Computationally the 3D structures 
can be generated by three methods: (i) manually by sketching 
the structures interactively in a 3D-computer graphics 
interface, (ii) numerically by using mathematical techniques 
like distance geometry, quantum or molecular mechanics, and 
(iii) by automatic methods that are often used for building 3D-
structure databases. 
After the generation of the starting 3D-molecular structures, their 
geometries are refined by minimizing their conformational energies 
using theoretical calculation methods. Commonly used structure 
optimization techniques include: 
 Molecular Mechanics methods which usually does not 
explicitly consider the electronic motion, and thus are fast, 
reasonably accurate and can be used for very large 
molecules like enzymes. 
 Quantum Mechanics or ab initio methods which takes into 
account the 3D distribution of electrons around the nuclei, and 
therefore are extremely accurate but time consuming, 
computationally intensive and cannot handle large molecules. 
 Semi-empirical methods which are basically quantum 
mechanical in nature but employs an extensive use of 
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approximation as in molecular mechanics. Generally, the 
molecular geometry is optimized by molecular mechanics 
methods, and its atomic charges are calculated mostly by 
semi-empirical or ab initio methods. 
4. Conformational analysis of molecules – It is a well 
recognized fact that each compound containing one or more 
single bonds is existing at each moment in many different so-
called rotamers or conformers. Although small molecules may 
have only a single lowest energy conformation, large and 
flexible molecules exist in multiple conformations at 
physiological conditions. Therefore, it becomes necessary to 
include various such conformations in a 3D-QSAR study.
84
 
Depending upon the type of molecules in the study, any of the 
following conformational search can be adopted: 
4a.   Systematic search (or grid search) method which 
generates all possible conformations, by 
systematically varying each of the torsion angles of a 
molecule by some increment, keeping the bond 
lengths and bond angles fixed. 
4b.  Random search method which generates a set of 
conformations by repetitively and randomly changing 
either the Cartesian (x, y, z) or the internal (bond 
lengths, bond angles and torsion/dihedral angles) 
coordinates of a starting geometry of the molecule 
under consideration. 
4c.  Monte Carlo method which simulates dynamic 
behaviour of a molecule and generates the 
conformations by making random changes in its 
structure, calculating and comparing its energy with 
that of the previous conformation and accepting it if it 
is unique. 
4d.  Molecular dynamics method which employs the 
Newton‘s second law of motion (force = mass x 
acceleration) to simulate the time-dependent 
movements and conformational changes in a 
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molecular system, and results in a so-called trajectory 
showing how the positions and velocities of atoms of 
atoms in the molecular system vary with time. 
4e.  Simulated annealing which heats up the molecular 
system under consideration to high temperature to 
overcome huge barriers, and after equilibrating there 
for some time using molecular dynamics, cools down 
the system slowly and gradually to obtain the low 
energy conformations according to the Boltzmann 
distribution. 
4f.  Distance geometry algorithm which generates a 
random set of coordinates by selecting random 
distances within each pair of upper and lower bounds 
to form constraints in a distance matrix, which are then 
used to generate energetically feasible conformations 
of a set of molecules. 
4g.  Genetic and evolutionary algorithms which are based 
on the concept of biological evolution and works by 
first creating a population of possible solutions to the 
problem. The solutions with best fitness scores 
crossovers and mutations over a time, and propagate 
their good characteristics down the generation to 
result in better solutions in the form of new 
conformers. 
5. Alignment of molecules – One of the most crucial problems 
in most of the alignment-based 3D-QSAR methods is that 
their results are highly sensitive to the manner in which the 
bioactive conformations of all molecules are superimposed 
over each other.
66,84
 In cases where all the molecules in a 
data set have a common rigid core structure, molecules can 
be aligned easily using least-square fitting procedure. 
However, in case of structural heterogeneity in the dataset, 
alignment of highly flexible molecules becomes quite difficult 
and time consuming. Several approaches have been 
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proposed to superimpose the molecules as accurately as 
possible, some of which are the following: 
5a.  Atom overlapping based superimposition: This 
method involves corresponding atom by atom pairing 
between molecules. It is also called the 
pharmacophore approach and is the most popular 
method since it gives the best matching of the 
preselected atom positions.  
5b. Binding sites based superimposition: In this method, 
molecular alignment is obtained by superimposing the 
receptor active sites or the receptor residues that 
interact with the ligands.  
5c. Fields/pseudofields based superimpositions: This 
method performs superimposition by comparing the 
similarities in the calculated interaction energy fields 
between the molecules.  
5d. Pharmacophore based superimpositions: This method 
uses a hypothetical pharmacophore as a useful 
common target template. Each molecule is 
conformationally directed to assume the shape 
obligatory for its sub-molecular features to match with 
either a known pharmacophore or the one which is 
generated during the conformational analysis. 
5e. Multiple conformers based superimposition: This 
method is particularly useful in cases where the 
ligands may bind to a receptor in multiple ways, or 
when the correct binding mode is unknown and the 
ligands have a fair degree of freedom of 
conformational flexibility. 
Molecular Interaction Fields – Molecular interaction fields 
(MIFs) can be calculated for any molecule of known three-
dimensional (3D) structure. A MIF describes the spatial variation of 
the interaction energy between a molecular target and a chosen 
probe. The target may be a macromolecule or a low molecular 
weight compound or a molecular complex. The probe may be a 
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molecule or a fragment of a molecule. MIFs can be applied in many 
ways.87 They can guide the process of structure-based ligand 
design, may be used to dock ligands to macromolecules88
,89 and are 
also frequently used to derive quantitative structure–activity 
relationships (QSARs) for low molecular weight compounds.
68 
Additionally, MIFs can be used to study the structure–activity 
relationships of macromolecules.90
,91 MIFs can also be applied to the 
prediction of pharmacokinetic properties, such as in the VolSurf 
methodology.92 
In this work, MIFs will be described primarily with reference to 
their calculation with the GRID program. 93
,94 Other programs may be 
used to compute MIFs; these have different energy functions and 
parametrizations. 
Calculation of MIFs – The target. The starting point for a MIF 
calculation is provided by the atomic coordinates of the target 
molecule. These may have been determined experimentally or 
theoretically. In many calculations of MIFs, the target is treated as a 
rigid structure. However, in applications, it is often important to treat 
target flexibility, at least partially. There are several strategies for 
doing this: 
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 Compute MIFs for multiple conformations of the target; the 
conformations may come from an NMR ensemble or from 
conformational searches or molecular dynamics simulations. 
 Permit adaptation of the position of some atoms in the target to 
optimize the interaction energy of the probe during calculation 
of the MIFs. In the GRID program, this is routinely done for 
rotatable hydrogen atoms. It is also possible for the user to do 
calculations with specified side chains containing several non 
hydrogen atoms treated as movable in response to the probe 
position.  
The target is also usually considered to have a single titration state 
and to be unaffected by the position of the probe. However, the 
GRID program does allow for probe-induced switching between 
histidine tautomers. 
The target may consist of a single molecule or a complex of 
molecules or molecules and ions, such as e.g. for metalloproteins. 
Well ordered water molecules may also be considered part of the 
target. GRID also permits the possibility for a water-bridged target–
probe interaction to be considered without a priori defining the 
position of the water molecule. The remaining solvent molecules are 
treated as a continuum that modulates the interaction energy 
between probe and target and may also have an entropic effect on 
the probe–target interaction. 
The probe – MIFs are computed for positions of the probe at 
points on a rectilinear grid superimposed on the target. It is this grid 
that gives the GRID program its name. Grids of target–probe 
interaction energy values can be read into many molecular graphics 
programs which can display the MIFs as isoenergy contours or 
project the energies onto molecular surfaces. The probe is placed at 
each grid point in turn to compute a MIF. At its simplest, the probe is 
a unit positive charge representing a proton; in this case the MIF is 
the molecular electrostatic potential (MEP). Most probes are 
spheres parametrized to represent a specific atom or ion type. 
Hydrogen atoms are usually treated implicitly. For example, a 
carbonyl carbon atom and a methyl CH3 group are both treated as 
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spherical probes but the methyl probe has a larger radius because 
of the hydrogen atoms bonded to the carbon atom. Polar hydrogen 
atoms that can make hydrogen bonds can also be treated implicitly 
but the directional character of their hydrogen bonds must also be 
modelled. Nonspherical probes containing more than one non-
hydrogen atom may also be used. In this case, the relation between 
the probe position and orientation and the grid point is not 
completely symmetric and has to be defined. In the GRID 
programme, a carboxylate group, for example, is treated as a 3-
point probe with one of the oxygen atoms centred on the grid point. 
At each grid point, the probe is rotated around the grid point oxygen 
to energetically optimize its orientation.  
The Interaction Function – Above, MIFs have been described 
as fields of probe–target interaction energies. The MIFs thus provide 
information on where the favourable and the unfavourable locations 
for the probe around the target are. The probe–target interaction 
function is typically an empirical molecular mechanics energy 
function. Its functional form is chosen to represent the underlying 
physical interactions and the function is parametrized against 
experimental observations. The energy function may contain explicit 
entropic terms or be parametrized such that it represents an 
interaction free energy rather than just an interaction energy. More 
recently, functions, sometimes referred to as potentials of mean 
force or knowledge-based functions, derived from statistical analysis 
of molecular structures have been derived to map out favourable 
and unfavourable locations for a probe with respect to a target 
molecule These functions, unlike an energy function, are not 
required to take a physically meaningful form. Given enough 
experimental data, they may reproduce experimental observations 
better than empirical energy functions but this can be at the 
disadvantage of a lack of analytical differentiability and of a 
transparent physical interpretation. They are most often used as 
scoring functions for ligand docking but some can be used to 
compute MIFs. The empirical energy functions used to compute 
CHAPTER 1  COMPUTATIONAL APPROACHES 
  
39 
 
MIFs can consist of the sum  of one or more terms. In the GRID 
program, the energy function is given by the following terms: 
E = EVDW + EEL + EHB + S 
where EVDW is the van der Waals energy, EEL is the electrostatic 
energy, EHB is the hydrogen-bond energy and S is an entropy 
term.95
 
 
Data pretreatment and scaling – Usually in 3D-QSAR, before 
proceeding with the chemometric analysis, a pretreatment of the raw 
data is necessary in order to minimize redundancy.84 One of the 
common reduction methods is based on the standard deviation cut-
off, in which all the energy columns with a low standard deviation 
are eliminated from the data since they require longer computing 
time without contributing significantly to the results. Moreover, 
several variable selection methods are available and they can be 
used to reduce collinearity among the descriptors in order to prevent 
data over-fitting and to improve the prediction performance of the 
model.  
After the pretreatment, the data is subjected to a scaling 
procedure which assigns equal weight to all the descriptors and 
places them on a common platform for a meaningful statistical 
analysis. Scaling significantly improves the signal to noise ratio and 
allows ranking of the individual variables based on their relative 
importance. Different scaling techniques are available and can be 
effectively used in 3D-QSAR approaches as for example:  
Autoscaling, a method that scales the variables to a mean of 
zero and assigns them a unity variance (unit standard deviation) by 
dividing each column with its standard deviation; 
Block-scaling, which provides each category of variables with the 
same weight by dividing initial autoscaled weights of descriptors in 
one class by the square root of the number of descriptors in that 
class; 
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Block-adjusted scaling, which is particularly useful when other 
variables are included along with the energy values in the analysis. 
This scaling gives other variables a comparable weight to the total 
variables. 
Sometimes the pretreated data is subjected to centering by 
subtracting the column means from all the data. This does not 
change any coefficient values or comparative weights of the 
descriptors, but the number of significant components deriving from 
PLS may be smaller (one unit) than the number of significant 
components obtained from the data without centering. The method 
is supposed to improve the ease of interpretation and numerical 
stability. 
Model Generation and Validation – After pretreatment and 
scaling, the molecular descriptors are then correlated to the 
biological activities of the molecules, assuming a liner relationship 
between them.
84,96
 Since the number of independent (x) variables is 
much greater than the number of the compounds in the data set, the 
traditional linear regression analysis cannot be used to perform the 
fitting process. Therefore, to extract a stable and robust 3D-QSAR 
model from a range of possible solutions, the Partial Least Squares 
(PLS) technique is used.52 PLS is an iterative regression procedure 
that produces its solutions based on linear transformation of a large 
number of original descriptors to a small number of new orthogonal 
terms called latent variables. PLS gives a statistically robust solution 
even when the independent variables are highly interrelated among 
themselves, or when the independent variables exceed the number 
of observations. Thus, PLS is able to analyze complex structure-
activity data in a more realistic way, and effectively interpret the 
influence of molecular structure on biological activity. This is one of 
the standard statistical methods used for development of predictive 
3D-QSAR models. Other methods to model linear relationships 
include MLR, PCA, PCR, etc.  
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In spite of using PLS, spurious results can still occur due to the 
noise hidden in the obtained matrix. The GOLPE (which stands for 
generating optimal linear PLS estimation) approach was developed 
to identify which variables are meaningful for the prediction of the 
biological activity and to remove those with no predictivity.70
,71 Within 
this approach, fractional factorial design (FFD) is initially applied to 
test multiple combinations of variables.71 For each combination, a 
PLS model is generated and only variables which significantly 
increase the predictivity are considered. Variables are then 
classified considering their contribution to predictivity. A further 
advance in GOLPE is the implementation of the smart region 
definition (SRD) procedure.
97
 This is aimed at selecting the cluster of 
variables, rather than the single variable mainly responsible for 
activity. The SRD technique seems less prone to change correlation 
than any single variable selection, and improves the interpretability 
of the models.79 
The most important criterion for judging the quality of a QSAR 
model is its ability to accurately predict not only the activities of the 
training set molecules (internal prediction), but also the activity of 
molecules that have been not included in the development of the 
statistical model (external prediction).
96
 Various approaches used for 
this purpose are described: 
 The correlation coefficient r, is a measure of the degree of 
linearity of the relationship. It signifies the quality of the 
models fitting and quantifies the variance in the data.
98
 In an 
ideal situation the correlation coefficient must be equal to or 
approach 1, but actually due to the complexity of biological 
data, any value above 0.9 is appreciable. Correlation 
coefficients for the variables in a data set are compiled in a 
correlation matrix, which shows the relationship of one 
descriptor to another. The correlation matrix ensures that 
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variables or significance are orthogonal to each other. The 
addition of every new variable to the model always 
increases the value of r, unless the new variable is a 
constant of a linear combination of other variables, which 
would not produce any effect. The increase in r caused by 
adding new variables signifies over-fitting of the data. 
 The coefficient of multiple determinations also called 
Pearson correlation coefficient r
2
, is the squared correlation 
coefficient which informs about how well the model 
reproduces the experimental data.98 It is a quantitative 
measure of the precision of adjustment for the fitted values 
and the observed ones. The closer it approaches to the 
unity, the bigger is the similarity of the adjusted values to the 
experimental ones, suggesting that the model fits the data 
unerringly. However, an r
2
 close to 1 does not mean that the 
model is perfect; the addition of any new descriptor to the 
model induces an ever-increasing of r
2
, even if the newly 
added descriptor does not contribute to the model. Thus, 
other measures are required to determine precisely the 
predictive capability of the model. 
Cross–validation (CV) is one of the most extensively employed 
methods for the internal validation of a statistical model.
99
 In cross – 
validation, the predictive ability of a model is estimated using a 
reduced data set of structural data. Usually, one element of the set 
is extracted each time, and a new model is derived based on the 
reduced data set, which is then employed to predict the activity of 
the excluded molecule. The procedure is repeated n number times 
until all compounds have been excluded and predicted once. This is 
the so called leave-one-out (LOO) method. Analogously, leaving out 
more than one molecule of the data set at a time is termed as leave-
n-out or leave-many-out CV method.
96
 The outcome of LOO 
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procedure is  cross-validated correlation coefficient (r
2
cv or q
2
) which 
is a criterion of both robustness and predictive ability of the model: 
r
2
cv = (PRESS0 – PRESS) / PRESS0) 
where PRESS0 is the mean of the observed biological activity 
PRESS is the sum of the squares of the differences between the 
predicted and the observed activity values.
100
 Many researchers 
consider high q
2
 as the ultimate proof of high predictive power of the 
QSAR model which is generally considered as incorrect. Q
2
 value 
should be regarded as a measure of internal consistency of the 
derived model rather than as a true indicator of the predictability. It 
should be noted that, since it is easier to fit the experimental data 
than to predict them from the QSAR model, r
2
 of the model is always 
higher than q
2
. Cross – validation is not foolproof. In highly redundant 
data sets with fewer degrees of freedom, it can give an over-
optimistic result. It may also improperly indicate a lack of correlation if 
all the compounds in the data set are unique. Therefore, we can 
conclude that despite its wide acceptance, a high value of q
2
 alone is 
an insufficient criterion for a QSAR model to be highly predictive. 
Predictive ability of the model can also be evaluated by 
forecasting the activity of an external test set of molecules using the 
models derived from the training set. Predictive correlation 
coefficient (r
2
pred), which is analogous to cross-validated r
2
 (or q
2
) is 
a measure of the predictive ability of the derived QSAR model and is 
calculated by the following formula:
101
 
r
2
pred = (SD –PRESS) / SD 
where SD is the sum of squared deviations between the biological 
activities of the test set molecules and the mean activity of the 
training set molecules, while PRESS is the sum of squared 
deviations between the observed and the predicted activities of the 
test set molecules. 
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The Fischer statistic (F value) parameter is one of the several 
variance-related parameters that can be used as a measure of the 
level of statistical significance of the regression model.
102
 A higher F 
value implies that a more significant correlation has been reached. It 
is used as a criterion to determine whether a more complex model is 
significantly better than a less complex one. 
Display of results – One of the biggest advantages of 3D-QSAR 
over classical QSAR is the graphical interpretability of the statistical 
results. Equation coefficients can be visualized in the region around 
the ligands. Upon visual inspection, regions of space contributing 
most to the activity can be easily recognized. The interpretation of 
the graphical results allows one both to check the reliability of the 
models easily and to design modified compounds with improved 
activity or selectivity. In this respect 3D-QSAR methods like CoMFA 
and GRID/GOLPE have proven to be very useful.72 
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2. ANTIVIRAL STRATEGIES: AN OVERVIEW 
The study of viruses has historically provided and continues to 
provide the basis for much of our most fundamental understanding 
of modern biology, genetics, and medicine. Virology has had an 
impact on the study of biological macromolecules, processes of 
cellular gene expression, mechanisms for generating genetic 
diversity, processes involved in the control of cell growth and 
development as well as in the study of several aspects of molecular 
evolution. 
In essence, viruses are collections of genetic information directed 
toward one aim: their own replication. They are the ultimate and 
prototypical example of ‗selfish genes‘. The viral genome contains 
the ‗blueprints‘ for virus replication enciphered in the genetic code, 
and must be decoded by the molecular machinery of the cell that it 
infects to gain the objective. Viruses are, thus, obligate intracellular 
parasites dependent on the metabolic and genetic functions of living 
cells. This defining feature has a number of consequences for the 
development and application of antiviral drugs. The intracellular 
replication and the appropriation of cellular pathways for purposes of 
the pathogen makes it difficult to define virus-specific targets for 
therapeutic intervention, and inhibition strategies have to be highly 
specific to prevent cell toxicity. Furthermore, because of the viral 
dependence on suitable host cells and the fact that the pathogen is 
too small to be visible by light microscopy, complex systems are 
required for the propagation of viruses in the laboratory, the 
detection of virus replication, and the testing of potential inhibitors.  
2.1. Principles of Viral Replication and Its Inhibition 
Compared to bacteria and eukaryotic parasites, viruses are very 
simple pathogens. They have been described as ‗a piece of bad 
news, wrapped in protein‘ – genomes encased by a protective shell 
composed of protein(s) and, in the case of enveloped viruses, of 
lipids. In contrast to mammalian cells or bacterial, fungal, or parasitic 
pathogens, viruses as a group do not share the same tupe of 
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genome or the principle of its replication. Viral genomes can consist 
of single- or double-stranded DNA or RNA, and viruses have been 
classified according to the type of genome and the genome 
replication strategy used (Fig. 2.1). 
 
 
Figure 2.1. Classification of  viruses by their genome replication strategy according 
to Baltimore. Examples for important human pathogens falling into the respective 
class are listed above. Black: DNA, gray: RNA; arrows to the right: (+) strand 
polarity (i.e., corresponding to mRNA); arrows to the left; (-)strands; asterisk: 
enveloped viruses. 
 
Furthermore, they can be naked (i.e., containing only a protein shell) 
or enveloped by a lipid membrane that surrounds the protein shell 
and is derived from a host cell membrane.  
Important human pathogens can be found in many different virus 
families. This has implications for antiviral intervention. While 
double-stranded DNA viruses largely use cellular pathways for 
genome replication, RNA viruses, or viruses replicating in the 
cytoplasm, have to provide own enzymes to mediate their virus-
specific replication strategies. These enzymes represent targets for 
specific inhibition. 
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Although the details of the replication mechanism differ 
significantly between viruses, all viruses undergo the general 
replication steps outlined in Figure 2.2. First, the virion (defined as  
 
 
Figure 2.2. Basic steps of viral replication: (a) binding, (b) entry, (c) genome 
replication, (d) gene expression, (e) assembly, and (f) release. 
 
the infectious viral particle) attaches to its host cell. Recognition of 
the appropriate target cell and binding is mediated by viral surface or 
envelope proteins interacting with one or more cellular membrane 
protein(s) and/or other attachment factor or plasma membrane (e.g., 
heparan sulfate proteoglycans, sialic acid). Subsequently, virus 
enter the cell either by uptake through a variety of endocytic 
pathways or directly at the plasma membrane. The following 
uncoating step, that is, the release of the viral genome from its 
protective proteinaceous shell, is currently poorly understood for 
most viruses. The subsequent replication of the viral genome occurs 
by different mechanisms for different viruses, depending on the type 
of the viral genome and the site of virus replication within the cell. 
Transcription, post-transcriptional modification of viral mRNA, and its 
translation are in most cases carried out by cellular machineries, but 
CHAPTER 2 BIOLOGICAL ISSUES 
  
50 
 
these may be modifies by virus-encoded factors. Newly generated 
viral proteins and genomes are transported through cellular 
pathways to specific assembly sites within the host cell (e.g., the 
plasma membrane or intracellular virus factories), where they form 
progeny particles. Release of these particles can occur by cell lysis 
as observed for most naked viruses, or, in the case of enveloped 
viruses, by budding from a cellular membrane, leading to the 
acquisition of a lipid envelope. 
In principle, each of these steps can be considered a target for 
antiviral intervention. Thus, inhibition of virus replication could be 
either accomplished by interfering with the specific virus-receptor 
interaction at the plasma membrane or the viral entry process, or by 
blocking viral enzymes involved in the genome replication or 
proteolytic maturation, or by affecting virus release. Targeting steps 
that rely mostly on cellular factors (transcription, translation, 
transport of viral components) is conceptually more difficult, while 
cellular factors or cellular machineries could present attractive 
targets due to their genetic stability if inhibited without major toxic 
effects. Specific interference with host cell factors or cellular 
machineries usurped by viruses may be achievable, provided that 
detailed knowledge on how the particular virus uses these pathways 
and on the viral and cellular factors involved is available. In addition 
to the direct interference with viral functions and factors, antiviral 
treatment can also involve immunomodulatory strategies. 
2.2. Development of Antivirals 
Several principles, requiring different levels of knowledge and 
methodology, can be applied to the identification of antiviral 
substances. First, a compound already in use as a therapeutic or 
known to inhibit another pathogen could be fortuitously discovered 
to inhibit the replication of a pathogenic virus. This principle is 
exemplified by the nucleoside analogs used as inhibitors of viral 
polymerases (see later) are related to antiproliferative drugs 
targeting cellular polymerases in highly replicating tumor cells. 
However, fortuitous discovery does obviously not represent an ideal 
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strategy for development of specific and affective drugs. In a more 
systematic approach, inhibitory compounds can be identified by 
random screening. For this purpose, a number of compound 
libraries compiled according to different principles are available from 
commercial and non-commercial sources. Random testing for 
inhibition of the replication of a given virus in tissue culture is rather 
unbiased towards specific inhibitory mechanisms and yields some 
preselection for compounds that do not display significant 
cytotoxicity and can be taken up into the cell. However, although 
tissue culture of many types of mammalian cells has become a 
routine method, screening in this setting is relatively expensive, time 
consuming, and not easily automated. Furthermore, not all viruses 
can be easily propagated in tissue culture: in the case of the 
important human pathogens hepatitis C virus (HCV) and hepatitis B 
virus (HBV), significant progress towards a routine tissue culture 
system has been accomplished only within last years, and only very 
recently have the systems been developed to allow medium to high 
throughput screening approaches. 
Alternatively, a system for high-throughput random screening of 
antivirals can be set up by defining a specific viral target and 
establishing an in vitro assay appropriate to measure the function of 
this viral factor in the presence or absence of an inhibitors. Virus-
encoded enzymes are particularly well suited targets for this 
approach, because in this case one can build on long-standing 
expertise from similar approaches in other areas of drug 
development, for example, metabolic diseases. However, in vitro 
systems mimicking non-enzyme mediated steps in virus replication, 
for example, virus assembly or protein-protein interactions between 
viral and cellular factors, are also being developed. Both types of 
random screening from compound libraries are not likely to identify a 
drug suited for treatment in the first round, but rather yield lead 
compounds that have to be validated by alternative assay 
procedures and subsequently improved in potency and 
pharmacological properties by iterative cycles of chemical 
modification and testing. 
CHAPTER 2 BIOLOGICAL ISSUES 
  
52 
 
A fundamentally different approach is the procedure of rational 
drug design. Starting from detailed information on the molecular 
structure and function of a specific viral target, substances expected 
to bind to this target and to interfere with its function are identified by 
computer-aided drug design and subsequently synthesized and 
tested for inhibitory action. Again, suitable assay procedures to test 
for the inhibitory potential of in silico defined lead compounds have 
to be developed and the properties of the substance have to be 
improved by an iterative procedure. The application of in-silico 
technologies to antiviral research has already lead to the design of 
several compounds approved by the FDA and now used in clinical 
therapy.
103
 Indeed, one of the earliest successes of these 
techniques is represented by the discovery of Zanamivir.
104
 Palese 
at al. postulated that the sialidase enzyme was fundamental for 
influenza virus pathogenesis in man, although the first inhibitors of 
that enzyme failed to demonstrate their efficacy as anti-flu agents.
105
 
Only after the determination of the 3D structure of sialidase
105,106,107
 
the opportunity arose to design new selective inhibitors by structure-
based approaches. Despite the initial limited commercial success of 
Zanamivir, the computer aided drug design strategies employed in 
its development were important first-steps in the development of 
further sialidase inhibitors. 
Nowadays, many antiviral drug discovery programs include a 
molecular modelling component. The present work summarizes 
efforts made for the study and the development of new 
computational methodologies with the aim to discover new hits 
active versus hepatitis C virus (HCV). 
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3. HEPATITIS C VIRUS 
Hepatitis C virus (HCV), the agent responsible for most cases of 
blood-borne hepatitis, was discovered by Choo et al. 20 years 
ago.
108
 HCV is the leading cause of chronic liver disease worldwide. 
It is estimated that about 170 million people are chronically infected 
with HCV, and HCV accounts for approximately 20% of cases of 
acute hepatitis and 70% of cases of chronic hepatitis.
109
 Chronic 
hepatitis C is a major cause of cirrhosis and hepatocellular 
carcinoma. Moreover, HCV-related end-stage liver disease is, in 
many countries, the first cause of liver transplantation. 
The mechanisms responsible for the persistence of viral infection 
and for the liver lesions are not well understood. Despite an active 
immune response of the host, HCV has the capability to escape. It is 
believed that the quasispecies nature of HCV is one of the major 
mechanisms allowing the virus to cause chronic infection. HCV is 
not directly cytopathic and liver lesions are mainly related to immune 
mediated mechanisms. Co-factors influencing the outcome of the 
disease, including age, gender and alcohol consumption, are poorly 
understood and other factors, e.g., immunologic and genetic, may 
play an important role. 
Since the first study by Hoofnagle et al. in 1986,
110
 many 
controlled trials have shown the efficacy of alpha interferon in 
patients with chronic hepatitis C with a sustained response in a 
minority of patients. Earlier studies have shown that the efficacy of 
treatment was significantly improved by the combination of 
interferon and ribavirin, which is nowadays the preferred treatment. 
Predictors of sustained response to therapy, mainly viral load and 
genotype, have been identified. Despite this remarkable progress 
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and the forthcoming use of improved forms of ribavirin,
111 
 it is 
unlikely that current treatment will succeed in curing all patients. 
Actually, besides the incomplete efficacy of genotypes 1,
112
 
combination therapy has significant side effects and is poorly 
tolerated in particular by individuals affected by other diseases. 
Consequently, many patients cannot be treated with current 
combination therapy and overall chances of cure for patients are 
probably below 50%. Given the high prevalence of the disease, the 
development of more effective, convenient and tolerated treatments 
is a major public health objective. Similar to the HIV antiviral 
research, efforts to develop antiviral agents for HCV have mostly 
focused on inhibition of key viral enzymes. With the aim of 
understanding the virology and pathogenesis of HCV, a description 
of the viral genome structure and replication will be discussed in this 
chapter.  
3.1. Virology and Pathogenesis 
Hepatitis C is caused by a small RNA virus that is included in the 
Flaviviridae family and has been classified as the sole member of 
the genes hepacivirus.
113
 HCV has a 9.6 single-stranded RNA which 
encodes a single polyprotein of about 3000 aminoacids.
114
 This HCV 
polyprotein is cleaved into a number of structural and non-structural 
proteins including: 2 envelope protein (core-C) and several non-
structural (from NS2 to NS5) proteins. 
Recent studies have classified some of the functions of these 
viral proteins. NS3 has helicase and protease activities while NS5 
contains the RNA dependent RNA polymerase activity. All these 
enzymatic activities are essential for HCV replication and are 
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currently considered as targets for the development of new antiviral 
compounds.
115
 
Some of the viral proteins have been recently implicated also in 
the pathogenesis of the liver disease and in the development of 
resistance to interferon therapy. The HCV core proteins, which exist 
as full-length and truncated forms, have been shown to regulate 
apoptosis of infected cells
116
 and might be therefore directly 
implicated in the pathogenesis of liver disease, of cell proliferation 
and liver cancer development. The core proteins, as well as NS5A, 
have also been reported to interfere with intracellular metabolism of 
lipoproteins with a direct effect on the development of steatosis
117
 
which is a characteristic feature of hepatitis C. Last but not least, 
NS5A may contain a sequence domain able to regulate the cellular 
response to interferon. This region, which has been termed as 
interferon sensitivity determining region (ISDR) encodes for a NS5A 
protein sequence that can bind and inhibit protein kinase R (PKR), a 
protein whose activity is of fundamental importance in the 
development of an intracellular antiviral state in response to 
interferon.
118
 Despite these advances in the understanding of HCV 
pathogenesis, the knowledge on HCV replication and viral proteins 
has been limited by the lack of suitable cell culture systems for 
expression and propagation of HCV and of simple small animal 
models of HCV infection. 
Analysis and modelling of HCV kinetics during the early phase of 
interferon therapy seem to indicate that the rate of virus production 
is quite high in patients with hepatitis C, in the range of 10
10
 - 10
12 
virions per day, with a very rapid viral turnover and a predicted half 
                                                        
115
 Lauer, G. M.; Walker, B. D. Hepatitis C virus infection. N. Engl. J. Med. 2001, 345, 41-52. 
116
  Ruggieri, A.; Harada, T.; Matsuura, Y.; Miyamura, T. Sensitization to Fas-mediated apoptosis 
by hepatitis C virus core protein. Virolgy 1997, 229, 68-76. 
117
 Perlemuter, G.; Sabile, A.; Letteron, P.; Vona, G.; Toplico, A.; Chretien, Y.; Koike, K.; 
Pessayre, D.; Chapman, J.; Barba, G.; Brèchot, C. Hepatitis C virus core protein inhibits 
microsomal triglyceride transfer activity and very low density lipoprotein secretion: a model of 
viral-related steatosis. FASEB J. 2002, 16, 185-194. 
118
 Tan, S. L.; Katze, M. G. How hepatitis C virus counteracts the interferon response: the jury is 
still out on NS5A. Virology 2001, 284, 1-12. 
CHAPTER 3 HCV 
  
58 
 
life of 2 -3 h.
119
 Recently, the development of subgenomic replicons 
of HCV has provided a new research tool for hepatitis C. These in 
vitro systems can support efficient HCV-RNA replication and 
synthesis of all viral proteins, although unfortunately complete virus 
particles production has not yet been achieved. Currently, the 
replicon system is actively used for testing the antiviral effect of new 
antiviral drugs as all viral enzymes that are the major target foe 
antiviral therapy (NS2-3 and NS3 proteinases, NS3 helicase, NS5B 
RNA-dependent RNA-polymerase) are encoded by the replicon 
RNAs. On the other hand, in the absence of complete HCV particles 
production, these systems have limited impact in the understanding 
of HCV replication and pathogenesis. 
Studies conducted during natural infection in humans indicate 
that chronicity of hepatitis C is related to rapid production of virus, 
and a lack of vigorous T-cell immune response to HCV with 
emergence of HCV variants which are prone to escape immune 
control.
120
 
The pathogenesis of liver damage is most likely due to a 
combination of direct cytopathic effects of viral proteins and of 
immune mediated mechanisms including cytolytic and non-cytolytic 
reactions mediated by CTLs (cytotoxic T lymphocytes) and 
inflammatory cytokines.
121
 
Recent data indicate that oxidative stress is an important 
pathogenic factor in HCV related liver damage.
122
 Hepatitis steatosis 
is also a characteristic feature of hepatitis C and contributes to the 
progression of liver disease and fibrosis development.
123
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3.2. Structural Biology of Hepatitis C Virus 
Structural analyses of HCV components provide an essential 
framework for understanding of the molecular mechanisms of HCV 
polyprotein processing, RNA replication, and virion assembly and 
may contribute to a better understanding of the pathogenesis of 
hepatitis C. As abovementioned, studies of this virus have been 
hampered by the lack of a productive cell culture system; most 
information thus has been obtained from analysis of the HCV 
genome, heterologous expression systems, in vitro and in vivo 
models, and structural analyses. 
The HCV genome is a single-stranded RNA molecule of positive 
polarity. It contains a single open reading frame (ORF) encoding a 
polyprotein of about 3,000 amino acids (Figure 3.1). The ORF is 
flanked by 5‘ and 3‘ untranslated regions (UTR) of 341 and 
approximately 230 nucleotides in length, respectively. Both 5‘ and 3‘ 
UTR bear highly conserved RNA structures essential for polyprotein 
translation and genome replication.
124
 The structural proteins include 
the core (C), which forms the viral nucleocapsid, and the envelope 
glycoproteins E1 and E2. They are released by host-cell signals 
peptidases.  
Most of the C protein is found in the cytoplasm, where it is bound 
to ER membranes or located at the surface of lipid droplets.
125
 A 
small proportion of the core protein also may be found in the 
nucleus. In addition to its role in nucleocapsid formation, HCV core 
protein may modulate gene transcription, cell proliferation, cell 
death, and cell signalling; may interfere with lipid metabolism; and 
may suppress host immune responses.
126
  
The two envelope glycoproteins, E1 and E2, are thought to play 
pivotal roles at different steps of HCV replication cycle. There is now 
strong evidence that they are essential for host-cell entry, by binding 
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to receptor(s) and inducing fusion with host-cell membrane.
127
 As in 
other Flaviviridae, they are thought to play a major role in viral 
particle assembly.
128
  
 
 
 
Figure 3.1. HCV genome organization (top) and polyprotein processing (bottom). 
The 5‘ UTR region consists of four highly structured domains and contains the 
internal ribosome entry site. The 3‘ UTR consists of stable stem-loop structures and 
an internal poly(U)/polypyrimidine tract. The central 9.6-kb ORF codes for a 
polyprotein of slightly more than 3000 aa depending on the HCV genotype. S and 
NS correspond to regions coding for structural and nonstructural proteins, 
respectively. The polyprotein processing and the location of the 10 HCV proteins 
relative to the ER membrane are schematically represented. Scissors indicate ER 
signal peptidase cleavage sites; cyclic arrow, autocatalytic cleavage of the NS2-NS3 
junction; black arrows, NS3/NS4A proteinase complex cleavage sites; 
intramembrane arrow, cleavage by the signal peptide peptidase. The 
transmembrane domains of E1 and E2 are shown after signal-peptidase cleavage 
and reorientation of the respective C-terminus hydrophobic stretches (dotted 
rectangles). 
 
These distinct functions imply that the envelope proteins adopt 
markedly different conformations and that the later must be 
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controlled tightly to occur at the appropriate phases of the replicative 
cycle. 
The nonstructural (NS) proteins NS2 to NS5B are involved in 
polyprotein processing and viral replication. The proteolytic 
processing of NS polyprotein part is complex and requires two 
distinct proteinases: the NS2–NS3 zinc–dependent 
metalloproteinase, and the NS3 serine protease located in the N-
terminal region of NS3. The NS2–NS3 proteinase appears to be 
dedicated solely to cleavage at the NS2/NS3 site that occurs rapidly 
and by a conformation-dependent, autocatalytic mechanism.
129
 The 
remaining NS proteins are released by the NS3 proteinase 
associated with its cofactor, NS4A. The C-terminal region of NS3 
protein includes RNA helicase and NTPase activities.The NS3 
serine proteinase domain associates with the NS4A cofactor, 
stabilizing the proteinase and activating it to cleave sites 4A/4B, 
4B/5A/, and 5A/5B. The serine proteinase activity of NS3 is an 
attractive target for new drugs that block viral replication efficently. 
NS4B is an integral membrane protein of unknown function. NS5A is 
a membrane-associated polyphosphorylated protein of unknown 
function in the HCV replication complex that has attracted 
considerable interest because of its potential role in modulating the 
response to interferon alpha therapy.
130,131 
Japanese studies 
suggested the existence of a discrete region of NS5A, tentatively 
named the interferon sensitivity determining region, and NS5A has 
also been reported to interfere with the activity of the double 
stranded-RNA-activated protein kinase in vitro.
132,133 
However, these 
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findings are controversial, and the role of NS5A in the viral 
replication resistance to interferon-α remains elusive. Many other 
potential functions recently have been attributed to NS5A, including 
transcriptional activation and involvement in the regulation of cell 
growth and cellular signalling pathways.
134
 Recently,
135
 researchers 
at the Bristol-Myers Squibb R&D have reported two new 
iminothiazolidinone based compounds (BMS-858 and BMS-790052) 
characterized with a potent HCV replication inhibitory activity. The 
antiviral activity of BMS-790052 maps to the first 100 amino acids of 
HCV NS5A. These results provide clinical validation for the first in a 
new class of HCV inhibitors that target a viral protein with no known 
enzymatic function and an as yet poorly understood role in viral 
replication. 
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4. SMALL MOLECULE INTERFERON INDUCERS 
Hepatitis C is becoming an increasingly common cause of 
mortality especially in the HIV-coinfected group. Due to the efficacy 
of interferon (IFN) based therapy in the treatment of Hepatitis C, 
various compounds possessing IFN-inducing activity have been 
hitherto reported.  
In the present study,
136
 we describe how steric, electrostatic, 
hydrophobic and hydrogen-bonding interactions might influence the 
biological activity of a published set of IFN inducers, using a Three-
Dimensional Quantitative Structure–Activity Relationships (3D-
QSAR) approach. Analyses were conducted evaluating different 
series of compounds structurally related to 8-hydroxyadenines and 
1H-Imidazo[4,5-c]quinolines. A ligand-based alignment protocol in 
combination with the GRID/GOLPE approach was applied; 62 3-D 
QSAR models were derived using different GRID probes and 
several training sets. Performed 3D-QSAR investigations proved to 
be of good statistical value displaying r
2
, q
2
CV-LOO and cross-
validated SDEP values of 0.73, 0.61, 0.61 and 0.89, 0.64, 0.58 using 
the OH or the DRY probe, respectively. Additionally, the predictive 
performance was evaluated using an external test set of 20 
compounds. Analyses of the resulting models led to the definition of 
a pharmacophore model that can be of interest to explain the 
observed affinities of known compounds as well as to design novel 
low molecular weight IFN-inducers (IFNIs). 
To the best of our knowledge, this is the first 3D-QSAR application 
on IFN-inducing agents. 
4.1. Introduction 
All current treatment protocols for hepatitis C are based upon 
interferon alpha (IFN-a) alone or in combination with Ribavirin.
137,138
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Despite progress of therapeutic strategies such as the development 
of pegylated interferon,
139
 sustained viral response (SVR) rates are 
still typically poor for genotype-1 infections that predominate in 
Europe, Japan and US too.
140
 Additionally, the aforementioned 
therapy is often accompanied by significant problems:
138
 i) 
recombinant IFNs, in fact, are genetically engineered bringing to the 
recognition by the body‘s immune system as ―foreign‖. 
Consequently, the benefit of the treatment is strongly affected by the 
immune responses and the formation of neutralizing antibodies; ii) 
the cost of treatment is very high because of the inordinately 
expensive IFN preparations; iii) administration of IFN by 
intramuscular or subcutaneous injection frequently causes pain and 
irritation at the site of injection. Due to the above mentioned issues, 
the enhancement of the endogenous IFN release by the 
administration of orally available small molecular weight compounds 
is a promising approach in the anti-HCV therapy. Compounds 
possessing IFN-inducing activity have been already reported. 
Among them, small molecule IFN inducers (IFNIs) include 
tilorone,
141,142
 BL-20803,
143
 atabrine,
144
 CP-28888,
145
 ABMP,
146
 
                                                                                                                       
138
 Chevaliez, S.; Pawlotsky, J. M. Interferon-based therapy of hepatitis C. Adv. Drug Deliv. Rev. 
2007, 59, 1222-1241. 
139
 Hayashi, N.; Takehara, T. Antiviral therapy for chronic hepatitis C: past, present, and future. J. 
Gastroenterol. 2006, 41, 17-27. 
140
 Dymock, B. W. Emerging therapies for hepatitis C virus infection. Expert. Opin. Emerg. Drugs 
2001, 6, 13-42. 
141
 Stringfellow, D. A.; Glasgow, L. A. Tilorone hydrochloride: an oral interferon-inducing agent. 
Antimicrob. Agents Chemother. 1972, 2, 73-78. 
142
 Mayer, G. D.; Krueger, R. F. Tilorone hydrochloride: mode of action. Science 1970, 169, 1214-
1215. 
143
 Siminoff, P.; Bernard, A. M.; Hursky, V. S.; Price, K. E. BL-20803, a new, low-molecular-weight 
interferon inducer. Antimicrob. Agents Chemother. 1973, 3, 742-743. 
144
 Glaz, E. T.; Szolgay, E.; Stoger, I.; Talas, M. Antiviral activity and induction of interferon-like 
substance by quinacrine and acranil. Antimicrob. Agents Chemother. 1973, 3, 537-541. 
145
 Hoffman, W. W.; Korst, J. J.; Niblack, J. F.; Cronin, T. H. N,N-dioctadecyl-N',N'-bis(2-
hydroxyethyl) propanediamine: antiviral activity and interferon stimulation in mice. Antimicrob. 
Agents Chemother. 1973, 3, 498-502. 
146
 Nichol, F. R.; Weed, S. D.; Underwood, G. E. Stimulation of murine interferon by a substituted 
pyrimidine. Antimicrob. Agents Chemother. 1976, 9, 433-439. 
CHAPTER 4  INTERFERON INDUCERS 
   
67 
 
DRB,
147
 10-carboxy- methyl-9-acridone,
148
 bropirimine
149
 and 
imiquimod (Chart 4.1).
150,151 
 
 
  
BL-20803 Tilorone ABMP 
 
 
 
DRB Atabrine 
10-carboxy-9-
acridone 
   
CP-28888 Bropirimine Imiquimod 
Chart 4.1. Chemical structures of small molecular weight IFNIs. 
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Imiquimod (1) is a well known IFN inducer (IFNI), clinically used 
in US for treatment of exophytic warts caused by the human 
papillomavirus.
150
 As reported by Akira and co-workers,
152
 Imiquimod 
acts via Toll-like receptor 7 (TLR7) signaling pathway inducing the 
endogenous IFN release. However, due to the serious adverse 
effects arose during clinical trials, Imiquimod based strategy against 
HCV
153
 was abandoned. Even if, analogues were discovered to be 
more effective than Imiquimod, up to now no IFN inducers are 
clinically employed in the anti-hepatitis C therapy.
154
 Three-
Dimensional Quantitative Structure-Activity Relationships (3D-
QSAR) continues to be a vigorous field and an increasingly 
attractive discipline in the scientific community. 3D-QSAR methods 
such as Comparative Molecular Field Analysis (CoMFA) and the 
GRID/GOLPE combination, have been successfully applied in many 
instances to guide the design of bioactive molecules. Although 
several series of IFNIs have been disclosed, to the best of our 
knowledge, no 3D-QSAR studies have been performed on these 
classes of compounds. The present study is the application of the 
GRID/GOLPE procedure to different series of IFNIs. Robust and 
predictive 3D-QSAR models were built in order to gain insights into 
how steric, electrostatic, hydrophobic, and hydrogen-bonding 
interactions might influence their biological activity. The aim of this 
work was the development of useful models for future designing and 
forecasting the activity of untested IFNIs. 
4.2. Results 
176 IFNIs structure-activity data were considered in the present 
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study. The whole set of adenines
150,155,156,157,158
 and 1H-imidazo[4,5-
c]quinolines related structures (Figure 4.1) were selected from 
literature. Compounds and biological activities are detailed in Tables 
S1-S6 in the Supporting Information. 
 
  
Adenines 
 
1H-imidazo[4,5-c]quinolines 
Figure 4.1. Adenine and 1H-imidazo[4,5-c]quinoline molecular scaffolds 
 
IFNIs of Tables S1-S6 were firstly collected into five distinct 
groups according to both molecular scaffolds (1H-imidazo[4,5-
c]quinolines and Adenines) and substituents at positions 2, 8 and 9 
on the adenine ring, providing: 1H-imidazo[4,5-c]quinolines (group 
G1), 2-hydrogen/ alkyl/ cycloalkyl/ aryl-8-hydroxy/ mercapto-9-
(substituted)arylalkyl adenines (group G2), 2-(alkyl)amino-8-
hydroxy-9-benzyladenines (group G3), 2-alkylamino-8-hydroxy-9-
(substituted)arylalkyl/ alkyl/ alkylhydroxy (group G4) and 2-alkoxy/ 
alkylthio-8-hydroxy-9-benzyladenines (group G5). G1-G5 groups 
chemical structures and biological activities are reported in Table 4.1 
– 4.5, respectively. Activity data correspond to the minimum effective 
micromolar concentration required to observe IFN induction, as 
                                                        
155
 Isobe, Y.; Kurimoto, A.; Tobe, M.; Hashimoto, K.; Nakamura, T.; Norimura, K.; Ogita, H.; 
Takaku, H. Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine 
derivatives as potent interferon inducers. J. Med. Chem. 2006, 49, 2088-2095. 
156
 Isobe, Y.; Tobe, M.; Ogita, H.; Kurimoto, A.; Ogino, T.; Kawakami, H.; Takaku, H.; Sajiki, H.; 
Hirota, K.; Hayashi, H. Synthesis and structure-activity relationships of 2-substituted-8-
hydroxyadenine derivatives as orally available interferon inducers without emetic side effects. 
Bioorg. Med. Chem. 2003, 11, 3641-3647. 
157
 Kurimoto, A.; Ogino, T.; Ichii, S.; Isobe, Y.; Tobe, M.; Ogita, H.; Takaku, H.; Sajiki, H.; Hirota, 
K.; Kawakami, H. Synthesis and structure-activity relationships of 2-amino-8-hydroxyadenines as 
orally active interferon inducing agents. Bioorg. Med. Chem. 2003, 11, 5501-5508. 
158
 Kurimoto, A.; Ogino, T.; Ichii, S.; Isobe, Y.; Tobe, M.; Ogita, H.; Takaku, H.; Sajiki, H.; Hirota, 
K.; Kawakami, H. Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent 
interferon inducers with improved oral bioavailabilities. Bioorg. Med. Chem. 2004, 12, 1091-1099. 
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reported in the original papers. All derivatives
159
 with activity values 
reported in μg/mL were transformed in μM to have uniformity of 
data.  
Compounds were then submitted to 3D-QSAR analyses with the 
aim of identifying and understanding structural properties and 
features able to influence their biological activity. In this context, 
starting with two dimensional text formats as input and using the 
stand-alone version of PRODRG program
160,161
 in conjunction with 
the molecular mechanics of GROMACS,
162
 coordinates and 
molecular topologies of the ligands were generated. 
                                                        
159
 Gerster, J. F.; Lindstrom, K. J.; Miller, R. L.; Tomai, M. A.; Birmachu, W.; Bomersine, S. N.; 
Gibson, S. J.; Imbertson, L. M.; Jacobson, J. R.; Knafla, R. T.; Maye, P. V.; Nikolaides, N.; 
Oneyemi, F. Y.; Parkhurst, G. J.; Pecore, S. E.; Reiter, M. J.; Scribner, L. S.; Testerman, T. L.; 
Thompson, N. J.; Wagner, T. L.; Weeks, C. E.; Andre, J. D.; Lagain, D.; Bastard, Y.; Lupu, M. 
Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon 
production. J. Med. Chem. 2005, 48, 3481-3491. 
160
 Schuttelkopf, A. W.; van Aalten, D. M. PRODRG: a tool for high-throughput crystallography of 
protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 2004, 60, 1355-1363. 
161
 van Aalten, D. M.; Bywater, R.; Findlay, J. B.; Hendlich, M.; Hooft, R. W.; Vriend, G. PRODRG, 
a program for generating molecular topologies and unique molecular descriptors from coordinates 
of small molecules. J. Comput. Aided Mol. Des. 1996, 10, 255-262. 
162
 Berendsen, H. J. C.; van der Spoel, D.; van Drunen, R. GROMACS: A message-passing 
parallel molecular dynamics implementation. Comput. Phys. Commun. 1995, 91, 43-56. 
CHAPTER 4  INTERFERON INDUCERS 
   
71 
 
 
Table 4.1. Group G1: 1H-imidazo[4,5-c]quinolines. 
 
entry R1 R2 R3 R4 R5 R6 MEC
a
 
1 CH2CH(CH3)2 H H H H H 2.08 
2
c
 CH2CH(OH)CH2OH H H H H H 9.68 
3 CH3 H H H H H 2.52 
4 CH2CH3 H H H H H 2.36 
5 CH2CH2CH3 H H H H H 2.21 
6 CH(CH3)2 H H H H H 2.21 
7 CH2CH2CH2CH3 H H H H H 2.08 
8 CH2(CH2)3CH3 H H H H H 1.97 
9 CH2(CH2)4CH3 H H H H H 1.86 
10 CH2(CH2)5CH3 H H H H H 1.77 
11 CH2CH2OH H H H H H 2.19 
12
c
 CH2CH(CH3)OH H H H H H 1.03 
13 CH2C(CH3)2OH H H H H H 1.95 
14 CH2Ph H H H H H 0.36 
15 CH2CH2Ph H H H H H 1.73 
16 CH2CH2CH2CH2Ph H H H H H 0.32 
17
b
 H H H H H H 2.71 
18 CH2CH(CH3)2 H H H H H 0.2 
19 CH2CH(CH3)2 CH2CH3 H H H H 0.19 
20 CH2CH(CH3)2 CH2CH2CH3 H H H H 0.18 
21b CH2CH(CH3)2 CH2CH2CH2CH3 H H H H 0.03 
22 CH2CH(CH3)2 CH2(CH2)3CH3 H H H H 0.16 
23 CH2CH(CH3)2 CH2(CH2)4CH3 H H H H 1.54 
24 CH2CH(CH3)2 CH2(CH2)5CH3 H H H H 2.95 
25
b
 CH2CH(CH3)2 CH2OPh H H H H 0.29 
26
b
 CH2CH(CH3)2 CH2Ph H H H H 0.15 
27 CH2CH(CH3)2 CH2CH2Ph H H H H 2.9 
28 CH2CH(CH3)2OH CH3 H H H H 0.18 
29 CH2CH(CH3)2OH CH2CH3 H H H H 0.18 
30 CH2CH(CH3)2OH CH2CH(CH3)2 H H H H 0.03 
31 Ph CH2CH2CH2CH3 H H H H 1.58 
32 CH2CH(CH3)2 H OH H H H 3.9 
33 CH2CH(CH3)2 H H CH3 H H 1.97 
34 CH2CH(CH3)2 H H OCH3 H H 3.7 
35 CH2CH(CH3)2 H H OH H H 1.95 
a 
minimum effective concentration (μM);
b 
compounds used in the test set; 
c 
compounds 
containing a stereogenic centre. 
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Table 4.2. Group G2: Adenine derivatives substituted at positions C-2, C-8 and N-9. 
 
entry R1 R2 R3 MECa 
36 H OH CH2-Ph 10.0 
37 H SH CH2-Ph 10.0 
38 H OH -naphthylphenyl 10.0 
39 H OH CH2C6H4(4-F) 10.0 
40 H OH CH2C6H4(4-Cl) 10.0 
41 H OH CH2C6H4(4-CH3) 10.0 
42 H OH CH2C6H4(2-OCH3) 10.0 
43 H OH CH2C6H4(3-OCH3) 10.0 
44 H OH CH2C6H4(4-OCH3) 10.0 
45 CH3 OH CH2-Ph 1.0 
46 C2H5 OH CH2-Ph 0.3 
47 C3H7 OH CH2-Ph 0.1 
48
b
 C4H9 OH CH2-Ph 0.01 
49 Ph OH CH2-Ph 10.0 
50 C5H11 OH CH2-Ph 0.03 
51 C6H13 OH CH2-Ph 1.0 
52 i-Pr OH CH2-Ph 0.1 
53
b
 c-Pr OH CH2-Ph 0.1 
54 i-Bu OH CH2-Ph 1.0 
55 c-Hex OH CH2-Ph 0.3 
56 CH2-c-Pen OH CH2-Ph 0.1 
57 CH2-c-Hex OH CH2-Ph 0.1 
58
b
 3-Pyridyl OH CH2-Ph 10.0 
59 Benzyl OH CH2-Ph 0.1 
60 4-F-Benzyl OH CH2-Ph 0.1 
61 CF3 OH CH2-Ph 0.1 
62 CHF2 OH CH2-Ph 0.1 
63 CF2CF3 OH CH2-Ph 0.3 
64 (CF2)2CF3 OH CH2-Ph 0.3 
65 (CH2)2CF3 OH CH2-Ph 0.1 
a 
minimum effective concentration (μM); 
b 
compounds used in the test set. 
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Table 4.3. Group G3: 2-(alkyl)amino-8-hydroxy-9-benzyladenine derivatives. 
 
entry R1 R2 MEC
a 
66 iso-Pr H 1.0 
67 iso-Bu H 0.1 
68
c
 s-Bu H 0.1 
69 cyclohexyl H 0.1 
70 (CH2)2OH H 1.0 
71 (CH2)3OH H 1.0 
72 (CH2)4OH H 1.0 
73 (CH2)3NMe2 H 10.0 
74 (CH2)2OMe H 0.1 
75 (CH2)3OMe H 0.1 
76
b
 Bn H 0.01 
77
b
 Ph H 1.0 
78 (CH2)2Ph H 1.0 
79 3-MeO-Bn H 1.0 
80 4-MeO-Bn H 1.0 
81 4-Me-Bn H 0.1 
82 4-NMe2-Bn H 1.0 
83 4-F-Bn H 1.0 
84 2-Pyridylmethyl H 1.0 
85 3-Pyridylmethyl H 1.0 
86
b
 4-Pyridilmethyl H 0.1 
87
b
 Bn Me 10.0 
88 -(CH2)2NMe(CH2)2- 1.0 
89 -(CH2) 2O(CH2)2- 1.0 
90 -(CH2)2CHMe(CH2)2- 1.0 
91 H H 10.0 
92 CH3 H 1.0 
93 C2H5 H 1.0 
94 C3H7 H 0.1 
95 C4H9 H 0.1 
96 C5H11 H 0.1 
a 
minimum effective concentration (μM); 
b 
compounds used in the test set; 
c 
compounds 
containing a stereogenic centre. 
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Table 4.4. Group G4: 2-alkylamino-8-hydroxy-9-substituted derivatives. 
 
entry R1 R2 MEC
a
 
97 2-Cl-Ph Bu 0.03 
98 3-Cl-Ph Bu 0.03 
99 4-Cl-Ph Bu 0.01 
100 2-Me-Ph Bu 0.03 
101 3-Me-Ph Bu 0.03 
102 4-Me-Ph Bu 0.01 
103 4-F-Ph Bu 0.01 
104 4-CF3-Ph Bu 0.01 
105 4-NO2-Ph Bu 0.01 
106 4-OMe-Ph Bu 0.01 
107 4-OBnn-Ph Bu 0.1 
108 4-n-Bu-Ph Bu 0.1 
109 4-t-Bu-Ph Bu 0.03 
110 4-Ph-Ph Bu 0.1 
111 4-OH-Ph Bu 0.01 
12b 3,4-Cl2-Ph Bu 0.01 
113 3,4-F2-Ph Bu 0.01 
114 2-Cl-4,5-OCH2O-Ph Bu 0.1 
115 1-naphthyl Bu 0.01 
16b 2-naphthyl Bu 0.03 
17b 5-thiophen(2-Cl) Bu 0.01 
118 CMe2OH Bu 0.1 
119 i-propyl Bu 0.1 
120 c-hexyl Bu 0.03 
121 2-Py Bu 0.03 
122 3-Py Bu 0.003 
123 4-Py Bu 0.01 
124 2-pyrazine Bu 0.03 
125 4-F-Ph MeO(CH2)2 0.03 
126 4-F-Ph PhCH2 0.1 
127 4-F-Ph 4-Py-CH2 0.01 
128 2-Me-3-Py Bu 0.01 
129 5-Me-3-Py Bu 0.003 
130 6-Me-3-Py Bu 0.003 
131 2-Cl-3-Py Bu 0.01 
132 4-Cl-3-Py Bu 0.1 
133 6-Cl-3-Py Bu 0.003 
134 6-OMe-3-Py Bu 0.003 
135 6-NMe-3-Py Bu 0.003 
136 2-Cl-6-Me-3-Py Bu 0.01 
137 2,6-Cl-3-Py Bu 0.03 
a
 minimum effective concentration (μM); 
b
 compounds used in the test set. 
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Table 4.5. Group G5: 2-alkoxy/2-alkylthio 8-hydroxy-9-benzyladenine derivatives. 
 
entry X R MEC
a
 
138 S iso-Pr 0.1 
139 S iso-Bu 0.1 
140
c
 S s-Bu 0.05 
141 S cyclohexyl 0.1 
142 S cyclohexylmethyl 0.1 
143 S Ph 1.0 
144 S Bn 0.1 
145 S (CH2)2Me 0.1 
146 S 3-Chlorobenzyl 1.0 
147
b
 S 4-Chlorobenzyl 1.0 
148 S 3-Methoxybenzyl 0.1 
149 S 4-Methoxybenzyl 0.1 
150 S CH2OMe 0.01 
151 S (CH2)2OMe 0.1 
152 S (CH2)2OEt 0.1 
153 S (CH2)3OEt 0.1 
154 S (CH2)2NMe2 10.0 
155 S (CH2)3NMe2 0.1 
156 S (CH2)2OH 0.1 
157 S (CH2)3OH 0.1 
158 S (CH2)4OH 0.1 
159 O (CH2)2OMe 0.01 
160 O (CH2)2OEt 0.1 
161 O (CH2)3OEt 1.0 
162
b
 O (CH2)2OH 1.0 
163 O (CH2)3OH 1.0 
164 S H 10.0 
165 S CH3 0.1 
166 S C2H5 0.1 
167 S C3H7 0.01 
168
b
 S C4H9 0.01 
169 S C5H11 10.0 
170 S (O)C4H9 0.01 
171 O H 0.1 
172 O CH3 0.1 
173 O C2H5 0.1 
174 O C3H7 0.01 
175 O C4H9 0.001 
176 O C5H11 0.01 
a
 minimum effective concentration (μM); 
b
 compounds used in the test set; 
c
 compounds containing a 
stereogenic centre. 
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In 3D-QSAR, a crucial role is played by the relative spatial 
orientation of structures within the grid.
74
 To this purpose, all data 
set compounds have to be properly aligned. The generation of 3D 
conformations and alignment of compounds is often a difficult 
procedure particularly when the ligands are flexible and/or the 
accurate position/orientation in the binding site is unknown. In our 
case, experimental bound conformation of ligands (G1-G5 groups) 
are not yet available since no crystal structure of the putative 
receptor TLR7 co-crystallized with an IFNI has been reported. To 
overcome this lack of knowledge, the crystal structure of 
Imiquimod
163
 was used as a starting point for the alignment 
procedure. First step was to superimpose the most active compound 
(175, MEC = 0.001 M) together with the most rigid analog (17) to 
the crystal structure of Imiquimod by means of Surflex-Sim
164
 which 
generates molecular alignments and hypothesis of bioactive ligand 
conformations for 3D approaches. Using Morphological Similarity
165
 
algorithm based on the shape of molecules, H-bonding and 
electrostatic properties, Surflex optimizes the alignment of 
molecules and maximizes their three-dimensional similarity. So 
aligned Imiquimod, 175 and 17 were therefore used as template for 
the alignment of the other molecules (Figure 4.2). 
The next step was the calculation and application of the 
molecular interaction fields (MIFs) describing the spatial variation of 
the interaction energy between a molecular target and a chosen 
probe. This task was accomplished by the use of the GRID program. 
Briefly, the protocol involves the computation of MIFs for positions of 
the probe at points on a rectilinear grid superimposed on the target. 
Thus, the MIFs provide information on where the favorable and the 
unfavorable locations for the probe around the target are. To this 
                                                        
163
 Zhao, B.; Rong, Y. Z.; Huang, X. H.; Shen, J. S. Experimental and theoretical study on the 
structure and electronic spectra of imiquimod and its synthetic intermediates. Bioorg. Med. Chem. 
Lett. 2007, 17, 4942-4946. 
164
 Jain, A. N. Ligand-based structural hypotheses for virtual screening. J. Med. Chem. 2004, 47, 
947-961. 
165
 Jain, A. N. Morphological similarity: a 3D molecular similarity method correlated with protein-
ligand recognition. J. Comput. Aided. Mol. Des. 2000, 14, 199-213. 
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aim, OH2, OH, DRY, O, N1 and combined DRY+OH GRID probes 
were in turn employed. 
 
 
Figure 4.2. Stereoview of superimposition of the full data set compounds according 
to Surflex-Sim alignment protocol. For the sake of clarity, hydrogen atoms are 
omitted. 
 
The most widespread application of MIFs is likely the derivation 
of 3D-QSARs by diverse approaches such as CoMFA or 
GRID/GOLPE. Since in 3D-QSAR the biological activity may be 
seen as a function of the physicochemical characteristics of the 
compounds of interest, the need to convert such numerical data to 
useful information has led to the development of methodologies that 
rely on statistics and applied mathematics. Among them, an efficient 
tool deriving from the Principal Component regression is the Partial 
Least Square (PLS) methodology, in which the original variables are 
replaced by a small set of linear combinations thereof. Generated 
latent variables are then used for multivariate regression in order to 
maximize the communality of predictor and response variable 
blocks. Additional attractive features of PLS are the ability to 
correctly work even when interdescriptor correlations exist and/or to 
reduce the risk of chance correlations. 
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To this point, due to the presence of asymmetric carbon atoms 
bearing compounds in groups G1, G3 and G5 (Table 4.1, 4.3 and 
4.5) our work proceeded considering both R and S enantiomers. As 
a consequence, eight training sets (G1-R, G1-S, G2, G3-R, G3-S, 
G4, G5-R and G5-S) were obtained. The self-consistencies of 
training sets G1-G5(R, S) were evaluated developing
166
 48 3D-
QSAR sub-models (see models A–AV in Table S7 in the Supporting 
Information) distinguished by values of correlation coefficient (r
2
), 
cross-validated correlation coefficient (q
2
) and cross-validated 
Standard Deviation Errors of Prediction
167
 (SDEPCV) falling in the 
ranges 0.65-0.99, 0.40-0.87, and 0.23-0.56, respectively. Then, to 
estimate the predictive power of each sub-model, the training sets of 
the other sub-models were in turn used as external test sets. Thus, 
whereas a good self-consistency was observed for each sub-model, 
some of them were affected by a low prediction capability (SDEPext) 
(see Table S8 in the Supporting Information). The latter results 
highlight the intrinsic limitation of any statistical modeling or machine 
learning approach (extrapolation problem) and thus apply also to the 
above A-AV 3D-QSAR models. 
In order to overcome extrapolation problems, two global 
molecular sets (GMSs) were obtained (GMS-R and GMS-S) by 
merging G1-R, G2, G3-R, G4 and G5-R and G1-S, G2, G3-S, G4 
and G5-S series. GMSs were therefore split into a training set of 156 
inducers and a test set of 20 inducers (see experimental section). 
Both training and test sets compounds were selected to cover the 
range of bioactivities and structures of the GMSs. By the use of 
aforementioned probes and performing the same procedure, further 
12 3D-QSAR models resulted (M1-R–M6-R, M1-S–M6-S). In the 
early stage, the internal predictive power of each individual 3D-
QSAR model was checked by ‗leave-one-out‘ (LOO) cross-
                                                        
166
 Ragno, R.; Simeoni, S.; Valente, S.; Massa, S.; Mai, A. 3-D QSAR Studies on Histone 
Deacetylase Inhibitors. A GOLPE/GRID Approach on Different Series of Compounds. J. Chem. 
Inf. Model. 2006, 46, 1420-1430. 
167
 Cruciani, G.; Baroni, M.; Clementi, S.; Costantino, G.; Riganelli, D.; Skagerberg, B. Predictive 
ability of regression models. Part I. Standard deviation of prediction errors (SDEP). J. Chemom. 
1992, 6, 335-346. 
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validations (CV). The latter indicated that the optimal principal 
component was the 2
nd
 one for all models except for DRY based 
ones (see Table 4.6, models M3-R and M3-S). In fact, cross-
validation correlation coefficient q
2
 and SDEPs for OH2, OH, N1, O 
and DRY+OH models showed lower (q
2
) and higher (SDEP) values 
for the 3
rd
, 4
th
 and 5
th
 principal components. Although, statistical 
coefficients were not as good as those obtained for the previous 48 
sub-models (A-AV in Table S7 in the Supporting Information), the r
2
, 
q
2
CV-LOO and SDEPCV-LOO values, included in the ranges of 0.62-0.90, 
0.47-0.64 and 0.58-0.71, respectively, can be still considered 
statistically significant as the q
2
CV-LOO values are greater than the 
threshold values of 0.25, as suggested by Cramer III
168
 and in the 
majority of cases satisfy the more stringent rules depicted by 
Tropsha.
169
 Moreover, different cross-validated PLS analyses were 
carried out to establish the models robustness (leave-two-out, LTO, 
leave-some-out, LSO-5, leave-half-out, LHO), confirming the LOO 
principal components optimal number. It could be argued that the 
conventional r
2
 values for models M1-R, M1-S, M2-R, M2-S, M4-R, 
M4-S, M5-R and M5-S are not fully satisfying, ranging between 0.62 
(M1-R) and 0.73 (M2-R and M2-S). Nevertheless, by definition of the 
PLS paradigm, they are highly containing informative and relatively 
highly robust models in terms of cross validation. As a general trend, 
the (R) configuration training set showed similar or slightly better 
statistical profiles than models containing the (S) enantiomers. 
Analyzing values in Table 4.6, it is not surprising that the DRY 
model shows larger r
2
, as the number of latent dimensions is 5 
versus 2 for the other models. The DRY model has the largest r
2
, 
the highest dimensionality, but not significantly better q
2
 or SDEPs. 
However, information contained in the DRY based models are of 
peculiar interest and can be very useful for detecting hydrophobic 
patches, thus we decided to use it for interpretations.
                                                        
168
 Clark, M.; Cramer, R. D., III. The probability of chance correlation using partial least squares 
(PLS). Quant. Struct.-Act. Relat. 1993, 12, 137-145. 
169
 Golbraikh, A.; Tropsha, A. Beware of q
2
! J. Mol. Graph. Model. 2002, 20, 269-276. 
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Achiral models were also investigated. Compounds 2, 12, 68 and 
140 were kept out from the training set (152 IFNIs) which was in turn 
analyzed with OH and DRY GRID probes. Resulting 3-D QSAR 
models did not show statistically significant differences when 
compared with models M1-R, M1-S, M3-R, M3-S. The omitted 
compounds were added to the original test set and used for external 
validation.  
It is likely that the tiny differences observed for the (R) and (S) 
models stem from the independent generation of 
conformers/alignments, or maybe slightly different positions of the 
aligned molecules in the grid. Statistical results for achiral models 
are detailed in Table S10 in the Supporting Information.  
Along with the internal validation (cross validation), the predictive 
capabilities of models (M1-R–M6-R) and (M1-S–M6-S) were 
estimated by the preselected test set consisting of 20 compounds 
(see Tables 4.1-4.5). The predictive ability of models containing (R) 
enantiomers showed a slightly better profile than those including (S) 
enantiomers. As represented in Table 4.6, the SDEPext values were 
comprised between 0.98 and 1.09. Due to the higher statistical 
profile and the lower SDEPext, models obtained via OH and DRY 
probes (M2-R and M3-R in Table 4.6) were selected for a deeper 
analysis and graphical interpretations.  
4.3. Discussion 
3D-QSAR models interpretations. One of the most important 
features of 3D-QSAR is the graphical representation of the model 
making its interpretation easier. In fact, by using GOLPE software, 
one may display the final model by several available options. Among 
them, PLS pseudo coefficients, present field and activity contribution 
plots are very useful. 
The basic plot is the PLS pseudo-coefficients plot which allows 
the grid points visualization of determined molecules/probe 
interaction energy level, providing whole training set graphical 
information. As a result, the contour coefficient maps indicate those 
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areas in which the model has found a high correlation between the 
ligand-probe interaction energy and the bioactivity. 
 
 
 
Figure 4.3. GRID/GOLPE PLS Coefficients contour maps for the M2-R and M3-R 
3D-QSAR models (contour levels 0.0049 yellow, -0.0049 cyan; contour levels 
0.00452 yellow, -0.00452 cyan, respectively). To aid interpretation only the highest 
active compound (175 in red) and one of the lowest active compounds (36 in green) 
are shown. For the sake of clarity hydrogen atoms are omitted. 
 
In Figure 4.3 are shown the PLS coefficients plots for models 
M2-R (OH probe) and M3-R (DRY probe). The most important areas 
are located in four regions (herein referred to as A, B, C and D) 
which encompass the adenine and quinoline scaffolds. In particular, 
a positive PLS coefficients area (colored in yellow) is located around 
the C-2 position of the adenine scaffold corresponding to the 
quinoline 5a carbon atom (region A). Due to the GRID force field 
characteristics of the OH probe, A reflects areas in which the ligands 
could make either electrostatic or steric interactions. To properly 
allocate the nature of region A, an additional 3D-QSAR model was 
built using the C3 probe (mainly steric information).71 Statistical 
results of the latter model (see Table S9 in the Supporting 
Information) showed to be in good agreement with the previous 
models. In fact, comparing the C3 probe PLS coefficients with those 
of M2-R, a full overlap was detected (compare Figure S1 in the 
Supporting Information with Figure 4.3) highlighting as mainly steric 
or hydrophobic the characteristics of region A. Moreover, for 
chemical interpretation one must remember that substituents being 
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able to favorably interact with an OH probe led to negative GRID 
energies. Hence, cyan contours indicate attractive interactions, 
which will increase biological affinity, while repulsive, unfavorable 
interactions will lower activity. In contrast, yellow contours in 
coefficients maps (see Figure 4.3, OH probe) suggest that repulsive 
interactions (space filling) increase affinity, while attractive 
interactions decrease activity. While the PLS coefficients plot 
provides whole training set graphical information, the activity 
contribution plots (resulting from the multiplication of PLS 
coefficients by the actual field values of each object) help focusing 
on spatial regions that are individually important for the selected 
molecules. In the bottom of Figure 4.4 (model M2-R activity 
contribution plot for 175, the most active IFNI), yellow polyhedrons 
appear in the region surrounding the 2-butyloxy group, suggesting 
that this substituent may increase IFN-inducing activity. On the other 
hand, in the activity contribution plot of compound 36, one of the 
less active IFNIs lacking of any substituents in position C-2, in 
region A some yellow polyhedrons are converted into cyan colored 
ones (negative activity contribution). This confirms the steric nature 
of region A that somehow has to be filled with neutral groups. 
Region B is located in proximity of substituents on adenine N-9 
or imidazoquinoline N-1 positions. The majority of compounds are 
characterized by hydrophobic bulky alkyl, aryl or heteroaryl groups 
at this position. For instance, the most active compound of our 
training set (175) displays a benzyl substituent at this position. As 
shown in the right side of Figure 4.3, some cyan polyhedrons 
(negative PLS coefficients) are close to the hydrophobic moieties 
and, since DRY probe gives rise only to negative field values (Figure 
S2 in the Supporting Information), the presence of a hydrophobic 
group in this region positively contributes to the biological activity. 
Furthermore, to properly explain the influence of the regiochemistry 
of the substituents at various positions on the benzene ring, we 
examined PLS-coefficients and activity contribution plots of para-, 
meta- and ortho-substituted compounds (Figure 4.5). As clearly 
depicted, para-substituted compound 99 (colored in orange) 
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displays a yellow polyhedron in proximity of the 4-chloro group even 
in the PLS coefficients plot or in the activity contributions one (see 
also Figure 4.6). In contrast, compounds 97 and 98, respectively, 
ortho- and meta-chloro substituted, did not orient their groups into 
this yellow contour (PLS-coefficient plots). Moreover, with reference 
to the activity contributions plots of both derivatives 97 and 98 
(Figure 4.6), it is obvious the deficiency of the yellow polyhedron 
(positive activity contribute) in the vicinity of the chloro groups, 
somehow confirming
155
 the importance for the biological activity of a 
correct regiochemistry of the substituents in this area. 
 
  
  
Figure 4.4. On the top, graphical representation of Present Field contour maps 
(contour levels 3.7787 yellow; -2.3306 cyan) for compounds 175 (in red) and 36 (in 
green). On the bottom, Activity Contribution plots (contour levels 0.0230 yellow; -
0.0230 cyan) for the same compounds. 
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Figure 4.5. GRID/GOLPE PLS Coefficients contour maps for the M2-R 3-D QSAR 
model (contour levels 0.0049 yellow, -0.0049 cyan). Compounds 97, 98 and 99 are 
depicted in green, yellow and orange, respectively. For the sake of clarity hydrogen 
atoms are omitted. 
 
 
 
 
 
   
Figure 4.6. Graphical representation of the Activity Contribution plots (contour 
levels 0.0270 yellow, -0.0270 cyan) for the compounds 97, 98 and 99 are depicted 
in green, yellow and orange, respectively. For the sake of clarity hydrogen atoms 
are omitted. 
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Regarding regions C and D of Figure 4.3, as previously 
reported
150,159
 an hydroxyl group at adenine C-8 position (region C) 
and an amino group at adenine C-6 or imidazoquinoline C-4 
positions (region D) are essential for IFN-inducing activity. Despite 
the reported structure-activity relationships (SARs), in the PLS 
coefficients plots of Figure 4.3 only some small yellow polyhedrons 
are present in proximity to these positions. However, due to the 
constant presence of both the C-8 hydroxyl substituent and the C-
6/C-4 amino groups the fractional factorial design (FFD) selection 
led to the exclusion of the majority of grid points around these 
groups, resulting in a small number of polyhedrons. The fewness of 
selected lattice points in these areas does not mean that these 
groups have no influence on the biological activity, but that the 
majority of compounds included in the training set exert similar 
influence in that particular area. Nevertheless, since visible in Figure 
4.3 only, small polyhedrons suggest the influence of hydrogen 
bonding in these positions. 
4.4. Conclusions 
In this work we report the first GRID/GOLPE 3D-QSAR study on 
a training set of 156 IFN-inducers, including 8-hydroxyadenines and 
1H-imidazo[4,5-c]quinolines derivatives. Twelve 3D-QSAR final 
models were built and analyzed. All models displayed good 
statistical coefficient values and using an external test set, model 
M2-R proved to be predictive showing low standard error of 
predictions. Results from 3D-QSAR model interpretation, let us 
individuate the most important areas around the molecules and are 
also in fully agreement with the previously reported SARs. Analysis 
in terms of principal interaction points between the most actives and 
the GRID probes let to the definition of a plausible pharmacophoric 
model (Figure 4.7). To this, around the adenine and quinoline 
scaffold four regions seem particularly important for the modulation 
of the IFN inducing activity: (a) a fillable steric pocket (S); (b) a 
hydrophobic area (Hy); (c) an acceptor hydrogen bonding region 
close to the adenine C-6/quinoline C4 amino groups (HA) and (d) a 
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polarized area, possibly with donator hydrogen bonding 
characteristics close to adenine C-8. These features are fully in 
agreement with several anti-HCV derivatives able to stimulate 
interferon release in PBMC (peripheral blood mononuclear cell), 
recently reported by Czarniecki
170
 and Chong in a 2008 patent.
171
 
 
 
Figure 4.7. Graphical representation of the pharmacophoric model obtained from 
the analysis of the 3D-QSAR models.  
 
4.5. Experimental section 
Data sets. For the investigation, 221 IFNIs were selected from 
literature (see paragraph 4.2). According to the original papers, in 
vitro bioactivities were expressed as minimum effective 
concentration (MEC, μM) the concentration of compounds required 
for more than 1 IU/mL induction of interferon. These numbers were 
then transformed to the decadic log values of the molar MEC which 
                                                        
170
 Czarniecki, M. Small Molecule Modulators of Toll-like Receptors. J. Med. Chem. 2008, 51, 
6621-6626. 
171
 Chong, L. S.; Desai, M. C.; Gallagher, B.; Graupe, M.; Halcomb, R. L.; Yang, H.; Zhang, J. R. 
Preparation of purine and thiadeazapurine phosphonate derivatives as modulators of toll-like 
receptor 7. PCT Int. Appl. WO 2008005555, 2008. 
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were used as dependent variables in the present 3-D QSAR 
analyses. All IFNIs with not defined MEC values were excluded from 
the work leading to a global set of 176 compounds (data set, Tables 
S1-S6 in the Supporting Information).  
IFNIs of tables S1-S6 were firstly collected into five distinct 
groups according to both molecular scaffolds (1H-imidazo[4,5-
c]quinolines and adenines) and substituents at positions 2, 8 and 9 
on the adenine ring, providing: 1H-imidazo[4,5-c]quinolines (group 
G1), 2-hydrogen/ alkyl/ cycloalkyl/ aryl-8-hydroxy/ mercapto-9-
(substituted)arylalkyl adenines (group G2), 2-(alkyl)amino-8-
hydroxy-9-benzyladenines (group G3), 2-alkylamino-8-hydroxy-9-
(substituted)arylalkyl/ alkyl/ alkylhydroxy (group G4) and 2-alkoxy/ 
alkylthio-8-hydroxy-9-benzyladenines (group G5). G1-G5 groups 
chemical structures and biological activities are reported in Table 
4.1- 4.5, respectively. 
For the final 3D-QSAR models, the training set comprises a 
series of 156 interferon inducers, whose chemical structures belong 
to the 8-hydroxyadenines and 1H-imidazo[4,5-c]quinolines classes. 
The remaining 20 compounds were used as external test set. Either 
training or test sets were selected so that they span the whole 
descriptor (chemical) space occupied by the entire data set and 
cover the same range of bioactivities. Even if, test set compounds 
are only 20, they do contain the maximal diversity in terms of 
molecular structures and bioactivities. All derivatives
159
 with activity 
values reported in μg/mL were transformed in μM to have uniformity 
of data. Attempts to use concentrations of IFN induced by 
compounds as dependent variables for our 3-D QSAR models, were 
unsuccessful (data not shown). 
Molecular Modeling and Alignments. All molecules were built 
starting from ASCII text using the stand-alone version of 
PRODRG
160,161
 in conjunction with GROMACS
162
 suite and UCSF 
CHIMERA
172
 as graphical user interface on a 3GHz AMD CPU 
equipped IBM compatible workstation with the SUSE 9.0 version of 
                                                        
172
 Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; 
Ferrin, T. E. UCSF Chimera--a visualization system for exploratory research and analysis. J 
Comput Chem 2004, 25, 1605-12. 
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the Linux operating system. SURFLEX
164,165
 software was employed 
for the alignment procedure. Molecular graphics images were 
produced using the UCSF Chimera package from the Resource for 
Biocomputing, Visualization, and Informatics at the University of 
California, San Francisco. 
GRID Calculations. The GRID
93,94
 program (version22) was 
used to describe the aligned molecular structures. Due to the 
presence of asymmetric carbon atoms in compounds of groups G1, 
G3 and G5 (Table 4.1, 4.3 and 4.5), both (R) and (S) enantiomers 
were considered. As a result, eight initial training sets (G1-R, G1-S; 
G2; G3-R, G3-S; G4 G5-R and G5-S) were obtained. Since no X-ray 
data for the TLR7 receptor is still available, a random probe 
selection was accomplished. Calculations on the 48 obtained sub-
models were carried out using probes OH2 (water), OH (hydroxyl 
group bonded to an aromatic system), DRY (hydrophobic), O (sp
2
 
carbonyl oxygen), N1 (neutral flat NH) and combined DRY+OH. The 
energy calculations were implemented using a 1Å spacing between 
the grid points. Each set of calculated interaction energies contained 
in the resulting three-dimensional matrix, arranged as one-
dimensional vector, was used as input for the program GOLPE. The 
xyz coordinates (in Angstrom) of the grid rectangular box used for 
the computation are: Xmin/Xmax= 6.57/10.95, Ymin/Ymax= 6.83/13.24, 
Zmin/Zmax = 10.82/10.19. 
The models graphical interpretation was conducted considering 
OH and DRY probes. To aid graphical interpretation, further 3D- 
QSAR models were built using the C3 GRID probe. 
GOLPE Analyses. PLS models were calculated with GOLPE 
4.6.0 running on a PC IBM compatible hardware running the Linux 
operating system. To measure the goodness of the model the 
statistical indices r
2
, q
2
 and SDEP were employed using different 
cross-validation methods.  
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where Yi = experimental value; Yfit = recalculated value; Y = mean 
value; Ycv = predicted value and N = number of experiments. 
Variable Preselection. The resulting probe-target interaction 
energies for each compound were first unfolded to produce one-
dimensional vector variables then assembled in the so-called X 
matrix. The matrix was pretreated using a cutoff of 5 kcal/mol in 
order to produce a more symmetrical distribution of energy values. 
To obtain a model with better predictive capability, variable selection 
was operated by zeroing values with absolute values smaller than 
0.01 kcal/mol and removing variables with standard deviation below 
0.05. In addition, variables taking only two and three distribution 
were also removed. Attempts to use other settings in the variable 
preselection did not lead to any improvement of the models. 
Smart Region Definition (SRD). A number of seeds (1000) 
were selected using a D-optimal design criterion in the weights 
space. Structural differences between different molecules in the 
series will be reflected in groups of variables, and therefore groups 
were generated around each seed in the 3D space. Variables with a 
critical distance cutoff of 2 Å to the seeds were included in the 
groups. If two neighboring groups (with a distance smaller than 10 
Å) contained the same information the groups were collapsed. The 
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groups were used in the variable selection procedure replacing the 
original variables. The effect of the groups on the predictability was 
evaluated and groups instead of individual variables were removed 
from the data file. Attempts to use other settings in the SRD did not 
lead to any improvement of the models. 
Variable Selection. The effect of the grouped variables on the 
predictive ability was evaluated using a fractional factorial design 
(FFD) procedure. A number of reduced models (twice the number of 
variables) were built removing some of the variables according to 
the FFD design. The effect of dummy variables (20%) on the 
predictive ability was calculated and only variables with a positive 
effect on the predictability larger than the effect of the average 
dummy variable were included in the final model. During FFD the 
predictive ability of the generated matrices was evaluated by cross-
validation, using 5 random groups and 100 randomizations. Weights 
were recalculated after objects exclusion. Variables which were 
found to be uncertain were retained. The FFD selection was 
repeated until the r
2
 and q
2
 value did not increase significantly for all 
models. In the FFD selection the cross validation was conducted 
using 5 random groups and a maximum of 5 principal components. 
Cross-Validation. All 3D-QSAR models were tested by cross-
validation using LOO (leave-one-out), LTO (leave-two-out), LSO-5 
(leave-some-out with 5 random groups) and LHO (leave-half-out) 
methods with 100 randomizations. The optimum number of principal 
components used in any 3D-QSAR model, was chosen on the basis 
of the different cross-validated PLS analyses setting to 5 the 
maximum number of principal components to be extracted. For all 
3D-QSAR models in the present study, the optimal number of 
principal components (PC= 2 for OH2, OH, N1, O and DRY+OH 
based models and PC= 5 for DRY based model) refers to the ones 
where SDEPcv assumes the minimum value and the cross-validation 
correlation coefficient q
2
 the maximum value. Attempts to increase 
the maximum principal components during either CVs or in the 
above FFD variable selection did not lead to any substantial different 
model.
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4.6. Supporting Information Available  
Molecular structures and biological activities of the compounds 
as reported in the original papers (Table S1-S6), various statistical 
results (Table S7-S10) and C3 based 3D-QSAR GOLPE contour 
maps. 
 
Table S1. 1H-imidazo[4,5-c]quinolines.  
 
Paper
a 
R1 R2 R3 R4 R5 R6 MEC
b 
Imi CH2CH(CH3)2 H H H H H 2.08 
1 CH2CH(OH)CH2OH H H H H H 9.68 
2 CH3 H H H H H 2.52 
22 CH2CH3 H H H H H 2.36 
23 CH2CH2CH3 H H H H H 2.21 
24 CH(CH3)2 H H H H H 2.21 
25 CH2CH2CH2CH3 H H H H H 2.08 
28 CH2(CH2)3CH3 H H H H H 1.97 
29 CH2(CH2)4CH3 H H H H H 1.86 
30 CH2(CH2)5CH3 H H H H H 1.77 
33 CH2CH2OH H H H H H 2.19 
34 CH2CH(CH3)OH H H H H H 1.03 
35 CH2C(CH3)2OH H H H H H 1.95 
37 CH2Ph H H H H H 0.36 
38 CH2CH2Ph H H H H H 1.73 
40 CH2CH2CH2CH2Ph H H H H H 0.32 
41 H H H H H H 2.71 
42 CH2CH(CH3)2 H H H H H 0.20 
43 CH2CH(CH3)2 CH2CH3 H H H H 0.19 
44 CH2CH(CH3)2 CH2CH2CH3 H H H H 0.18 
45 CH2CH(CH3)2 CH2CH2CH2CH3 H H H H 0.03 
46 CH2CH(CH3)2 CH2(CH2)3CH3 H H H H 0.16 
47 CH2CH(CH3)2 CH2(CH2)4CH3 H H H H 1.54 
48 CH2CH(CH3)2 CH2(CH2)5CH3 H H H H 2.95 
50 CH2CH(CH3)2 CH2OPh H H H H 0.29 
52 CH2CH(CH3)2 CH2Ph H H H H 0.15 
53 CH2CH(CH3)2 CH2CH2Ph H H H H 2.90 
54 CH2C(CH3)2OH CH3 H H H H 0.18 
55 CH2C(CH3)2OH CH2CH3 H H H H 0.18 
56 CH2C(CH3)2OH CH2CH(CH3)2 H H H H 0.03 
57 Ph CH2CH2CH2CH3 H H H H 1.58 
66 CH2CH(CH3)2 H OH H H H 3.90 
67 CH2CH(CH3)2 H H CH3 H H 1.97 
68 CH2CH(CH3)2 H H OCH3 H H 3.70 
69 CH2CH(CH3)2 H H OH H H 1.95 
a
 compound enumeration as in the original paper; 
b
 minima effective concentration (μM). 
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Table S2. Adenine derivatives substituted at position 2, 8 and 9.  
 
Paper no.
a 
R1 R2 R3 MEC
b 
6 H OH CH2Ph 10.0 
8 H SH CH2Ph 10.0 
16 H OH -naphtylmethyl 10.0 
17 H OH CH2C6H4 (4-F) 10.0 
18 H OH CH2C6H4 (4-Cl) 10.0 
19 H OH CH2C6H4 (4-CH3) 10.0 
20 H OH CH2C6H4 (2-OCH3) 10.0 
21 H OH CH2C6H4 (3-OCH3) 10.0 
22 H OH CH2C6H4 (4-OCH3) 10.0 
24 CH3 OH CH2Ph 1.0 
25 C2H5 OH CH2Ph 1.0 
26 C3H7 OH CH2Ph 1.0 
27 C4H9 OH CH2Ph 0.03 
28 Ph OH CH2Ph 10.0 
29 SH OH CH2Ph 10.0 
30 SCH3 OH CH2Ph 0.10 
31 SC2H5 OH CH2Ph 0.10 
32 SC3H7 OH CH2Ph 0.01 
33 SC4H9 OH CH2Ph 0.01 
34 SC5H11 OH CH2Ph 10.0 
35 SCH2Ph OH CH2Ph 0.10 
36 S(O)C4H9 OH CH2Ph 0.01 
37 NH2 OH CH2Ph 10.0 
38 NHCH3 OH CH2Ph 1.0 
39 NHC2H5 OH CH2Ph 1.0 
40 NHC3H7 OH CH2Ph 0.10 
41 NHC4H9 OH CH2Ph 0.10 
42 NHC5H11 OH CH2Ph 0.10 
43 OH OH CH2Ph 0.10 
44 OCH3 OH CH2Ph 0.10 
45 OC2H5 OH CH2Ph 0.01 
46 OC3H7 OH CH2Ph 0.01 
47 OC4H9 OH CH2Ph 0.001 
48 OC5H11 OH CH2Ph 1.0 
a
 compound enumeration as in the original paper; 
b
 minima effective concentration (μM). 
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Table S3. 2-alkyl-8-hydroxy-9-benzyl adenine derivatives.  
 
Paper no.
a 
R1 R2 R3 MEC
b 
9e Pen OH CH2Ph 0.03 
9f Hep OH CH2Ph 1.0 
9g i-Pr OH CH2Ph 0.10 
9h c-Pr OH CH2Ph 0.10 
9i i-Bu OH CH2Ph 1.0 
9j c-Hex OH CH2Ph 0.10 
9k CH2-c-Pen OH CH2Ph 0.10 
9l CH2-c-Hex OH CH2Ph 10.0 
9n 3-Pyridyl OH CH2Ph 0.10 
9o Benzyl OH CH2Ph 0.10 
9p 4-F-Benzyl OH CH2Ph 0.10 
9q CF3 OH CH2Ph 0.10 
9r CHCF2 OH CH2Ph 0.10 
9s CF2CF3 OH CH2Ph 0.30 
9t (CF2)2CF3 OH CH2Ph 0.10 
9u (CH2)2CF3 OH CH2Ph 0.10 
a
 compound enumeration as in the original paper; 
b
 minima effective concentration (μM). 
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Table S4. 2-Amino-8-hydroxy-9-Benzyl adenine derivatives.  
 
Paper no.
a 
R1 R2 MEC
b 
9f i-Pr H 1.0 
9g i-Bu H 0.10 
9h s-Bu H 0.10 
9i c-Hex H 0.10 
9j (CH2)2 OH H 1.0 
9k (CH2)3 OH H 1.0 
9l (CH2)4 OH H 1.0 
9n (CH2)3 NMe2 H 10.0 
9o (CH2)2 OMe H 0.10 
9p (CH2)3 OMe H 0.10 
9q Bn H 0.01 
9r Ph H 1.0 
9s (CH2)2Ph H 1.0 
9t 3-MeO-Bn H 1.0 
9u 4-MeO-Bn H 1.0 
9v 4-Me-Bn H 0.10 
9w 4-NMe2-Bn H 1.0 
9x 4-F-Bn H 1.0 
9y 2-Pyridylmethyl H 1.0 
9z 3-Pyridylmethyl H 1.0 
9aa 4-Pyridylmethyl H 0.10 
9ab Bn Me 10.0 
9ac -(CH2)2NMe(CH2)2- 1.0 
9ad -(CH2)2O(CH2)2- 10.0 
9ae -(CH2)2CHMe(CH2)2- 1.0 
a
 compound enumeration as in the original paper; 
b
 minima effective concentration (μM). 
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Table S5. 2-alkylthio/2-alkoxy-8-hydroxy-9-benzyl adenine derivatives.  
 
Paper no.
a 
X R MEC
b 
11f S i-Pr 0.10 
11g S i-Bu 0.10 
11h S s-Bu 0.10 
11i S c-Hex 0.10 
11j S c-HexMe 0.10 
11k S Ph 1.0 
11m S (CH2)2Ph 0.10 
11n S 3-ClBn 1.0 
11o S 4-ClBn 1.0 
11p S 3-OMeBn 0.10 
11q S 4-OMeBn 0.10 
11r S CH2OMe 0.01 
11s S (CH2)2OMe 0.10 
11t S (CH2)2OEt 0.10 
11u S (CH2)3OEt 0.10 
11v S (CH2)2NMe2 10.0 
11w S (CH2)3NMe2 0.10 
11x S (CH2)2OH 0.10 
11y S (CH2)3OH 0.10 
11z S (CH2)4OH 0.10 
13f O (CH2)2OMe 0.01 
13g O (CH2)2OEt 0.1 
13h O (CH2)3OEt 1.0 
13i O (CH2)2OH 1.0 
13j O (CH2)3OH 1.0 
a
 compound enumeration as in the original paper; 
b
 minima effective concentration (μM). 
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Table S6. 2-amino-substituted-8-hydroxy-9-substituted adenine derivatives.  
 
 
paper no.
a 
R1 R2 MEC
b 
9a 2-Cl-Ph Bu 0.03 
9b 3-Cl-Ph Bu 0.03 
9c 4-Cl-Ph Bu 0.01 
9d 2-Me-Ph Bu 0.03 
9e 3-Me-Ph Bu 0.03 
9f 4-Me-Ph Bu 0.01 
9g 4-F-Ph Bu 0.01 
9h 4-CF3-Ph Bu 0.01 
9i 4-NO2-Ph Bu 0.01 
9j 4-OMe-Ph Bu 0.01 
9k 4-OBnn-Ph Bu 0.10 
9l 4-n-Bu-Ph Bu 0.10 
9m 4-t-Bu-Ph Bu 0.03 
9n 4-Ph-Ph Bu 0.10 
13 4-OH-Ph Bu 0.01 
9o 3,4-Cl2-Ph Bu 0.01 
9p 3,4-F2-Ph Bu 0.01 
9q 2-Cl-4,5-OCH2O-Ph Bu 0.10 
9s 1-naphthyl Bu 0.01 
9t 2-naphthyl Bu 0.03 
9u 5-thiophen(2-Cl) Bu 0.01 
9v CMe2OH Bu 0.10 
9w i-propyl Bu 0.10 
9x c-hexyl Bu 0.03 
9y 2-Py Bu 0.03 
9z 3-Py Bu 0.003 
9aa 4-Py Bu 0.01 
9ab 2-pyrazine Bu 0.03 
20 4-F-Ph MeO(CH2)2 0.03 
21 4-F-Ph PhCH2 0.10 
22 4-F-Ph 4-Py-CH2 0.01 
9ac 2-Me-3-Py Bu 0.01 
9ad 5-Me-3-Py Bu 0.003 
9ae 6-Me-3-Py Bu 0.003 
9af 2-Cl-3-Py Bu 0.01 
9ag 4-Cl-3-Py Bu 0.10 
9ah 6-Cl-3-Py Bu 0.003 
9ak 6-OMe-3-Py Bu 0.003 
23 6-NMe-3-Py Bu 0.003 
9ai 2-Cl-6-Me-3-Py Bu 0.01 
9aj 2,6-Cl-3-Py Bu 0.03 
a
 compound enumeration as in the original paper; 
b
 minima effective concentration (μM). 
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Table S7. PLS results analyses for G1-R-G5-S groups using five different single 
probes and one combined DRY+OH one. 
Models Probes Groups q
2 
r
2 
SDEP PC 
A OH2 G1-R 0.46 0.65 0.44 1 
B OH2 G1-S 0.67 0.93 0.34 3 
C OH2 G2 0.86 0.99 0.35 5 
D OH2 G3-R 0.78 0.98 0.33 5 
E OH2 G3-S 0.77 0.98 0.34 4 
F OH2 G4 0.77 0.99 0.23 5 
G OH2 G5-R 0.54 0.86 0.54 3 
H OH2 G5-S 0.54 0.87 0.54 3 
I OH G1-R 0.69 0.97 0.34 5 
J OH G1-S 0.70 0.96 0.33 4 
K OH G2 0.82 0.99 0.41 5 
L OH G3-R 0.81 0.99 0.30 5 
M OH G3-S 0.72 0.95 0.38 3 
N OH G4 0.76 0.99 0.23 5 
O OH G5-R 0.57 0.91 0.52 3 
P OH G5-S 0.54 0.87 0.54 3 
Q DRY G1-R 0.40 0.76 0.47 2 
R DRY G1-S 0.44 0.98 0.45 5 
S DRY G2 0.80 0.98 0.42 4 
T DRY G3-R 0.72 0.99 0.38 5 
U DRY G3-S 0.70 0.99 0.41 5 
V DRY G4 0.62 0.99 0.29 5 
W DRY G5-R 0.51 0.95 0.56 4 
X DRY G5-S 0.41 0.95 0.54 4 
Y N1 G1-R 0.68 0.97 0.34 5 
Z N1 G1-S 0.69 0.97 0.34 5 
AA N1 G2 0.87 0.99 0.34 5 
AB N1 G3-R 0.78 0.99 0.34 5 
AC N1 G3-S 0.76 0.95 0.35 3 
AD N1 G4 0.78 0.99 0.23 5 
AE N1 G5-R 0.56 0.87 0.53 3 
AF N1 G5-S 0.54 0.86 0.54 3 
AG O G1-R 0.64 0.97 0.36 5 
AH O G1-S 0.50 0.70 0.43 1 
AI O G2 0.81 0.98 0.41 5 
AJ O G3-R 0.78 0.99 0.34 5 
AK O G3-S 0.74 0.95 0.36 3 
AL O G4 0.73 0.96 0.25 5 
AM O G5-R 0.62 0.92 0.49 4 
AN O G5-S 0.66 0.94 0.49 4 
AO DRY+OH G1-R 0.68 0.98 0.34 5 
AP DRY+OH G1-S 0.69 0.96 0.34 4 
AQ DRY+OH G2 0.82 0.99 0.30 5 
AR DRY+OH G3-R 0.84 0.99 0.29 5 
AS DRY+OH G3-S 0.79 0.98 0.33 4 
AT DRY+OH G4 0.77 0.99 0.23 5 
AU DRY+OH G5-R 0.56 0.92 0.53 4 
AV DRY+OH G5-S 0.59 0.92 0.50 4 
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Table S8. PLS results for different probes in order to evaluate 
the predictive capability of submodels 
H2O 
Training Set R SDEPext 
 G1 G2 G3 G4 G5 
G1  0.93 0.82 1.94 1.32 
G2 0.81  0.946 1.10 0.93 
G3 0.69 1.023  1.32 1.18 
G4 1.93 2.056 1.64  1.30 
G5 1.58 1.31 1.26 0.72  
Training Set S SDEPext 
 G1 G2 G3 G4 G5 
G1  0.81 0.76 1.65 1.13 
G2 0.80  0.95 1.10 0.93 
G3 0.74 1.08  1.29 1.17 
G4 1.93 2.05 1.65  1.30 
G5 1.71 1.29 1.31 0.72  
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DRY 
 
DRY Training Set 
R 
SDEPext 
 G1 G2 G3 G4 G5 
G1  0.86 0.68 1.83 1.25 
G2 1.02  0.88 1.94 1.27 
G3 0.60 0.98  1.51 1.099 
G4 1.66 2.04 1.58  1.16 
G5 0.91 1.45 1.23 0.88  
Training Set 
S 
SDEPext 
 G1 G2 G3 G4 G5 
G1  0.87 0.78 1.87 1.22 
G2 1.017  0.92 1.94 1.26 
G3 0.60 0.99  1.47 1.05 
G4 1.66 2.04 1.58  1.16 
G5 1.02 1.46 1.30 0.86  
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OH 
Training Set R SDEPext 
 G1 G2 G3 G4 G5 
G1  0.89 0.82 1.73 1.15 
G2 0.73  0.91 1.17 0.98 
G3 0.71 1.037  1.309 1.17 
G4 1.88 2.019 1.63  1.30 
G5 1.68 1.30 1.32 0.77  
Training Set S SDEPext 
 G1 G2 G3 G4 G5 
G1  0.80 0.83 1.62 1.077 
G2 0.72  0.916 1.17 0.98 
G3 0.75 1.08  1.27 1.14 
G4 1.88 2.019 1.63  1.30 
G5 1.65 1.307 1.18 0.74  
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N1 
Training Set R SDEPext 
 G1 G2 G3 G4 G5 
G1  0.91 0.86 1.80 1.32 
G2 0.80  0.96 1.064 0.95 
G3 0.71 1.06  1.33 1.106 
G4 1.85 2.057 1.63  1.32 
G5 1.66 1.30 1.18 0.79  
Training Set S SDEPext 
 G1 G2 G3 G4 G5 
G1  0.89 0.806 1.83 1.16 
G2 0.78  0.96 1.064 0.95 
G3 0.71 1.13  1.29 1.16 
G4 1.84 2.057 1.63  1.32 
G5 1.46 1.28 1.08 0.83  
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O 
Training Set R SDEPext 
 G1 G2 G3 G4 G5 
G1  0.94 0.91 1.92 1.52 
G2 0.65  0.88 1.29 1.03 
G3 0.81 1.08  1.33 1.16 
G4 1.81 2.026 1.59  1.28 
G5 1.43 1.37 1.59 0.72  
Training Set S SDEPext 
 G1 G2 G3 G4 G5 
G1  0.91 0.90 1.95 1.32 
G2 0.646  0.87 1.29 1.03 
G3 0.67 1.19  1.44 1.21 
G4 1.808 2.026 1.7  1.28 
G5 1.56 1.40 1.62 0.68  
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DRY+OH 
Training Set R SDEPext 
 G1 G2 G3 G4 G5 
G1  0.87 0.85 1.79 1.27 
G2 0.74  0.91 1.16 0.99 
G3 0.75 1.038  1.32 1.17 
G4 1.87 2.018 1.61  1.3 
G5 1.77 1.31 1.35 0.72  
Training Set S SDEPext 
 G1 G2 G3 G4 G5 
G1  0.79 0.85 1.67 1.14 
G2 0.73  0.91 1.16 0.99 
G3 0.74 1.067  1.29 1.13 
G4 1.87 2.018 1.62  1.30 
G5 1.60 1.28 1.256 0.74  
 
Table S9. Statistical results of the 3D-QSAR models obtained using C3 GRID 
probe. 
Absolute 
configuration 
r
2 
q
2 
SDEPcv SDEPext PC 
R 0.67 0.53 0.67 1.2 2 
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Figure S1.GRID/GOLPE PLS Coefficient contour maps for the C3 probe 3-D 
QSAR model (contour levels 0.0049 yellow, -0.0049 cyan. To aid interpretation 
only the highest active compound (175 in red) and one of the lowest active 
compounds (36 in green) are shown. For the sake of clarity hydrogen atoms are 
not shown. 
 
 
 
 
Figure S2.Graphical representation of Present Field contour maps (contour levels 
-2.5506 cyan). 
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5. NS5B RNA-DEPENDENT RNA POLYMERASE 
The remarkable clinical success of human immunodeficiency 
virus reverse transcriptase and protease inhibitors, as well as the 
availability of several crystal structures, has motivated HCV drug 
discovery efforts to focus mainly on the development of protease 
and polymerase inhibitors. HCV NS5B is an RNA-dependent RNA 
polymerase that is responsible for the replication of the viral 
genome. In vitro, NS5B can initiate RNA synthesis either by primer-
independent initiation, using a single nucleotide complementary to 
the base at the 3‘ end of the viral genome (also referred as de novo 
initiation), or by primer-dependent initiation using either DNA or RNA 
as primers.
173
 As is the case for other members of the Flaviviridae 
family of viruses
174
, de novo initiation of RNA synthesis is thought to 
be the mechanism used by the polymerase for initiation of RNA 
synthesis in HCV infected cells.
175
 
The HCV RdRp is a ―tail-membrane-anchored protein‖, i.e., 
membrane association is mediated by a C-terminal 21 amino acid 
hydrophobic α-helix. The presence of the C-terminal membrane-
anchor is necessary for the assembly of a functional replication 
complex on the ER of infected cells. However, the same region is 
fully dispensable for in vitro polymerase activity. The crystal studies 
of HCV polymerase from genotype 1 lacking the 21 or 55 C-terminal 
residues (ΔC21 and ΔC55), were solved initially in the absence of 
bound substrate or template (apoenzyme).
176,177 
The HCV polymerase structure shares the same general right-
handed configuration consisting of finger, thumb, and palm domains 
                                                        
173
 Zhong, W., Uss, A. S.; Ferrari, E.; Lau, J. Y.; Hong, Z. De novo initiation of RNA synthesis by 
hepatitis C virus non-structural protein 5B polymerase. J. Virol. 2000, 74, 2017-2022. 
174
 Ortin, J.; Parra, F. Structure and function of RNA  replication. Annu. Rev. Microb. 2006, 60, 
305-306. 
175
 Butcher, S. J.; Grimes, J. M.; Makeyev, E. V.; Bamefod, D. H.; Stuart, D. I. A mechanism for 
initiating  RNA-dependant RNA polymerazation. Nature, 2001, 410, 235-240. 
176
 Lesburg, C. A.; Cable, M. B.; Ferrari, E.; Hong, Z.; Mannarino, A. F.; Weber, P. C. Crystal 
structure of the RNA-dependent polymerase from hepatitis C virus reveals a fully encircled active 
site. Nat. Struct. Biol. 1999, 6, 937-943.  
177
 Bressanelli, S.; Tomei, L.; Roussel, A.; Incitti, I.; Vitale, R. L.; Mathieu, M.; De Francesco, R.; 
Rey, F. A. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. 
Natl. Acad. Sci. U. S. A. 1999, 96, 13034-13039. 
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(Figure 5.1), and the same catalytic machinery observed in DNA-
polymerases and HIV-RT. The active site of the enzyme is located in 
the palm domain that is structurally conserved in all polymerases. 
Morevover, it is defined by the Asp-(Xaa)4-Asp and the signature 
GDD motives typical of most polymerases. 
 
 
 
Figure 5.1. Ribbon representation of the HCV NS5B polymerase with domains 
colored according to thumb (green), palm (yellow), and fingers (orange). 
 
The carboxylate side chains of the first aspartate of each motif 
coordinate two Mg
2+
 ions involved in the catalytic phosphor-transfer 
reaction. Compared to DNA polymerases, NS5B has two elongated, 
flexible loops (Λ1 and Λ2) that extend from the finger domain to the 
thumb domain resulting in a relatively closed spherical appearance 
for the enzyme (Figure 5.2).176
,177 The RNA-template and nucleoside 
triphosphate (NTPs) access the active site, located on the palm 
domain, through two positively charged tunnels and are then 
positioned for the reaction through interactions with the thumb and 
finger domains. Further, a -hairpin in the thumb subdomain (also 
referred as -flap) protrudes toward the enzyme active cavity and 
has been proposed to act as a ‗gate‘ which monitors the correct 
binding of the 3‘-terminus of the RNA, assuring correct initiation and 
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replication from the terminus of the HCV genome.
178,179 
Crystal 
structures of the NS5B polymerase bound to a short RNA-
template
180
 or to NTPs
181
 have also been solved providing insights 
into template binding and mechanism of de novo initiation reaction. 
In these structures, RNA binding occurred without 
rearrangements in the enzyme domains. Interestingly, the structure 
of the NS5B-GTP complex has also showed that, in addition to the 
active site, GTP can also bind to an allosteric site on the surface of 
the thumb domain, 30 Å away from the polymerase catalytic center, 
and in close proximity to a lipophilic region involved in the interaction 
to the tip of the fingertip Λ1 loop. This external GTP binding site is 
thought to be an allosteric regulator of finger-thumb interactions and 
was proposed to exert a regulatory activity by modulating the 
interactions between fingers and thumb during RNA synthesis.
181,182 
However, a role for the external GTP in the NS5B enzymatic activity 
has not been firmly demonstrated. The essential role of NS5B for 
viral replication and the success obtained in the clinic with inhibitors 
of HIV reverse transcriptase (RT) and hepatitis B virus (HBV) DNA 
polymerase
183,184
 have prompted many laboratories to search for 
inhibitors of the HCV polymerase that could be used in the 
therapeutic intervention against the virus. 
 
                                                        
178
 Hong, Z.; Cameron, C. E.; Walker, M. P.; Castro, C.; Yao, N.; Lau, J. Y.; Zhong, W. A novel 
mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase. Virology 2001, 
285, 6-11. 
179
 Zhong, W.; Ferrari, C. A.; Lesburg, C. A.; Maag, D.; Ghosh, S. K.; Cameron, C. E.; Lau, J. Y.; 
Hong, Z. Template/primer requirements and single nucleotide incorporation by hepatitis C virus 
nonstructural protein 5B polymerase. J. Virol. 2000, 74, 9134-9143. 
180
 O‘Farrell, D.; Trowbridge, R.; Rowlands, D.; Jager, J. Substrate complexes of hepatitis C virus 
RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation. J. Mol. 
Biol. 2003, 326, 1025-1035. 
181
 Bressanelli, S.; Tomei, L.; Rey, F. A.; De Franesco, R. Structural analysis of the hepatitis C 
virus RNA polymerase in complex with ribonucleotides. J. Virol. 2002, 76, 3482-3492. 
182
 Lohmann, V.; Overton, H.; Bartenschlager, R. Selective stimulation of hepatitis C virus and 
pestivirus NS5B RNA polymerase activity by GTP. J. Biol. Chem. 1999, 274, 10807-10815. 
183
 El Safadi, Y.; Vivet-Boudou, V.; Marquet, R. HIV-1 reverse transcriptase inhibitors. Appl. 
Microbiol. Biotechnol. 2007, 75, 723-737. 
184
 Rivkin, A. A review of entecavir in the treatment of chronic hepatitis B infection. Curr. Med. 
Res. Opin. 2005, 21, 1845-1856. 
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Figure 5.2. Three-dimensional structure of the HCV NS5B RNA-dependent RNA 
polymerase and non-nucleoside inhibitor binding sites. The finger, palm, and thumb 
domains are coloured in red, green and dark blue respectively. The panels in the 
lower part of the figure show a close up view of the allosteric GTP binding site;
185
 
NNI site A with a bound indole-acetamide inhibitor (in yellow); NNI site B with a 
bound diphenylalanine inhibitor (in green); NNI site C with a bound phenyl-acylic 
acid inhibitor (in orange).  
 
5.1. Inhibitors of the NS5B polymerase 
The majority of approved antiviral drugs exploit the inhibition of 
viral polymerase as the primary mechanism of action.
186
 Therefore, 
it is not surprising that a major effort by several pharmaceutical 
companies has focused on identifying novel inhibitors of the HCV 
NS5B polymerase. Existing inhibitors of viral polymerases can be 
tentatively classified into three categories according to their 
                                                        
185
 De Francesco, R.; Carfi, A. Advances in the development of new therapeutic agents targeting 
the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C 
virus. Adv. Drug Del. Rev. 2007, 59, 1242-1262. 
186
 De Clercq, E. Antiviral drugs: current state of the art. J. Clin. Virol. 2001, 22, 73-89. 
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chemical structure and their mechanism of action: (i) nucleoside 
(substrate) analogues, (ii) non-nucleoside inhibitors (NNI), and (iii) 
pyrophosphate mimics. 
Nucleoside analogues are substrate analogues that need to be 
phosphorylated to their corresponding nucleoside triphosphate 
(nucleotide) in the cytoplasm of infected cells in order to become 
active against the viral polymerases. The nucleotide may be 
incorporated by the polymerase during processive nucleic acid 
synthesis, leading to early termination of the elongation reaction and 
thus inhibition of the virus life cycle. Nucleoside inhibitors of the viral 
polymerase are used therapeutically for HIV, hepatitis B and herpes 
viruses. A few different classes of nucleoside analogues have been 
reported to inhibit HCV replication and, as of today, two 
investigational agents, valopicitabine (Idenix/Novartis) and R1626 
(Roche) have shown anti-HCV activity as single agents in clinical 
trials. 
The NNI class comprises structurally heterogeneous compounds, 
which usually bind to a site on the enzyme surface away from the 
enzyme active site, such as an allosteric site. Even if a very large 
number of HCV polymerase NNI classes have been reported, only 
one of them, HCV-796 (Viropharma/Wyeth) has displayed significant 
antiviral activity in HCV-infected patients. In the following sections, 
different classes of HCV NS5B inhibitors, their mechanism of action, 
resistance and clinical relevance will be described. 
5.1.1. Nucleoside Analogues 
Nucleoside analogues can be considered as prodrugs. These 
inhibitors are normally synthesized in the non-phosphorylated form 
in order to facilitate their access into the cell, and are then converted 
in the active triphosphate (NTP) form by cellular kinases in the 
cytoplasm of infected cells.
187
 If the newly generated NTP analogue 
is accepted as a substrate by the HCV NS5B polymerase, it can be 
incorporated in the nascent RNA chain. After insertion of the 
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modified nucleotide, the particular structure present on the sugar 
moiety will prevent further addition of subsequent bases resulting in 
the premature arrest of the elongation of the growing polymer chain. 
Nucleoside analogues that act according to this mechanism of 
action are therefore referred to as ―chain terminators‖.
188
 
Bioavailability, efficiency of conversion to the active form by cellular 
kinases, competition with the natural NTP pool, as well as metabolic 
deamination and cleavage of the glycosidic bond are all factors to be 
specifically taken in account for the development of this class of 
inhibitors.
189
 For this reason, development of NIs for HCV has 
required complex structure-activity relationship (SAR) studies aimed 
at simultaneous and convergent optimization of the potency of the 
corresponding NTPs in polymerase enzymatic assays and in cell 
based replicon or infectivity assays, on one hand, and the 
pharmacokinetic and metabolic properties, on the other hand.
43 
Deoxy-ribonucleoside analogues have been used in the past to 
target HIV-RT and hepatitis B virus and herpes viruses DNA 
polymerases. However, the HCV NS5B enzyme is an RNA-
dependent RNA-polymerase so is surprising that all the HCV NS5B 
NIs are considered ribonucleoside analogues where chain 
termination function has been achieved by relatively small 
modifications at 2‘ and 4‘ position of the ribose. The advantage of 
such molecules is that they are not expected to be recognized by 
the endogenous DNA polymerases, avoiding therefore the potential 
for cytotoxic and genotoxic side effects.  
5.1.1.1. 2‘-modified nucleoside analogues 
2‘-Methyl nucleosides have been identified by two independent 
groups as specific inhibitor of HCV NS5B-dependent RNA 
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synthesis.187 Researchers at Idenix reported the nucleoside 
analogue 2‘-C-methyl-cytidine as an inhibitor of HCV replication.189 
This compound was initially identified as an inhibitor of the HCV-
related bovine viral diarrhea virus (BVDV) and later shown to have 
modest activity in the HCV replicon system. Valopicitabine, (Chart 
5.1) formerly known as NM283, is an orally bioavailable 3‘-L-valine 
ester of 2‘-C-methyl-cytidine,189
,190 
that has progressed to advanced 
clinical trials, in collaboration with Novartis, for the treatment of 
chronic HCV infection. 
In early phase I/IIa clinical trials in patients that included 
treatment naïve as well as non-responders to previous treatments, 
valopicitabine monotherapy was shown to reduce viral load of HCV-
infected patients in a dose-dependent manner during 15 day 
treatment.
191
 Following these preliminary results and in order to 
enhance its antiviral potential, valopicitabine was dosed in 
combination with PEG-IFN--2a in patients chronically infected with 
genotype 1 HCV who had not responded to the previous treatments 
with the standard PEG-IFN/HCV therapy as well as in treatment-
naïve patients. In the course of phase II combination clinical trials, 
the valopicitabine dose had to be decreased because of severe 
gastrointestinal side effects observed in some patients at higher 
doses.  
The next steps in the valopicitabine development program 
included a ribavirin/valopicitabine drug-drug clinical interaction study 
preliminary to the investigation of triple PEG-IFN--
2a/ribavirin/valopicitabine in treatment-naïve patients. This study 
was necessary in light of the finding that, in cell culture, addition of 
ribavirin antagonizes the anti-HCV activity of the valopicitabine 
parent compound, 2‘-methylcytidine. In this respect, it has been 
recently disclosed that no negative drug interaction was observed 
between valopicitabine and ribavirin after 12 weeks of dosing in a 
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trial comparing the standard of care to valopicitabine/ribavirin/PEG-
IFN triple therapy.  
 
 
 
 
Chart 5.1. Chemical structures of some selected nucleoside inhibitors of the 
NS5B RdRp. 
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Other 2‘-methyl nucleosides that selectively inhibit HCV 
replication are 2‘-O-methyl-cytidine, 2‘-C-methyl-adenosine, 2‘-C-
methyl-guanosine, and 7-deaza-2‘-C-methyl-adenosine (Chart 5.1). 
These compounds are clinically less advanced, but some of them 
have been extensively characterized in vitro as well as in preclinical 
models of HCV infection.
192,193
 In particular, the high inhibitory 
potency and reduced cellular toxicity of 7-deaza-2‘-C-methyl-
adenosine, combined with a very promising pharmacokinetic profile 
in preclinical animal species, makes this compound an attractive 
candidate for clinical development. 
Lastly, R7128 (Roche/Pharmaset) is a 2‘-modefied nucleoside 
analogue that has recently entered early clinical trials. R7128 is an 
oral prodrug of 2‘-deoxy-2‘-fluoro-2‘-C-methyl-cytidine (PSI-6130; 
Chart 5.1), a pyrimidine nucleoside analogue that was shown to act 
as a non-obligate chain terminator of the NS5B polymerase activity 
and to efficiently inhibit the replication of HCV RNA in hepatoma cell 
lines. Data on the in vivo antiviral activity of R1728 are not yet 
available. 
5.1.1.2. 4‘-modified nucleoside analogues 
A 4-modified nucleoside, 4‘-azido-cytidine (R1479, Roche; Chart 
5.1), has been reported as a potent competitive inhibitor of NS5B-
dependent RNA synthesis and hepatitis C virus replication in cell 
culture. This compound was shown to inhibit RNA synthesis in a 
competitive manner and to be a moderately potent inhibitor of the 
replicon system. A triacylated oral prodrug of 4‘-azidocytidine 
(R1626; Chart 5.1) was dosed in a multiple ascending dose study to 
patients with chronic genotype 1 infection and was well tolerated, 
with reversible mild to moderate haematological changes observed 
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with increased doses. R1626 will enter a phase II trial in combination 
with PEG-IFN with or without ribavirin.
194
 
5.1.2. Non-nucleoside inhibitors of NS5B 
Screening of inhibitor libraries has resulted in the discovery of 
several classes of allosteric non-nucleoside inhibitors (NNIs).
188,195
 
The hallmark of all the allosteric HCV NNIs described so far is that – 
in contrast to active site nucleoside inhibitors – they are non-
competitive with NTPs and inhibit the polymerase at a stage 
preceding the elongation reaction. Despite this apparently common 
features in the mechanism of inhibition, several different allosteric 
binding sites for non-nucleoside inhibitors have been discovered on 
the NS5B RdRp surface. A combination of crystallographic, 
biochemical and mutagenesis studies have been exploited to 
identify the binding sites of several of these molecules. For some 
compounds, structural studies have also allowed to elucidate their 
mechanism of inhibition. Moreover, the use of these inhibitors in the 
replicon system allowed selection of clones with resistance 
mutations mapping in the NS5B polymerase. Of note, the identity 
and location of the mutations in the polymerase are largely 
dependent on the structural class of the inhibitor and on their binding 
site and, more importantly, the mutations obtained against inhibitors 
binding to one site generally do not confer resistance to compounds 
binding to a different site.
196
 This suggests that NS5B inhibitors with 
different binding sites could potentially synergize if used in 
combination and initial biochemical and replicon studies seem to 
confirm this hypothesis.
197
 The presence of several different binding 
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sites for small molecules inhibitors in the HCV polymerase is 
unprecedented and is surprising especially if NS5B is compared to 
HIV1 RT where only one binding site for NNIs and one for 
nucleoside analogues have been described. 
To date, at least four distinct allosteric binding sites have been 
described (Figure 5.2). Two of them, sites A and B, are located on 
the thumb domain whereas the other two, sites C and D, are close 
to the active site cavity and contact amino acids from both thumb 
and palm domains (Figure 5.2). 
5.1.2.1. NNIs binding to site A 
NNI site A is located in the thumb domain at 30 Å from the active 
site (Figure 5.2). Several structurally related inhibitors have been 
shown to bind to this site.
198
 Compounds with a benzimidazole 
scaffold (Chart 5.2) were initially disclosed by Japan Tobacco and 
Boehringer Ingelheim. Some of the initial molecules were shown to 
have activity in the cell based assays, with low cytotoxicity, and to 
be selective versus DNA polymerases.
199,200
 Two compounds of this 
structural family, JTK-109 and JTK-003 were the first HCV NNIs to 
enter clinical trials, but have now been abandoned. Later 
compounds with the structurally related indole-6-carboxylic acid 
(Chart 5.2) quinoline, thienoimidazole-5-carboxylic acid and 
thienopyrrole scaffolds have been described.
201
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Chart 5.2. Chemical structures of site-A non-nucleoside inhibitors of the NS5B 
RdRp. 
 
The indole and thienopyrrole resulted almost equally potent in 
the cell based assay and 2 orders of magnitude more potent that the 
corresponding benzimidazole presumably due to the higher 
hydrophobicity of their scaffolds.
202,203,204 
Site A-NNIs have provided 
encouraging pre-clnical results as anti-HCV agents. In particular 
indole-acetamide based inhibitors were shown to be devoid of off-
target activities and presented encouraging pharmacokinetic profile 
in preclinical animal studies. Some of the compounds belonging to 
the classes just described have very potent inhibitory activity on the 
genotype 1b and 3a HCV polymerases. On the contrary, all site A 
inhibitors described to date afford only marginal or no inhibition of 
the genotype 2 enzyme, presumably due to structural differences in 
the binding site that reduce the binding activity.  
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A high-resolution crystal structure of the NS5B polymerase 
bound to an indole-acetamide NNI has been reported.
205
 The indole 
and benzimidazole binding site revealed by the structure is 
consistent with the location of the resistance mutations and 
biochemical data. The inhibitor was found to bind in a pocket, on the 
upper part of the thumb domain, occupied in the apo-enzyme by a 
small helix, α-helix A, at the tip of the fingertip Λ1 loop (Figure 5.2). 
The binding pocket is located on the opposite side to the external 
GTP binding site respect to Pro495. However, whereas GTP 
interacts with amino acids in a α-helix A stabilizing its interaction 
with the thumb domain, binding of NNIs causes the displacement of 
the same helix thus freezing the enzyme in an inactive conformation, 
explaining the opposite effects in vitro on the activity of the enzyme 
activator, compared to site-A inhibitors.  
5.1.2.2. NNIs binding to site B 
In addition to the NNI-binding site just described at the top of the 
thumb domain, several structurally diverse NNIs have been shown 
to bind into a 30 Å long hydrophobic cleft present near the base of 
the thumb domain.195 This site, that here is referred as site B (Figure 
5.2), is formed by the other side of the helices forming the floor of 
the site A binding pocket and the initial part of the polymerase C-
terminal tail. Site B is 35 Å away from the active site and 10-15 Å 
from both the allosteric GTP binding site and from site A. Even 
though most of the amino acids composing this site are conserved 
across different genotypes and the only polymorphisms present in 
different viral isolates are found in the rim of the cleft, the 
polymerases form HCV genotypes different from 1 are not sensitive 
to inhibitors binding to this site.
206
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NNIs with very different scaffolds have been shown to bind site 
B. The first allosteric compounds binding to this site were based on 
a N,N-disubstituted phenylalanine scaffold (Chart 5.3). These 
compounds, although active against the enzyme, were inactive in 
the replicon and therefore of limited interest.
207
 The diphenyl alanine 
derivatives were followed by inhibitors based on 5-phenyl-thiophene 
scaffold (Chart 5.3) and a related carboxamide series, both with 
improved potency in the replicon assay.
208,209 
Other inhibitors 
binding to site B were subsequently described such as 
dihydropirone analogues (Chart 5.3), pyranoindoles, carbazoles and 
cyclopentaindoles.
210,211
 In a phase I study a pyranoindole 
developed by Viropharma/Wyeth (HCV-371; Chart 5.3) showed 
acceptable safety and tolerability but failed to show antiviral effects. 
Development of this series was therefore discontinued. 
Crystal structures of the HCV polymerases bound to different site 
B inhibitors have been reported.
200,201,212
 The inhibitors typically bind 
in the central region of the cleft, filling a dimple on the surface of the 
cleft formed by the side chains of Leu419, Arg422, Met423, Tyr477 
and Trp528. In agreement with the structural finding mutations in the 
HCV-1 polymerase of either Met423 (M423L/V), Leu419 (L419M) 
are able to confer resistance to a variety of site B inhibitors (Figure 
5.2). 
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Chart 5.3. Chemical structures of some selected site-B non-nucleoside inhibitors of 
the NS5B RdRp 
 
Compared to site A inhibitors, the mechanism of inhibition of site B 
molecules is less well understood. In all, the currently available 
structural data
213,214,215
 together with the observation that sites A and 
B share two α-helices suggests that inhibitors binding to these two 
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sites may inhibit by using a similar mechanism, namely by interfering 
with the interaction between fingertip and thumb domains.195 
5.1.2.3. NNIs binding to sites C and D 
Sites C and D are two overlapping sites located in the core of the 
polymerase in proximity of the enzyme active site cavity and at the 
interface between thumb and palm domains (Figure 5.2). Site C is 
located in a pocket in the active site cavity near the so-called primer 
grip, the C-terminal tail, the β-flap and the active site GDD motif. 
Several classes of compounds (Chart 5.4) are known to bind to this 
site,201 including benzathiadiazines, acrylic acids derivatives, 
pyrrolidine acids, rhodanine and isothiazoles derivatives. Crystal 
structures of the genotype 1b HCV polymerase with several 
inhibitors bound to site C have been reported.
216,217,218,219 
These 
structures show that the inhibitors are located in proximity of Met414 
(Figure 5.2), which is consistent with the resistance data. Of note, 
for the rhodanines derivatives and isothiazoles the structure showed 
the formation of a covalent disulfide bond between the inhibitor and 
the sulphur of the strictly conserved Cys366.
220
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Chart 5.4. Chemical structures of some selected site-C and site-D non-nucleoside 
inhibitors of the NS5B RdRp 
 
Inhibitors with a benzofuran scaffold (Chart 5.4) have been 
recently reported and the site of inhibition, site D, has been recently 
identified by X-ray crystallography.
221
 These compounds, also 
referred as ―hinge inhibitors‖, bind in the polymerase palm domain 
(Figure 5.2) and induce a hinge movement of the active site Arg200 
side-chain to generate a relatively small pocket where the inhibitor is 
accommodated. One of these molecules, HCV-796, has gone 
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through a Phase 1b proof-of-concept study.
222
 HCV-796 inhibits 
RNA synthesis in both cell-free and replicon assays. Changes in 
amino acids adjacent to the active site conferred reduced 
susceptibility to HCV-796, with a major resistance mutation 
generated in the replicon being C316Y in phase 1b studies, the 
combination of HCV-796 with Peg-IFN and ribavirin resulted in an 
enhanced antiviral activity and an ~3.3-log-unit reduction in HCV 
RNA levels in infected patients. The clinical development of HCV-
796 was, however, halted due to elevations in liver enzyme levels in 
the blood of some patients after prolonged treatment. Efforts to 
eliminate the side effects in this class of inhibitors may yet yield 
clinically useful compound.
223
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6. NS5B RESULTS ANALYSIS 
Herein, will be described how the combination of a complete 
computational procedure together with biological studies led to the 
identification of novel molecular scaffolds, hitherto untested toward 
NS5B polymerase.
224
  
Structure based 3D-QSAR models were generated employing 
NS5B non-nucleoside inhibitors (NNIs), whose bound conformations 
were readily available from the Protein Data Bank. These were 
grouped into two training sets of structurally diverse NS5B NNIs, 
based on their binding to the enzyme thumb (15 NNIs) or palm (10 
NNIs) domains. 
Ligand based (LB) and structure based (SB) alignments were 
rigorously investigated to assess the reliability on the correct 
molecular alignment for unknown binding mode modeled 
compounds. Both Surflex and Autodock programs were able to 
reproduce with minimal errors the experimental binding 
conformations of 24 experimental NS5B allosteric inhibitors. Eighty-
one (thumb) and 223 (palm) modeled compounds taken from 
literature were LB and SB aligned and used as external validation 
sets for the development of 3D-QSAR models. Low error of 
prediction proved the 3D-QSARs to be useful scoring functions for 
the in silico screening procedure.  
Finally, the virtual screening of the NCI Diversity Set led to the 
selection for enzymatic assays of 20 top-scoring molecules for each 
final model. Among the tested molecules, 10% resulted in inhibiting 
the NS5B RdRp activity at micromolar levels. 
Binding mode analysis of hit compounds within the NS5B 
polymerase thumb domain showed that one of them, NSC 123526, 
exhibited a docked conformation which was in good agreement with 
the thumb training set most active compound (6). 
                                                        
224 
Musmuca, I.; Caroli, A.; Mai, A.; Kaushik-Basu, N.; Arora, P.; Ragno, R. Combining 3-D QSAR 
with Ligand Based and Structure Based Alignment Procedures for in Silico Screening of New 
Hepatitis C Virus NS5B Polymerase Inhibitors. J. Chem. Inf. Model. 2010, 50, 662-676 
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6.1. Ligand-Based, Structure-Based and 3D-QSAR Protocol 
In any 3D-QSAR model preparation, after a careful selection of 
the training set, several steps need to be accomplished.
68,70,71,225
 
Among them, alignment rules (ligand-based or structure-based), 
statistical analysis (PLS and cross-validation)52
 
 and external 
validation (test sets) are of fundamental importance. Once these 
steps have been assessed, the model can be applied to predict the 
activity of untested molecules. The following section describes how 
we have addressed these steps, in order to develop an adequate 
procedure to efficiently predict the activity of new NS5B NNIs. 
Training Sets Selection. At the beginning of these studies, 27 
NS5B/NNIs complexes were available in the Protein Data Bank.
226
 
Analysis of the downloaded crystal structures revealed that ligands 
could be classified into three groups on the basis of their different 
binding sites on the NS5B RdRp (Figure 6.1). The first class 
consists of 15 crystallized NNIs that are believed to occupy a 
common binding site in the thumb subdomain (~35 Å from the 
polymerase active site) and thus, the ligands were collected and 
used as thumb training set.  
Figure 6.1. Ribbon show of the 
overall structure of NS5B RdRp 
with domains colored according to 
thumb (green), palm (yellow), and 
fingers (orange). Three allosteric 
binding sites surfaces are also 
shown. Dark red colored surface 
corresponds to the thumb 
allosteric bs, dark violet colored 
surface corresponds to the palm 
allosteric bs and  the dark blue 
colored surface corresponds to 
the allosteric binding site situated 
in the thumb domain,near but 
clearly distinct from the first one 
(dark red surface). 
 
                                                        
225
 Clark, M.; Cramer, R. D., III; Jones, D. M.; Patterson, D. E.; Simeroth, P. E. Comparative 
molecular field analysis (CoMFA). 2. Toward its use with 3D-structural databases. Tetrahedron 
Comput. Methodol. 1990, 3, 47-59. 
226
 Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. 
N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242. 
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This set of compounds is structurally related to N,N-disubstituted 
phenylalanine,
207,215
 thiophene,
208,209
 thiazolone,
227,228,229
 
dihydropyrones,
210,230
 and acyl pyrrolidine
231,232
 molecular scaffolds. 
PDB codes together with ligand names, structures and biological 
activities of thumb training set compounds are represented in Table 
6.1. The second class consisting of 10 crystallized NNIs, appear to 
bind approximately 10 Å from the catalytic site in the palm domain. 
Members of this class comprise the following NNIs: 
benzothiadiazine analogues,
216,233
 acyl pyrrolidine analogues,231
,232 
benzylidene analogues,
220,234
 acrylic acid derivatives,
217,218
 and 
proline sulfonamide analogues.
235
 These ligands were collected and 
used as palm training set and their PDB codes, structures and 
                                                        
227
 Yan, S.; Appleby, T.; Larson, G.; Wu, J. Z.; Hamatake, R.; Hong, Z.; Yao, N. Structure-based 
design of a novel thiazolone scaffold as HCV NS5B polymerase allosteric inhibitors. Bioorg. Med. 
Chem. Lett. 2006, 16, 5888-5891. 
228
 Yan, S.; Larson, G.; Wu, J. Z.; Appleby, T.; Ding, Y.; Hamatake, R.; Hong, Z.; Yao, N. Novel 
thiazolones as HCV NS5B polymerase allosteric inhibitors: Further designs, SAR, and X-ray 
complex structure. Bioorg. Med. Chem. Lett. 2007, 17, 63-67. 
229
 Yan, S.; Appleby, T.; Larson, G.; Wu, J. Z.; Hamatake, R. K.; Hong, Z.; Yao, N. Thiazolone-
acylsulfonamides as novel HCV NS5B polymerase allosteric inhibitors: convergence of structure-
based drug design and X-ray crystallographic study. Bioorg. Med. Chem. Lett. 2007, 17, 1991-
1995. 
230
 Love, R. A.; Parge, H. E.; Yu, X.; Hickey, M. J.; Diehl, W.; Gao, J.; Wriggers, H.; Ekker, A.; 
Wang, L.; Thomson, J. A.; Dragovich, P. S.; Fuhrman, S. A. Crystallographic identification of a 
non-competitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. J. 
Virol. 2003, 77, 7575-7581. 
231
 Burton, G.; Ku, T. W.; Carr, T. J.; Kiesow, T.; Sarisky, R. T.; Lin-Goerke, J.; Baker, A.; 
Earnshaw, D. L.; Hofmann, G. A.; Keenan, R. M.; Dhanak, D. Identification of small molecule 
inhibitors of the hepatitis C virus RNA-dependent RNA polymerase from a pyrrolidine 
combinatorial mixture. Bioorg. Med. Chem. Lett. 2005, 15, 1553-1556. 
232
 Slater, M. J.; Amphlett, E. M.; Andrews, D. M.; Bravi, G.; Burton, G.; Cheasty, A. G.; Corfield, 
J. A.; Ellis, M. R.; Fenwick, R. H.; Fernandes, S.; Guidetti, R.; Haigh, D.; Hartley, C. D.; Howes, P. 
D.; Jackson, D. L.; Jarvest, R. L.; Lovegrove, V. L.; Medhurst, K. J.; Parry, N. R.; Price, H.; Shah, 
P.; Singh, O. M.; Stocker, R.; Thommes, P.; Wilkinson, C.; Wonacott, A. Optimization of novel 
acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a 
development candidate. J. Med. Chem. 2007, 50, 897-900. 
233
 Dhanak, D.; Duffy, K. J.; Johnston, V. K.; Lin-Goerke, J.; Darcy, M.; Shaw, A. N. et al. 
Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-
dependent RNA polymerase. J. Biol. Chem. 2002, 277, 38322-38327. 
234 
Powers, J. P.; Piper, D. E.; Li, Y.; Mayorga, V.; Anzola, J.; Chen, J. M. et al. SAR and mode of 
action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase. J. Med. Chem. 
2006, 49, 1034-1046. 
235
 Gopalsamy, A.; Chopra, R.; Lim, K.; Ciszewski, G. et al. Discovery of proline sulfonamides as 
potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b 
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biological activities are represented in Table 6.2. It may be noted 
that compound 15, an acyl pyrrolidine derivative, (PDB entry code: 
2JC0),
231,232
 has been included in both training sets, since the 
available co-crystallized structure of this compound showed it bound 
in both allosteric pockets.  
 
Table 6.1. PDB Code, Ligand Name and Ligand Structures of the 15 NS5B 
polymerase NNIs that represent the thumb training set.  
PDB 
Code 
Ligand Name Entry Ligand Structure 
IC50 
(M) 
1NHU 
(2S)-2-[(2,4-dichloro-benzoyl)-
(3-trifluoromethyl-benzyl)-
amino] -3-phenyl-propionic 
acid 
1 
 
1.7 
1NHV 
(2S)-2-[(5-benzofuran-2-yl-
thiophen-2-yl methyl)-(2,4-
dichloro-benzoyl)-amino]-3-
phenyl-propionic acid 
2 
 
8.6 
1YVX 
3-[isopropyl(4-methyl benzoyl) 
amino]-5-phenylthiophene-2-
carboxylic acid 
3 
 
8.0 
1YVZ 
3-[(2,4-dichlorobenzoyl) 
(isopropyl)amino]-5-phenyl 
thiophene-2-carboxylic acid 
4 
 
4.4 
2GIR 
3-{isopropyl[(trans-4-methyl 
cyclohexyl)carbonyl]amino}-
5-phenylthiophene-2-
carboxylic acid 
5 
 
1.5 
2D3U 
5-(4-cyanophenyl)-3-{[(2-
methylphenyl)sulfonyl] 
amino}thiophene-2-
carboxylic acid 
6 
 
0.2663 
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PDB 
Code 
Ligand Name Entry Ligand Structure 
IC50 
(M) 
2D3Z 
5-(4-fluorophenyl)-3-{[(4-
methylphenyl) sulfonyl] 
amino}thiophene-2-
carboxylic acid 
7 
 
0.2918 
2D41 
5'-acetyl-4-{[(2,4-dimethyl 
phenyl) sulfonyl]amino} -
2,2'-bithiophene-5-
carboxylic acid 
8 
 
0.3073 
2HWH 
4-methyl-N-{(5E)-5-[(5-
methyl-2-furyl)methylene]-
4-oxo-4,5-dihydro-1,3-
thiazol-2-yl} 
benzenesulfonamide 
9 
 
2.0 
2HWI 
(2S)-({(5Z)-5-[(5-ethyl-2-
furyl)methylene]-4-oxo-4,5-
dihydro-1,3-thiazol-2-
yl}amino)(4-fluorophenyl) 
acetic acid 
10 
 
3.0 
2I1R 
(5Z)-5-[(5-ethyl-2-furyl) 
methylene]-2-{[(S)-(4-
fluoro- phenyl)(1H-tetrazol-
5-yl) methyl]amino} -1,3-
thiazol-4(5H)-one 
11 
 
9.7 
2O5D 
(2S)-2-({(5Z)-5-[(5-ethyl-2-
furyl)methylene]- 4-oxo-4,5-
dihydro-1,3-thiazol-2-yl} 
amino)-2-(4-fluorophenyl)-
N-[(4-nitrophenyl)sulfonyl] 
acetamide 
12 
 
7.0 
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PDB 
Code 
Ligand Name Entry Ligand Structure 
IC50 
(M) 
1OS5 
3-(4-amino-2-tert-butyl-5-
methyl-phenylsulfanyl)- 6-
cyclopentyl-4-hydroxy-6-[2-
(4-hydroxy- phenyl)-ethyl]-
5,6-dihydro-pyran-2-one 
13 
 
0.93 
2HAI 
(6S)-6-cyclopentyl-6-[2-(3-
fluoro-4-isopropoxyphenyl) 
ethyl]- 4-hydroxy-5,6-
dihydro-2H-pyran-2-one 
14 
 
0.53 
2JC0 
(2S,4S,5R)-2-isobutyl-5-(2-
thienyl)-1-[4-
(trifluoromethyl) 
benzoyl]pyrrolidine-2,4-
dicarboxylic acid 
15 
 
20.0 
 
A third class of compounds consists of indole-derived NNIs
205,236 
that was reported to bind to an allosteric pocket in the thumb 
domain, close in space but clearly distinct (Figure 6.1) from the cleft 
occupied by the above described thumb training set. In Table 6.3 
are shown PDB codes, ligand names, structures and biological 
activities of the third class. However, due to the limited number 
(three) of crystallized ligands in this group, it was not possible to use 
them as a further training set. Thus, in this study a total of 24 
NNIs/NS5B complexes were utilized, representing 15 thumb and 10 
palm allosteric NNIs, with 2JC0 complex included in both categories. 
All subsequent 3D-QSAR studies, molecular docking simulations 
and ligand-based alignments were carried with these two training 
sets.  
 
                                                        
236
 Ikegashira, K.; Oka, T.; Hirashima, S.; Noji, S.; Yamanaka, H. Discovery of conformationally 
constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors. 
J. Med. Chem. 2006, 49, 6950-6953. 
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Table 6.2. PDB Code, Ligand Name and Ligand Structures of the 10 NS5B 
polymerase NNIs that represent the palm training set.  
PDB 
Code 
Ligand Name Entry Ligand Structure 
IC50 
(M) 
1Z4U 
(2Z)-2-[(1-adamantylcarbonyl) 
amino]-3-[4-(2-bromophenoxy) 
phenyl]prop-2-enoic acid 
16 
 
0.07 
1YVF 
(2Z)-2-(benzoylamino)-3-[4-(2-
bromophenoxy)phenyl]- 2-
propenoic acid 
17 
 
0.10 
2AWZ 
(5R)-(4-bromophenylmethyl)-3-
(benzenesulfonylamino)- 4-oxo-
2-thionothiazolidine 
18 
 
0.70 
2AX0 
(5R)-(2E-methyl-3-phenyl-allyl)-
3-(benzene sulfonylamino)-4-
oxo-2-thionothiazolidine 
19 
 
0.20 
2AX1 
(5R)-(3,4-dichlorophenylmethyl)-
3-(2-thiophenesulfonylamino)-4-
oxo-2-thionothiazolidine 
20 
 
0.20 
2FVC 
3-(1,1-dioxido-4H-1,2,4-benzo- 
thiadiazin-3-yl)--4-hydroxy -1-(3-
methyl-butyl)quinolin-2(1H)-one 
21 
 
0.032 
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PDB 
Code 
Ligand Name Entry Ligand Structure 
IC50 
(M) 
2GIQ 
1-(2-cyclopropylethyl)-3-(1,1-
dioxido-2H -1,2,4-benzothia- 
diazin-3-yl)-6-fluoro-4-hydroxy- 
quinolin-2(1H)-one 
22 
 
0.010 
2JC0 
(2S,4S,5R)-2-isobutyl-5-(2-
thienyl)-1-[4 - (trifluoro methyl) 
benzoyl]pyrrolidine-2,4-
dicarboxylic acid 
15 
 
20.0 
2JC1 
(2S,4S,5R)-1-(4-tert-
butylbenzoyl)-2-isobutyl- 5-(1,3-
thiazol-2-yl)pyrrolidine-2,4-
dicarboxylic acid 
23 
 
3.80 
2GC8 
1-[(2-amino-4-chloro-5-methyl 
phenyl)sulfonyl]- L-proline 
24 
 
3.10 
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Table 6.3. PDB Code, Ligand Name and Ligand Structures of the indole-based 
NNIs. 
PDB 
Code 
Ligand Name Ligand Structure 
IC50 
(M) 
2BRK 
3-cyclohexyl-1-(2-morpholin-4-
yl-2-oxoethyl)-2-phenyl-1H-
indole-6-carboxylic acid 
 
0.026 
2BRL 
3-cyclohexyl-1-(2-{methyl[(1-
methyl piperidin-3-yl) methyl] 
amino}-2-oxoethyl)-2-phenyl-1H-
indole-6-carboxylic acid 
 
0.018 
2DXS 
N-[(13-cyclohexyl-6,7-dihydro- 
indolo[1,2-[1,4]benzooxazepin -
10-yl)carbonyl]-2-methyl-L-
alanine 
 
0.046 
 
Polymerase-Inhibitor Complex Structures Preparation. The 
NS5B RNA polymerase structures co-crystallized with allosteric 
inhibitors were downloaded from the Brookhaven Protein Data 
Bank. Of the 24 complexes, 15 were co-crystallized with ligands 
that bind the thumb subdomain of NS5B. The remaining 10 
complexes were co-crystallized with palm binding site NNIs. In 
order to reduce the geometric inaccuracy of the downloaded 
structures, the complexes were submitted to a molecular modeling 
protocol. All complexes were arbitrary superimposed using as 
template 2D3U, because it was one of the better resolved (R = 2.0 
Å) and with the smallest number of missing residues. The 
superimposition of the NS5B complexes was carried out by means 
of the program Chimera172 using the command-line implementation 
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of MatchMaker.
237
 All crystal waters were discarded, and hydrogen 
atoms were added using the tleap module of AMBER suite.
238,239
 
All ligands were individually inspected, and the correct protonation 
states at pH 7.4 were considered, i.e., lysines, arginines, 
aspartates, and glutamates were assumed to be in the ionized 
form and the parameter were calculated by means of the 
Antechamber module of AMBER suite. The complexes were 
solvated (SOLVATEOCT command) in a box extending 10 Å with 
water molecules (TIP3 model) and neutralized with Na
+
 and Cl
−
 
ions. The solvated complexes were then refined by a single point 
minimization using the Sander module of AMBER suite. Once 
minimized, all complexes were realigned with MatchMaker using 
the same reference complex as template. Subsequently, the 
minimized ligands were extracted from the proper minimized 
complex (experimental alignments) and used as training sets for 
the generation of two structure-based statistical models (3D- 
QSARs). 
Molecular Interaction Fields Calculation. The GRID force 
field was used to describe the previously superimposed molecular 
structures. Interaction energies between the selected probes and 
each molecule were implemented using a grid spacing of 1 Å. The 
xyz coordinates (in angstroms) of the grid rectangular box used for 
the computation are Xmin/Xmax = 4.0/52,0, Ymin/Ymax = 6.0/78.0, 
Zmin/Zmax = 13.0/80.0. Initially, many probes were tested (C1=, sp
2
 
carbon atom bonded to one hydrogen; C3, sp
3
 aliphatic carbon 
atom bonded to three hydrogen atoms; OH, oxygen atom bearing 
one acidic hydrogen in phenols or carboxy –COOH; O, explicit 
resonating sp
2
 oxygen with 2 lone pairs in carboxy acid anion or 
                                                        
237
 Meng, E. C.; Pettersen, E. F.; Couch, G. S.; Huang, C. C.; Ferrin, T. E. Tools for integrated 
sequence-structure analysis with UCSF Chimera. BMC Bioinformatics 2006, 7, 339. 
238
 Pearlman, D. A.; Case, D. A.; Caldwell, J. W.; Ross, W. S.; Cheatham, T. E.; DeBolt, S.; 
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91, 1-41. 
239
 Case, D. A.; Cheatham, T. E., 3rd; Darden, T.; Gohlke, H.; Luo, R.; Merz, K. M., Jr.; 
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CHAPTER 6 NS5B RESULTS ANALYSIS 
  
139 
 
pyridine oxide C5H5NO; N1, planar nitrogen bonded to one 
hydrogen atom and two other atoms, no lone pair; N1=, cationic 
sp
2 
nitrogen with one hydrogen, one other single and one double 
bond; N3+, cationic sp
3
 nitrogen bonded to 3 hydrogens and with 
one other rotatable bond; DRY, hydrophobic). Preliminary r
2
, q
2
 
and external standard deviation errors of prediction (SDEP) values 
by PLS, cross-validation and external validations (see Tables S1, 
S2, S3 &S4 in the Supporting Information) suggested the use of 
C1= probe for final 3D-QSAR interpretations of both training sets. 
Attempts to use a combination of different GRID probes did not 
lead to any improvement of the statistical models. 
Statistical Analyses. The MIFs of the training sets were 
imported into the GOLPE program. The associated biological 
activities expressed as IC50 (concentrations reflecting 50% 
inhibition of HCV NS5B RdRp activity) values (in M), were 
converted to molar pIC50 (-log IC50), and used as dependent 
variables in 3D-QSAR analysis. The correlation between biological 
activities and MIFs was carried out by a statistical PLS analysis as 
implemented in GOLPE program. Thus, a series of 3D-QSAR 
models for the thumb and the palm training sets were obtained 
(Tables S1 & S2 in the Supporting Information). The goodness of 
each model was measured by the statistical indices r
2
, q
2
 and 
SDEP using leave-some-out with five random groups (LSO-5) and 
cross-validation method. 
The resulting probetarget interaction energies for each 
compound were first unfolded to produce one-dimensional vector 
variables and then assembled in the so-called X matrix. The matrix 
was pretreated using a cutoff of 5 kcal/mol, in order to produce a 
more symmetrical distribution of energy values. Variable pre-
selection was operated by zeroing values with absolute values 
smaller than 0.01 kcal/mol and removing variables with standard 
deviation below 0.05. In addition, variables taking only two and 
three distributions were also removed. Attempts to use other 
settings in the variable pre-selection did not lead to any 
improvement of the models. 
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The smart region definition (SRD) algorithm was applied. This is 
a GOLPE implementation aimed at selecting cluster of variables, 
rather than the single variable mainly responsible for activity. The 
SRD technique seems less prone to change correlation than any 
single variable selection, and improves the interpretability of the 
models. A number of seeds (1000) were selected using a D-
optimal design criterion in the weight space. Structural differences 
between different molecules in the series will be reflected in groups 
of variables and, therefore, groups were generated around each 
seed in the 3D space. Variables with a critical distance cutoff of 2 Å 
to the seeds were included in the groups. If two neighboring groups 
(with a distance smaller than 10 Å) contained the same 
information, the groups were collapsed. The groups were used in 
the variable selection procedure replacing the original variables. 
The effect of the groups on the predictability was evaluated and, 
groups instead of the individual variables were removed from the 
data file. Attempts to use other settings in the SRD did not lead to 
any improvement of the models.  
All 3D-QSARs were internally tested by cross-validation using 
LSO-5 method with 100 randomizations. The optimum number of 
principal components used in any 3D-QSAR model was chosen on 
the basis of the different cross-validated PLS analyses, setting to 5 
the maximum number of principal components to be extracted. In 
the present study, the optimal number of principal components 
refers to the ones where SDEPCV assumes the minimum value and 
the cross-validation correlation coefficient q
2
 assumes the 
maximum value. Attempts to increase the maximum principal 
components during CVs did not lead to any substantially different 
model.  
Models Interpretations. The GRID/GOLPE method used 
within this study led to the definition of two final StructureBased 
3D-QSAR models. The statistical results obtained by using the C1= 
GRID probe are reported in Table 6.4. The internal predictive 
power of each model was checked by the leave-some-out with five 
random groups (LSO-5) cross-validation method (Figure 6.2). The 
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latter indicated that the optimal principal component was the third 
one. In fact the 2
nd
, 4
th
 and 5
th
 principal components showed lower 
q
2
 and higher SDEP values (data not shown).  
 
 
 
Figure 6.2. Fitting and Cross-Validation plots for the thumb (left) and palm (right) 
training sets. 
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As represented in Table 6.4, the statistical analysis yielded 
highly significant statistical coefficients with r
2
 values of 0.99 for 
both models and q
2
 of 0.69 for the thumb model and of 0.55 for the 
palm model, thus providing the goodness of the system.  
 
Table 6.4. PLS Analysis Results for the Thumb and the Palm Structure-Based 
3D-QSAR Models.
a 
model N GRID Probe V PC r
2 
q
2 
SDEPCV-L5O 
Thumb TS 15 C1= 5133 3 0.99 0.69 0.31 
Palm TS 10 C1= 3848 3 0.99 0.55 0.66 
a
 N, number of compounds in the training set; V, number of GOLPE variables; PC, 
optimal number of principal components; r
2
, conventional square correlation 
coefficient; q
2
, cross-validation correlation coefficient; SDEP, cross-validated 
standard error of prediction using the leave-five-out cross-validation method 
 
Moreover, an accurate graphical analysis of GOLPE contour 
maps led to the identification of the most representative areas 
selected by the models. In fact, one of the most interesting features 
of a GRID/GOLPE 3D-QSAR analysis is the possibility of 
translating back the PLS coefficients assigned to each variable to 
the 3D positions they occupy in real space. These values can be 
contoured at a particular significant level and can be displayed as a 
grid plot of PLS coefficients. The contour coefficient maps indicate 
those areas in which the model has found a high correlation 
between the ligand-probe interaction energy and the biological 
activity. However, the signs of PLS coefficients can induce errors in 
this plot. Coefficients could have opposite meaning depending on 
the positive or negative field values produced by the compound in 
the same area. In Figure 6.3 are shown the PLS coefficient plots 
for the thumb training set analyzed with the C1= GRID probe. One 
of the most important areas selected by the model is represented 
by a big red polyhedron located between the p-cyanophenyl 
thiophene and the 2-methylphenyl moieties of the most active 
compound (6), corresponding to the thiazole and the 4-F phenyl 
group of one of the lowest active compounds (11). For chemical 
interpretation, one must remember that red contours in coefficient 
maps suggest that repulsive interactions (positive GRID energies) 
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increase affinity, while attractive interactions (negative GRID 
energies) decrease activity. The sp
2
 aromatic carbon atom used for 
the calculation of the molecular field is a prevalently hydrophobic 
group. Thus, it might be suggested that these areas corresponds to 
hydrophobic surface of the thumb domain where van der Waals 
interactions as well as interactions with binding site residues, 
positively contributes to the biological activity. On the other hand a 
blue colored region around the tetrazole portion of compound 11 
clearly indicates that the steric hindrance in this area is not suitable 
for potency.  
 
 
Figure 6.3. Contour maps of the PLS Coefficients derived from C1= GRID probe 
analysis using the 15 compounds of the thumb training set (contour levels: 0.0008 
red, -0.0008 blue). To aid interpretation only the highest active (6 in cyan) and one 
of the lowest active (11 in orange) compounds are shown. Hydrogen atoms are 
omitted for the sake of clarity. 
 
In Figure 6.4 some small blue polyhedra near the carboxylate 
group of compound 6 are also depicted. To shed light on the 
nature of the interactions made by this substituent, we decided to 
analyze it by means of OH GRID probe derived 3D-QSAR (for 
statistical data see Tables S1 & S2 in the Supporting Information). 
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The hydroxyl probe used for the calculation of the molecular field is 
a prevalently polar group with the ability to participate in hydrogen 
bonds and electrostatic interactions. Thus, areas containing 
negative coefficients (blue polyhedrons) correspond to areas in the 
binding pocket where energetically favorable interactions produce 
an increase in the activity. These regions correspond to position of 
polar groups in the binding site. Consequently, blue polyhedra in 
this area mainly reflect hydrophilic features, which may be due to 
the presence of hydrogen bond donor residues in the binding 
pocket. 
 
 
Figure 6.4. Contour maps of the PLS Coefficients derived from OH GRID probe using 
the 15 compounds of the thumb training set (contour levels: 0.0008 red, -0.0008 blue). 
To aid interpretation only the highest active (6 in cyan) and one of the lowest active 
(11 in orange) compounds are shown. Hydrogen atoms are omitted for the sake of 
clarity. 
 
In Figure 6.5, the PLS coefficients plots for the palm training set 
are shown. The 3D-QSAR model graphical analyses was carried 
out by means of C1= probe. The red polyhedron situated around 
the benzo portion of the benzothiadiazine system of compound 22 
appears to be relatively important for the biological activity. In fact, 
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as previously reported,
216
 a key feature observed in all of the 
benzothiadiazine structures determined is an apparent edge-to-
face interaction between Phe193 and the benzene ring. 
Compound 15, an acyl pyrrolidine derivative, did not show any 
particular interaction in this area. This may be due to the relevant 
differences in the chemical structures of these molecules. 
Nevertheless, the red polyhedra located in proximity of the N-1 (2-
cyclopropyl)ethyl moiety (22) and the 4-trifluoromethyl benzoyl 
group of compound 15 imply that space filling in both positions 
might play a key role in further potency enhancements. 
 
 
Figure 6.5. Contour maps of the PLS Coefficients derived from C1= Grid probe 
using the 10 compounds of the palm training set (contour levels: 0.0010 red, -
0.0010 blue). To aid interpretation only the highest active (22 in cyan) and the 
lowest active (15 in orange) are shown. Hydrogen atoms are omitted for the sake of 
clarity. 
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6.2. Alignment Rules 
In the present study, ligand-based as well as structure-based 
alignment methodologies were explored with the aim to determine 
the alignment of molecules with unknown binding mode (test set). 
Several software that perform diverse alignment procedures are 
available, and among them, Surflex-Sim164
,165 and Autodock23 
were chosen since free for academics and of good quality as 
assessed by considerable references.
240,241,242,243,244,245,246
 In 
particular, for the LB approach, the application of the concept of 
morphological similarity, implemented in Surflex-Sim was used, 
while for the SB approach the program Autodock was selected.  
In the following paragraphs different levels of alignment 
assessment are reported for either LB or SB methods. Regarding 
LB approach, randomly built conformation for each ligand was 
generated and then aligned to the experimental binding 
conformation (re-surflex). This way the LB alignment procedure 
was first tested for self alignment and due to different topological 
atom descriptions between the experimental and modeled 
                                                        
240
 Cleves, A. E.; Jain, A. N. Robust ligand-based modeling of the biological targets of known 
drugs. J. Med. Chem. 2006, 49, 2921-2938. 
241
 Holt, P. A.; Ragazzon, P.; Strekowski, L.; Chaires, J. B.; Trent, J. O. Discovery of novel triple 
helical DNA intercalators by an integrated virtual and actual screening platform. Nucleic Acids 
Res. 2009, 37, 1280-1287. 
242
 Langham, J. J.; Cleves, A. E.; Spitzer, R.; Kirshner, D.; Jain, A. N. Physical binding pocket 
induction for affinity prediction. J. Med. Chem. 2009, 52, 6107-6125. 
243
 Ragno, R.; Mai, A.; Massa, S.; Cerbara, I.; Valente, S.; Bottoni, P.; Scatena, R.; Jesacher, 
F.; Loidl, P.; Brosch, G. 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a 
new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds 
through structure-based drug design and docking studies. J. Med. Chem. 2004, 47, 1351-1359. 
244
 Wang, M.; Zhang, J.; Andrei, D.; Kuczera, K.; Borchardt, R. T.; Wnuk, S. F. Are L-adenosine 
and its derivatives substrates for S-adenosyl-L-homocysteine hydrolase? J. Med. Chem. 2005, 
48, 3649-3653. 
245
 Taylor, C. M.; Barda, Y.; Kisselev, O. G.; Marshall, G. R. Modulating G-protein coupled 
receptor/G-protein signal transduction by small molecules suggested by virtual screening. J. 
Med. Chem. 2008, 51, 5297-5303. 
246
 Radi, M.; Falciani, C.; Contemori, L.; Petricci, E.; Maga, G.; Samuele, A.; Zanoli, S.; 
Terrazas, M.; Castria, M.; Togninelli, A.; Este, J. A.; Clotet-Codina, I.; Armand-Ugon, M.; Botta, 
M. A multidisciplinary approach for the identification of novel HIV-1 non-nucleoside reverse 
transcriptase inhibitors: S-DABOCs and DAVPs. ChemMedChem 2008, 3, 573-593. 
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structures, the surflex-aligned conformation was retained as a 
reference conformation in the subsequent calculations involving 
the use of modeled structures. Although arbitrary, this assumption 
was supported by the visual inspection of superimposed 
experimental versus the re-surflexed conformations (Figure 6.6). In 
the next step, each randomly built conformation is aligned to a 
target list which contains all ligands (in their binding conformation), 
except the corresponding experimental one (cross-surflex). 
 
 
Figure 6.6. Examples of Surflex alignment. Superimposition of the modeled ligand 
conformations (carbon atoms in green) to the experimental ones (carbon atoms in 
orange) of three compounds of training sets (from left to right, compounds 6, 12 and 
16). Atom bonds are in ball and stick fashion. Hydrogen atoms are omitted for the 
sake of clarity.  
 
Regarding the SB approach, a four steps procedure was set up. 
In the first step, Autodock program was tested for the ability to 
reproduce the bound state of a certain ligand using the respective 
receptor and the known binding conformation as starting point (re-
docking). In the second step, the same re-docking was repeated 
using as starting point a randomly generated conformation (re-
docking modeled). The third level of docking assessment was 
achieved by a cross-docking procedure using the experimental 
conformation docked in all the available receptors while excluding 
the native one (cross-docking). In the last step the cross-docking 
procedure was repeated using the modeled ligands (cross-docking 
modeled). In either cross-docking procedures, the output 
conformations were merged in a single file and then clustered 
using the internal clustering procedure of the Autodock program. 
The rationale of the docking assessment resides in the fact that 
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first the docking program was tested for the ability to correctly 
reposition the native ligand conformation within the respective 
experimental receptor pocket. Besides, a modeled ligand 
conformation was used in order to measure how the starting 
docking conformation can influence the docking program in the 
reproduction of the bound ligand conformation. Analogously cross-
docking experiments, using the experimental and modeled ligand 
conformations, were carried out to evaluate the docking program 
aptitude to predict the correct binding conformation using an 
ensemble of receptor conformations while keeping out the native 
co-crystallized one. In the cross-docking assessments, the 
clustering of poses coming from docking runs using different 
receptor conformations can be assumed a sort of full flexible 
docking simulation in which both the ligand and the receptor are 
allowed to move. In the case of the ligand the flexibility is achieved 
by the Solis-Wets algorithm,
247
 while for the receptor the 
experimental NS5B snapshots give the induced ligand 
conformational changes. Attempt to use Autodock side-chain 
flexibility feature was not successful (data not shown). 
6.2.1. Ligand-Based Alignment: Surflex Assessment 
The ligand-based alignment of the molecules was achieved 
using Surflex-Sim. This method optimizes the pose of a query 
molecule to an object molecule in order to maximize 3D similarity. 
Morphological similarity is defined as a Gaussian function of the 
differences in molecular surface distances of two molecules at 
weighted observation points on a uniform grid, thus yielding a 
value from 0 to 1. The function is dependent on the relative 
alignment of two molecules. 
First step of Surflex-Sim assessment was checking the 
goodness of the alignment when a randomly built ligand 
conformation is generated and then overlapped to the experimental 
binding conformation (self alignment). For this purpose, each of the 
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 Solis, F. J.; Wets, R. J. B. Minimization by Random Search Techniques. Math. Oper. Res. 
1981, 6, 19-30. 
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24 modeled compounds of the training sets were superimposed to 
the corresponding minimized ligands as extracted from their 
respective complex (re-surflex). Due to the differences in 
topological description of the molecules, the goodness of the self-
alignment was visually inspected. As an example of the alignment 
goodness, in Figure 6.6 are depicted the aligned conformations of 
three different modeled compounds (6, 12 and 16) superimposed 
on their respective experimental bound conformations. 
In the next alignment assessment step, each of the 24 modeled 
ligand conformations was overlapped to a target list containing all 
the ligands (in their SB experimental aligned binding 
conformations), except the corresponding experimental one (cross-
surflex). Here, the self-aligned surflex conformation was employed 
as a reference for measuring the root mean square deviation 
(rmsd) values between the cross-surflex aligned and the re-surflex 
one. As reported in Table S7 of the Supporting Information, the 
rmsd values for all 24 NS5B NNIs were below the cutoff value of 1, 
thus confirming a good alignment result. This validation of Surflex-
Sim‘s ability to accurately align randomly built conformations 
suggested us that it would exhibit a similar accuracy even with 
molecules of unknown binding conformation. Therefore, it can be 
considered as a useful tool for LB alignment of NS5B inhibitors 
(see external test set below) as well as for the alignment of 
molecules in a virtual screening protocol (see below). 
6.2.2. Structure-Based Alignment: General Docking Settings 
Autodock 4 was used for all docking calculations. The 
AutoDockTools (ADT) package was employed to generate the 
docking input files and analyze the docking results. The 24 ligands 
extracted from the minimized complexes (see Polymerase-Inhibitor 
Complex Structures Preparation section) were separated into two 
groups on the basis of their different binding sites on the NS5B 
polymerase receptor. The first group contains 15 NNIs that are 
believed to occupy a common binding site located in the thumb 
domain. The second group contains a total of 10 NNIs reported as 
CHAPTER 6 NS5B RESULTS ANALYSIS 
  
150 
 
binding an allosteric pocket located near the active site in the palm 
domain.  
Two different grid boxes, one for each binding site, were 
centered on the average mass center of the ligands. Thus, a grid 
box of 91 × 91 × 86 points and a grid spacing of 0.375 Å was set in 
order to accommodate the NNIs that bind the thumb domain of 
NS5B polymerase. The second grid box (spacing, 0.375 Å ) of 62 × 
75 × 75 points was implemented in such a way to accommodate 
the NNIs that bind the palm allosteric site of NS5B. Several atom 
probes (characterized by the same stereoelectronics properties as 
the atoms constituting the inhibitors) were moved on the grid 
nodes, while interaction energy between the probe and the 
inhibitors were calculated at each node. The, grid maps were 
generated for each atom probe, describing its interactions with the 
inhibitors. Autogrid 4, as implemented in the Autodock software 
package, was used to generate grid maps.  
The Lamarckian genetic algorithm (LGA)23 was employed to 
generate orientations or conformations of the ligands within the 
binding site. The global optimization started with a population of 
150 randomly positioned individuals, a maximum of 2.5 × 10
6 
energy evaluations, and a maximum of 27000 generations. A total 
of 100 runs were performed, while all the remaining run 
parameters were maintained at their default settings. A cluster 
analysis was carried out using 2 Å as the root-mean-square 
deviation tolerance. Docking experiments were also tried using a 
single grid box comprising the two binding sites. Although 
Autodock performed quite well in selectively positioning the ligands 
in the right pockets, the results in term of root-mean-square-
deviation (rmsd) values were not fully satisfying (data not shown). 
This is likely due to the fact that with only 100 runs such a large 
region is not sufficiently explored. Nevertheless higher number of 
conformation sampling, although not assuring better result, would 
have been too computationally demanding to be pursued. 
Assessment of Docking: Re-Docking. In order to check for the 
reliability of the docking protocol, we performed docking studies on 
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24 NS5B polymerase complexes. The docking results were 
evaluated through a comparison of the predicted docked positions 
of the ligand and the experimental ones. As a measure of docking 
reliability, the rmsd between the positions of heavy atoms of the 
ligand in the calculated and experimental structures was 
considered. The choice of the best conformation was based on the 
assumption that, although for high-throughput screening protocols 
only the first ranked docked conformation should be considered 
(that is, the conformer characterized by the lowest estimated free 
energy of binding),
248
 in other cases, the lowest energy conformer 
of the most populated cluster should also be taken into account.
249
 
In Table 6.5 the rmsd for the best docked, best cluster and lowest 
values obtained are reported. Analyses of these results show that 
in cases where the best cluster conformer does not coincide with 
the best docked conformer (1NHU, 1NHV, 1YVZ, 2GIR, 2HWH, 
2I1R, 2O5D, 1YVF, 2AWZ, 2AX1, and 2GIQ), a better rmsd value 
is observed, except for 1NHV, increasing the percentage of 
conformations found below the threshold value of 2 Å from 41.6% 
(best docked) to 70.8% (best cluster) to 100% (best fitted cluster). 
While the best docked is the lowest energy docked conformation of 
the first Autodock generated cluster, best cluster is the lowest 
energy docked conformation of the most populated cluster and 
best fitted cluster is the lowest energy docked conformation of the 
cluster showing the lowest rmsd value. In the ideal case, i.e. the 
error free docking program, the three conformations would have 
coincided. The fact that Autodock reproduces the correct 
conformation (best fitted cluster) by 100%, reflects the intrinsic lack 
of accuracy (at least for NS5B) of the implemented scoring function 
in selecting the right pose, and this is at the basis for the use of the 
above 3D-QSAR models (as external scoring function) during the 
virtual screening reported below. As proof of concept we compared 
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 Ragno, R.; Frasca, S.; Manetti, F.; Brizzi, A.; Massa, S. HIV-reverse transcriptase inhibition: 
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the Autodock predicted pKi values with the experimental pIC50 and 
only a poor correlation was found (data not shown).  
 
Table 6.5. Assessment of the Autodock Program in the Re-Docking Stage. 
RMSD Values for the First Ranked Pose (Best Docked), the Lowest Energy 
Docked Conformation of the Most Populated Cluster, (Best Cluster) and the 
One Closest to the Experimentally Bound Conformation (Best Fitted Cluster).  
Binding 
Site 
PDB 
Ligand 
Entry 
Best 
Docked 
Best Cluster Best Fitted Cluster 
Rmsd 
Cluster 
N° 
Rmsd 
Cluster 
N° 
Rmsd 
Thumb  
1NHU 1 3.17 3 2.17 3 0.89 
1NHV 2 4.13 2 4.75 26 1.86 
1OS5 13 3.46 1 3.46 9 1.50 
1YVX 3 3.81 1 3.81 6 1.58 
1YVZ 4 3.74 4 1.92 4 0.78 
2D3U 6 0.71 1 0.71 1 0.44 
2D3Z 7 0.75 1 0.75 1 0.60 
2D41 8 1.43 1 1.43 1 0.58 
2GIR 5 5.70 2 1.12 2 0.70 
2HAI 14 2.05 1 2.05 1 0.92 
2HW
H 
9 9.86 2 2.13 2 0.79 
2HWI 10 0.34 1 0.34 1 0.24 
2I1R 11 5.84 2 1.67 2 0.73 
2JC0 15 0.85 1 0.85 1 0.68 
2O5D 12 5.74 3 2.78 7 1.28 
Average Rmsd 3.44  2.00  0.90 
Palm 
1YVF 17 3.38 4 1.12 4 0.93 
1Z4U 16 0.89 1 0.89 1 0.57 
2AW
Z 
18 3.53 3 1.72 3 1.11 
2AX0 19 0.84 1 0.84 1 0.52 
2AX1 20 3.24 2 0.99 2 0.61 
2FVC 21 1.04 1 1.04 1 0.74 
2GC8 24 2.03 1 2.03 2 1.82 
2GIQ 22 3.49 5 1.91 5 1.81 
2JC0 15 0.65 1 0.65 1 0.42 
2JC1 23 0.74 1 0.74 1 0.47 
Average Rmsd 1.98  1.19  0.90 
 
Assessment of Docking: Re-Docking Modeled. In addition, the 
reliability of the docking protocol was evaluated by a re-docking 
modeled simulation. Our aim was to check more realistically 
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Autodock‘s ability to reproduce binding mode conformations of 
molecules with no experimental data. In this stage therefore, the 
same modeled conformations used in the Surflex assessment were 
used to test the Autodock ability. Similarly as reported in the cross-
surflex assessment section the docking assessment here was 
evaluated using as reference conformation the re-surflexed one. 
The modeled ligands were submitted to a re-docking simulation 
using the same docking settings as for the abovementioned re-
docking protocol. In Table S5 of the Supporting Information the 
best docked, best cluster and best fitted cluster rmsd values found 
are reported. Comparing the values of Table S5 (re-docking 
modeled) with Table 6.5 (re-docking), at a first glance they do not 
appear  to confirm the ability of Autodock to reproduce the correct 
binding conformation. However, a visual inspection of the re-
docked modeled conformation revealed that using the re-surflexed 
conformation could lead to a mis-interpretation of the Autodock 
potentials. In fact upon comparing the three conformations 
(experimental, re-surflexed and re-docked modeled), a better 
agreement between the experimental and the re-docked modeled 
conformations versus the re-surflexed and re-docked modeled one 
(the tabled rmsd) was noted. As an example of these results, 
Figure 6.7 depicts the best docked conformations, the reference 
conformations (Surflex-Sim aligned) and those extracted from the 
minimized complexes (experimental), for two arbitrarily chosen 
representatives of thumb (6) and palm (16) binding NS5B NNIs. 
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Figure 6.7. Examples of Re-Docking Modeled. Superimposition of the Surflex-
aligned conformation (carbon atoms in green) and the re-docked conformation 
(carbon atoms in magenta) to the experimental conformation (in orange) of one 
thumb NNI (6, on the top) and one palm NNI (16, on the bottom) within the NS5B 
(cyan colored ribbons). Atom bonds are in stick fashion. Hydrogen atoms are 
omitted for the sake of clarity. 
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Assessment of Docking: Cross Docking. Along with re-docking 
experiments (self docking), cross-docking simulations (docking 
each ligand into the binding pocket of a series of different ligand – 
receptor complexes) was also performed. The cross-docking 
method was based on docking each experimental conformation in 
all the available receptors, while excluding the native one (cross-
docking). Then, all output conformations were merged in a single 
file and clustered. The aim of such a cross-docking procedure was 
to evaluate the docking program‘s ability in proposing correct 
binding conformations, even if no structural data were available for 
a given modeled and yet untested ligand. In this docking 
assessment step, similar to the re-docking section, the inclusion of 
known experimental binding conformation is taken into account. 
Additional parameters included evaluation of conformational 
change during receptor–ligand docking simulations, as well as the 
consideration of the concept of ligand-induced fit.249 Autodock 4 
was used for all cross-docking calculations employing the same 
grid boxes parameters (thumb and palm binding sites) and 
Autogrid maps previously used for re-docking calculations. The 
numbers of runs of each docking experiment was set so that the 
number of generated conformations was comparable to that in the 
re-docking experiments. 
In Table 6.6, the rmsd values for the best docked, best cluster 
and best fitted cluster conformations are reported. As already 
outlined in the previous paragraph, the best cluster selection 
versus the best docked criteria gave the best results. Indeed, from 
analyzing Table 6.6, one can clearly see that the number of 
correctly docked conformations for the best cluster selection is 
higher than those obtained by the best docked criteria.  
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Table 6.6. RMSD Values Obtained by Cross-Docking Simulations 
Binding 
Site 
PDB 
Ligand 
Entry 
Best 
Docked 
Best Cluster Best Fitted Cluster 
Rmsd 
Cluster 
N° 
Rmsd 
Cluster 
N° 
Rmsd 
Thumb 
1NHU 1 2.25 1 2.25 3 1.87 
1NHV 2 4.37 14 3.68 19 2.54 
1OS5 13 7.59 5 3.61 32 1.81 
1YVX 3 3.51 2 1.77 10 1.58 
1YVZ 4 1.73 1 1.73 1 1.67 
2D3U 6 5.79 2 5.06 14 1.79 
2D3Z 7 5.36 2 3.75 8 1.22 
2D41 8 6.49 2 1.51 2 1.51 
2GIR 5 1.57 1 1.57 1 1.57 
2HAI 14 1.45 1 1.45 1 1.45 
2HWH 9 3.60 7 2.9 7 1.71 
2HWI 10 3.61 3 2.20 13 1.40 
2I1R 11 2.27 2 1.77 3 1.61 
2JC0 15 4.26 11 9.7 3 3.38 
2O5D 12 3.48 1 3.48 18 1.73 
Average Rmsd 3.82  3.1  1.79 
Palm 
1YVF 17 2.56 2 3.43 9 2.52 
1Z4U 16 2.26 2 3.87 12 1.78 
2AWZ 18 1.64 1 1,.64 1 1.64 
2AX0 19 1.85 1 1.85 3 1.58 
2AX1 20 1.68 1 1.68 1 1.68 
2FVC 21 1.88 1 1.88 3 1.06 
2GC8 24 11.13 2 2.08 6 1.84 
2GIQ 22 1.84 1 1.84 11 1.64 
2JC0 15 1.21 1 1.21 1 1.21 
2JC1 23 0.97 1 0.97 1 0.97 
Average Rmsd 2.7  2.09  1.59 
 
Assessment of Docking: Cross-Docking Modeled. Cross-
docking experiments of modeled training sets ligands were also 
carried out. Grid box parameters and all docking settings were the 
same as for the cross-docking simulations. In Table S6 of the 
Supporting Information, the rmsd for the best docked, best cluster 
and lowest rmsd values found are reported. As outlined above, we 
have evaluated the ability of the docking program ability in 
proposing correct binding conformations even when no structural 
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data are available for a given modeled and yet untested ligand. 
Here the docking program is tested as in a real case situation 
where a randomly chosen ligand conformation is being docked into 
a receptor binding pocked whose conformation do not bear any 
information on the actual ligand inducing fit.  
Table S6 again confirms that the best cluster conformation have 
to be considered instead of the best docked. Here again similarly, 
though it is less evident compared to the re-docking modeled 
assessment, the rmsd values seems to mis-lead in the abilities of 
Autodock to correctly reproduce acceptable docked conformations. 
Visual inspection (data not shown) revealed that there is a better 
agreement between the experimental and the cross-docked 
modeled conformations, than those observed between the re-
surflexed and cross-docked modeled conformation (rmsd values in 
Tables S5 and S6). 
Similarly as stated above for the cross-surflex experiments, in 
this last SB alignment assessment, the ability to accurately align 
randomly built conformations, suggested that Autodock can be 
used as an useful tool for SB alignment of NS5B inhibitors (see 
external test set below), and to some extent to align molecule in a 
virtual screening protocols (see below). A schematic description of 
the workflow of the alignment process is shown in Figure 6.8.  
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6.3. External Validation of the 3D-QSAR Models 
To evaluate the predictive ability of the 3D-QSAR models, two 
series of test sets were used. Compounds of the first test set 
include 81 NS5B NNIs selected from literature, that bind in the 
thumb subdomain of the receptor. Molecular structures of thumb 
test set are represented in Table S8 – Table S19 of the Supporting 
Information. Compounds of the second test set include 223 NS5B 
ligands reported in literature as palm subdomain allosteric 
inhibitors. Molecular structures of palm test set are represented in 
Table S20 – Table S36 of the Supporting Information. Test set 
compounds were selected so that they span the whole descriptor 
(chemical) space occupied by the training set and cover as much 
as possible the same range of bioactivities.  
All 304 test set molecules were generated by means of 
molecular mechanics of Chemaxon Marvin software 
(http://www.chemaxon.com/) and all molecular graphics images 
were produced using UCSF Chimera package from the Resource 
for Biocomputing, Visualization, and Informatics at the University of 
California, San Francisco on a 3 Ghz AMD CPU equipped IBM 
compatible workstation with the Debian 5.0 version of the Linux 
operating system. Then, test set compounds were submitted to the 
molecular alignment using the LB (cross-surflex) and SB (cross-
docking) protocols as reported above. In the alignment of the 
external test sets all the experimental ligands were used as target 
list (for each receptor site) in Surflex and all the receptor structures 
were used in the cross-docking experiments. 
Each test set compounds was then aligned twice (cross-surflex 
conformation and best cluster conformation from cross-docking) 
and the respective MIFs calculated. 
Application of the two SB 3-D QSAR models to the external test 
sets (C1= GRID probe) yielded low standard deviation error of 
predictions values, shown in Table S1–Table S2 of the Supporting 
Information for all GRID probes.  
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Analysis of individual error of predictions are graphically 
reported in Figure 6.9. Here, it is clearly visible how the 3D-QSAR 
models, coupled to LB and SB alignment methods, can be used as 
external scoring function. In particular, the use of quite large 
external test sets is a sort of a virtual screening simulation 
(although all molecules are known to bind NS5B). In particolar, 
from Figure 6.9, it is possible to observe a good agreement 
between the two alignment methods, and setting to 1 an arbitrarily 
threshold value of acceptable prediction error, the percentage of 
compounds well predicted ranged from 54% to 63% and rose to a 
maximum of 92% if the cutoff value would set to 1.5. 
The interesting results of the above mixed protocol prompted us 
to undertake a virtual screening approach, which is reported in the 
next section. It has to be pointed up that either training set or test 
set compounds were biologically tested in similar condition assays. 
 
Palm Prediction Surflex Alignment
122
45
56
> 1.5
> 1 .0
< 1.0
Palm Prediction Autodock Alignment
32
47
144
> 1.5
> 1 .0
< 1.0
 
Thumb Prediction Surflex Alignment
28
6
47
> 1.5
> 1 .0
< 1.0
Thumb Prediction Autodock Alignment
49
9
23
> 1.5
> 1 .0
< 1.0
 
Figure 6.9. Diagrams of number of compounds with an error of prediction greater 
than 1.5 (violet), 1.0 (dark red) and lower than 1.0 (pale yellow). 
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6.4. Virtual Screening 
Structure-based virtual screening has become an integral part 
of the drug design process and is now the most widely-used 
approach to leverage structure for ligand discovery. In receptor-
based virtual screening, the main purpose is to find a ligand that 
has a high binding affinity to the target receptor whose 3D structure 
is known. Ligand similarity searches also provide a very powerful 
method of quickly screening large databases of ligands to identify 
possible hits with activity against the target of interest. There are 
many tools available for performing these computational analyses 
and they can be categorized as being either ligand-based or 
receptor-based. For ligand-based methods, the strategy is to 
perform similarity search if one or more active molecules are 
known. This can be done by a variety of methods, QSAR and 3D-
QSAR models as well as pharmacophore matching.  
Receptor-based computational methods can be employed when 
the 3D structure of the target protein is known. These involve 
docking algorithms to put ligands into the binding site of the target, 
and thus producing a predicted binding mode for each database 
compound. The application of scoring functions which in turn 
produce a ranking list of compounds is necessary to identify 
potential hits. 
The VS protocol reported in this study is based on the 
application of two receptor-based 3D-QSAR models, on external 
test sets containing 81 molecules for the thumb model and 223 
molecules for the palm model (see Figure 6.10 for a detailed 
description of the VS workflow). This procedure proved them to be 
useful scoring functions for the virtual screening approach, using 
either a ligand-based (Surflex-Sim) or a structure-based 
(Autodock) molecular alignment. Consequently, the NCI Diversity 
Set (DS) (http://dtp.nci.nih.gov), a database consisting of over 
1990 compounds, was virtually screened. For each statistical 
model, the first 20 most active predicted molecules were selected 
for biological assays against recombinant NS5BCΔ21 (genotype 
1b).  
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Figure 6.10. Workflow of 3D-QSAR studies and alignment rules integration in the 
virtual screening process used in the present work. 
 
Among the selected compounds, preliminary data yielded four 
derivatives (Table 6.7) with IC50 values between 45-75 µM. The 
selected compounds have been tested for their activity using 
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similar biological conditions as for training set and external test set 
compounds (see biological data). It could be argued that the NCI 
DS may have limitations to screen for compounds active against 
NS5B. However, the NCI database is one of the most widely used 
as it exhibits  molecular diversity. Moreover the implicit limitation of 
such a choice further strengths the applied approach considering 
that 10% of the tested molecules were indeed found active in 
enzyme-based assay. 
 
Table 6.7. Molecular Structure and Antiviral Activity
a
 of the Compounds Selected 
by VS Protocol  
Thumb Domain Palm Domain 
 
  
 
NSC 123526 NSC 125626 NSC 169534 NSC 3354 
IC50 = 46.0 M IC50 = 73.3 M IC50 = 64.5 M IC50 = 54.3 M 
a 
The data represents an average of at least two independent experiments. 
6.4.1. Biological data: NS5B RdRp Assay 
Recombinant NS5BC21 was purified from the plasmid 
pThNS5BC21 expressed in Escherichia coli DH5 by Ni-NTA 
affinity chromatography, and employed for evaluating the inhibitory 
activity of the compounds on poly rA/U12 template-primer (TP) as 
previously reported.
250,251 
NS5B RdRp activity was determined in 
the absence or presence of the compounds at 30°C for 60 min in a 
                                                        
250
 Kaushik-Basu, N.; Bopda-Waffo, A.; Talele, T. T.; Basu, A.; Costa, P. R.; da Silva, A. J.; 
Sarafianos, S. G.; Noel, F. Identification and characterization of coumestans as novel HCV 
NS5B polymerase inhibitors. Nucleic Acids Res. 2008, 36, 1482-1496. 
251
 Kaushik-Basu, N.; Bopda-Waffo, A.; Talele, T. T.; Basu, A.; Chen, Y.; Kucukguzel, S. G. 4-
Thiazolidinones: a novel class of hepatitis C virus NS5B polymerase inhibitors. Front. Biosci. 
2008, 13, 3857-3868. 
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reaction buffer (25 L) containing 20 mM Tris–HCl [pH 7.0], 100 
mM NaCl, 100 mM sodium glutamate, 0.5 mM DTT, 0.01% BSA, 
0.01% Tween-20, 5% glycerol, 20 U/mL of RNase Out, 0.5 M poly 
rA/U12 (pre-annealed), 25 M UTP, 2–5 Ci [-
32
P]UTP, 0.5 mM 
MnCl2 and 300 ng of NS5BC21. Reactions were terminated by 
the addition of ice-cold 10% (v/v) trichloroacetic acid (TCA) 
containing 0.5 mM pyrophosphate. The quenched reaction 
mixtures were spotted on GF-B filters, washed with 5% (v/v) TCA-
0.5 mM pyrophosphate to remove unincorporated rNTPs, rinsed 
and quantified on a liquid scintillation counter (Packard). Activity of 
NS5B in the absence of the inhibitor was set at 100% and that in 
the presence of the inhibitor was calculated relative to this control. 
The 50% inhibition value (IC50) for the inhibitors was evaluated 
from the dose response curve employing typically 9-12 
concentrations of the compound and GraphPad Prism 5.0 soft. 
N,N-disubstituted phenylalanine derivative 14 (as numbered in the 
original paper),207 a documented NS5B inhibitor was included as 
positive control in each set of experiments. 
6.4.2. Binding Mode Analysis 
Analysis of the binding mode of selected compounds (Table 
6.7) within the NS5B RdRp polymerase thumb domain was 
performed with the aim of elaborating a putative way by which they 
inhibit the enzyme, and thus, getting insights on the peculiar 
chemical features that influenced their activity. Among the four 
active compounds, only one draws (NSC 123526) particular 
attention from a medicinal chemistry point of view. In fact, 
compound NSC 125626 is an oxirane (thus likely an irreversible 
inhibitor) and its structure is similar to a nucleoside, thus indicating 
it as a nucleoside inhibitor; compounds NSC 169534 and NSC 
3354 are structurally too rigid and structurally resemble a 
tetracycline and a colestane related compound, respectively. As a 
matter of fact, the resulting four complexes were visually inspected, 
and only NSC 123526 endowed with the lowest inhibitory activity 
(IC50 = 46.0 M), was found in good agreement with the orientation 
CHAPTER 6 NS5B RESULTS ANALYSIS 
  
165 
 
of the most active thumb binding compound 6. Moreover, a search 
for compound NSC 123526 in literature highlighted its effective 
activity against other polymerases diverse from NS5B RdRp.
252
 
Figure 6.11 shows the predicted binding mode of the minimum 
energy conformation of the hit compound NSC 123526 and the 
experimental conformation of the thumb inhibitor 6. In detail, the 
para-chlorine-phenyl ring of NSC 123526 is located in the region 
occupied by the ciano-phenyl-thiophene moiety of inhibitor 6 and 
characterized by van der Waals interactions with Leu419, Met423, 
Ile482, Ala486, Leu489 and Leu497. As reported,213 the ciano-
phenyl-thiophene moiety (6) is bound to a hydrophobic surface of 
the thumb domain. In a similar fashion to the 4-methyl-phenyl 
group of inhibitor 6, the tricyclic ring system of compound NSC 
123526 points towards the interior of the thumb domain, filling the 
primary binding cavity by making extensive van der Waals 
interactions with Leu419, Met423, Leu474, His475, and Trp528. In 
addition, one of the carboxylic oxygen atoms of NSC 123526 may 
be involved in a hydrogen bond with the guanidinium group of 
Arg501. This is in full agreement with experimental data that show 
one of the sulphonyl oxygen atoms of compound 6 bonded to the 
same group of Arg501.  
 
                                                        
252
 Silverman, J. E.; Ciustea, M.; Shudofsky, A. M.; Bender, F.; Shoemaker, R. H.; Ricciardi, R. 
P. Identification of polymerase and processivity inhibitors of vaccinia DNA synthesis using a 
stepwise screening approach. Antiviral Res. 2008, 80, 114-123. 
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Figure 6.11. Superimposition of inhibitor 6 (orange) and hit compound NSC 123526 
(magenta) structures, showing a comparable mode of binding within the NS5B 
thumb domain. The residues in the binding site are shown by stick representation 
with carbon, nitrogen, oxygen, and sulfur atoms in cyan, blue, red, and yellow, 
respectively. For the sake of clarity, hydrogen bond interactions are represented by 
black dotted lines, and only a few residues of the binding site were displayed. 
Hydrogen atoms are omitted. 
 
6.5. Conclusions 
Two structure-based 3D QSAR models coupled with both 
ligand-based and structure-based alignment methods were 
developed for NS5B non-nucleoside inhibitors. The overall protocol 
was extensively assessed for both alignment and predictive ability. 
As final test a virtual screening application using the NCI Diversity 
Set 1990 compounds led to the discovery of a new active 
compound (NSC 123526 ) with an unprecedented scaffold among 
NS5B known inhibitors. Further virtual screening are in due 
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progress on wider and more appropriate containing structures 
database (i.e. Maybridge), furthermore a focused virtual screening 
will be set up on a library of compounds structurally related with 
NSC 123526. 
 
6.6. Supporting Information Available 
Statistical results for the thumb and the palm training sets 
analyzed by different GRID probes, Rmsd values obtained by re-
docking simulations of modeled compounds, Rmsd values 
obtained by cross-docking simulations of modeled compounds, 
results from the assessment of Surflex-Sim. Molecular structures of 
223 NNIs used as test set for palm TS Sim LB alignment protocol 
and molecular structures of 223 NNIs used as test set for palm TS. 
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